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Abstract 
Tailored Metal Complexes for Imaging Applications 
The short-lived PET radionuclide 1 3 4 La (tj/2=6.7 minutes) is well suited to the repeated 
evaluation of blood perfusion, thus providing a method of following changes in tumour 
behaviour, in response to therapy. Ligands, both acyclic and macrocyclic, have been 
synthesised, and the complexes formed with 1 3 4 L a 3 + evaluated in vitro and in vivo. 
Other lanthanide complexes have also been evaluated for potential use in magnetic 
resonance imaging and photoimmunoassay studies. A preliminary crystal structure 
determination of a lanthanum tetrabenzylphosphinate complex reveals the presence of 
one water molecule in the inner co-ordination sphere. 
The development of monoclonal antibodies with a specificity for the surface features of 
tumour cells presents a method for the localisation of a radionuclide at the tumour. 
Copper-64 (tj/2=12.7 hours) uniquely combines the decay properties required for 
imaging and therapy. Ligands have been developed for derivatising antibody molecules 
with radioactive copper, whilst retaining specificity for the target antigen. Three 
modified proteins have been evaluated in vivo, and show a high tumour uptake 
compared with blood, but modest uptake compared with the liver, suggestive of some 
degree of protein denaturation during labelling. 
A more subtle approach has been developed, exploiting the affinity of biotin for avidin. 
Higher selectivity at much shorter post-administration time is potentially attainable by 
the use of a multi-step procedure. A copper binding ligand incorporating biotin has 
been synthesised. The ^Cu complex of the conjugate shows specificity for the protein 
avidin both in vitro and in vivo. 
The prognosis of patients with hepatoma or liver metastases is poor. A lipophilic 
copper complex has been synthesised and retention in the liver demonstrated in vivo. 
Measurements with three cell lines in vitro suggest that the complex is more readily 
taken up by tumour cells (and cells from metastases) compared to normal cells. 
Clive Edwin Foster, 1996 
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Chapter One 
Introduction 
1. Introduction 
After a brief introduction to the disease of cancer, (1.1.) a survey of the types of 
modalities, used in tumour diagnosis, is presented (1.2.) with emphasis on radionuclide 
methods. The array of potentially useful imaging radionuclides is introduced (1.3.) and 
nuclides selected for application to perfusion studies (1.4.) and radioimmuno-
scintagraphy. (1.5.) The possibility of extending protocols for imaging, towards 
radioimmunotherapy is considered. (1.6.) The machinery required to present the 
chosen radionuclides in an effective way to patients is reviewed. (1.7.) Finally, the 
material of subsequent chapters is introduced. (1.8.) 
1.1. Cancer 
Cancer is a common disease in man. One person in three will be diagnosed with the 
disease1 and cancer is responsible for the deaths of one in five in the developed world. 
Although cancer is not the primary cause of death, the disease is becoming more 
prevalent as life expectancy increases. Cancer has been known since antiquity, but it is 
only in the last forty years or so that effective means of controlling, and in some cases 
curing, the disease have arisen. The early diagnosis of cancer has a significant effect on 
the chance of survival and has a marked effect on the patient's quality of life. 
The incidence of the many different types of cancer varies between the sexes, racial 
groups and the country of residence. This suggests that behavioural, dietary or 
environmental factors may have a profound effect on incidence rates, and offers the 
prospect of cancer prevention by a change in lifestyle. 
The group of diseases, collectively known as cancer, arise from a loss of control of cell 
division. In normal tissues, cells have a finite lifetime and as cells expire, they are 
replaced with new ones, hence maintaining a constant number. If this regulation breaks 
down, and new cells are produced at a faster rate than old ones die, a tumour2 results. 
Tumours are often classified into two groups, benign and malignant. Benign tumours 
are those which do not spread, and in this respect are not "dangerous," however, the 
presence of a growing mass in a sensitive organ or near a major blood vessel does pose 
a potential threat to the patient's life. Surgery is often used to remove the tumour. 
Malignant tumours are aggressive tumours that have the ability to break up and invade 
the bloodstream or lymphatic system and, hence, spread to distant sites in the body, as 
depicted in the schematic (figure 1.1) below. Often these tumour fragments are trapped 
in either the lymph nodes, the liver, bones or lungs. These secondary tumours (called 
metastases) can be numerous and difficult to detect and treat. 
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Figure 1.1. Diagram illustrating the spread of tumour cells to sites remote from 
the primary tumour. Reproduced from reference 1. 
Despite the large number of deaths attributed to cancer, about four cases in ten can be 
cured. Whilst this is encouraging, further improvement is, without doubt, desirable. 
One way of improving cancer treatment and management is by early diagnosis of the 
disease. The graph below (figure 1.2.) illustrates the difference in likelihood of survival 
with early diagnosis. 
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Figure 1.2. Graph showing the percentage of patients surviving five or more 
years, when diagnosed at an early, middle or late stage of 
development. Reproduced from reference 1. 
1.2. Diagnosis of Cancer3 
Some cancers, for example tumours of the skin and breast, can be detected by inspection 
and palpitation. Others can be accessed for diagnostic purposes fairly easily with the 
use of an endoscope. These include tumours of the upper and lower ends of the 
alimentary canal. For more deep seated tumours, diagnostic information is usually 
acquired by histochemical techniques which detect changes in cellular chemistry. 
Invasive biopsy is used to assess the extent (staging) of the disease. This type of 
information may also be obtained by the use of various imaging modalities. 
Imaging Techniques 
There are several imaging techniques available to the clinician, all of which have their 
merits, but in the current climate of declining healthcare expenditure, a choice often has 
to be made, which is based on financial constraints as well as the therapeutic benefit, set 
against any adverse health cost to the patient. Many of the techniques are 
complementary i.e. different techniques yield answers to different questions. The most 
obvious difference is that, whilst some provide anatomical detail, others provide 
information on physiological and biochemical processes, as they occur in vivo. 
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The basic requirements of an imaging procedure are (i) an energy source, which 
interacts in a usefully non-uniform manner with the media in the field of view (ii) a 
method of detection, which reflects the contrasts attained in the aforementioned 
interaction and (iii) a means to present the information. 
The energy source may be external, in which case the difference in energy focused on 
the subject compared to that transmitted through the subject is measured. The differing 
ability of various tissues to absorb or transmit the energy is manifested in the image 
obtained. The mode in which the radiation is applied determines whether a simple 
photographic plate or a computed reconstruction is required for presenting the result. 
Alternatively, the energy source may be internal, as is the case with internally 
administered radiopharmaceuticals. Here, it is the position of the energy source which 
is determined, hence information is gained on the relative affinity each region of the 
subject has for the energy source. 
Radiography 
The use of X-rays may be useful for the detection of tumours in the lungs or bones, but 
is of limited use in the rest of the body, as the density of tumours is not significantly 
different from normal tissues. An increased definition may be obtained by the 
introduction of a contrast agent, but often this has to be done via cannula intra-arterially, 
with the associated risk of haemorrhage. 
Ultrasound 
Ultrasound is useful for detecting some tumours and has the advantage of avoiding 
radiation dose to the patient. Lesions as small as 5mm diameter can be detected, and the 
technique can easily distinguish between fluid filled and solid masses. 
Magnetic Resonance Imaging 
The action of radiofrequency pulses on samples containing hydrogen nuclei (protons) in 
the presence of a magnetic field, causes some nuclei to achieve a state of higher energy. 
Over time, the nuclei return to their original state, a process termed relaxation. The 
technique of magnetic resonance imaging (MRI) provides useful diagnostic information 
by the use of a gradient magnetic field. This causes water protons to absorb energy at a 
frequency dependent upon the position of the water molecule. A series of 
measurements allows a 3-dimensional anatomical picture to be built up. 
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The presence of paramagnetic ions shortens the water proton relaxation times, providing 
an increased contrast between areas of different paramagnetic ion concentration. The 
large number of unpaired electrons present in iron(III), manganese(II) and particularly 
gadolirdum(ffl) has resulted in a great deal of work to target these ions to specific 
tiss.ues. The degree of relaxation depends on the proximity of the water protons to the 
paramagnetic centre. Hence, rapidly exchanging ligated water molecules on a 
paramagnetic ion may be envisaged as the ideal contrast agent. Such ions would show 
little tissue specificity, however, being rapidly cleared by the kidney. It is, thus, 
essential that the metal be administered as a complex,4 tailored to distribute the ion in a 
specific manner. Since the gadolinium(III) ion is toxic, accumulating in the bones, the 
complex must be stable and excreted intact. 
The need for stability provides the chemist with an interesting challenge - to synthesise 
stable complexes, but, preferably, leaving the metal co-ordinately unsaturated, to permit 
the exchange of water molecules. Much effort has been centred around the need for 
stable complexes of gadolinium,5 and this provides a useful starting point for the design 
of ligands for other lanthanides, as the co-ordination chemistry is similar across the 
series. Minor differences arise as a result of the contraction in ionic radius as the series 
is traversed, and the occasional occurrence of the lanthanide(II) oxidation state. 
Radionuclide Imaging 
There are several imaging techniques utilising the characteristic emissions produced by 
unstable nuclides. The different decay pathways exhibited by radionuclides provide 
potential, not only for highly sensitive imaging procedures, but also offer scope for use 
in targeted therapy. 
The combination of protons and neutrons affect the energy, and, hence, stability of a 
nucleus. If the nucleus has too great an energy, arising from an excess of protons or 
neutrons, it will undergo transformations which result in a net lowering of energy. 
There are a number of different pathways for a nucleus to dissipate energy, either in the 
form of particles or as electromagnetic radiation. It is these emissions which provide 
the energy source for the imaging protocols. 
The unstable (i.e. radioactive) nucleus is called the parent nucleus, and the more stable 
product is called the daughter. The daughter may itself be radioactive and decay further 
- this forms the basis of generator systems (see below). 
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Radionuclides possess a set of characteristic properties such as the mode of decay, the 
type and energy of emissions and the half-life. The combination of these properties 
determines the suitability of the radionuclide for a certain application. 
Single Photon Planar Imaging and Single Photon Emission Tomography 
The technique of single photon imaging is in routine clinical use in a great number of 
hospitals around the world, whereas the tomographic mode of this technique (SPET)6 is 
becoming more widely available. The technique utilises a gamma camera to obtain an 
image of the distribution of the radionuclide. The radionuclides used in SPET decay 
principally via isomeric transition, electron capture and internal conversion. Other 
radionuclides which decay by other pathways can often be used in SPET, as y-emission 
often accompanies {5-decay. 
Isomeric Transition - The metastable nuclide achieves a greater stability by the release 
of a gamma ray. 
Electron Capture - The excess of protons in the nucleus can be reduced by the capture 
of an orbital electron. In this process, a proton and the captured electron combine to 
form a neutron, resulting in a reduction of one in the atomic number. 
p + e" - n 
A X + ° e A Y 
Z -1 Z-1 
The removal of an inner electron from the atom results in an outer electron falling into 
the vacant inner shell. For conservation of energy, an X-ray, characteristic of the 
daughter nuclide, is emitted which can be detected externally. The energies of emitted 
X-rays increase with mass number and it is only the X-rays of heavier elements which 
have sufficient energy to be clinically useful. The process of electron capture followed 
by X-ray emission is depicted in the scheme (figure 1.3.) below using the Bohr model. 
X-ray 
Figure 1.3. Electron capture is followed by the emission of an X-ray. 
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Internal Conversion - If a radionuclide transfers energy to an electron rather than 
emitting it as a Y-ray, then the electron is ejected from the atom. This results in an 
excited electronic configuration. The energy is dissipated by the emission of either an 
X-ray or another secondary (Auger) electron. Auger electrons are potentially useful 
therapeutically as a short range ionising radiation. These processes are illustrated in 
figure 1.4. 
X-ray 
electron emission 
Auger 
emission 
Figure 1.4. The process of internal conversion can lead to both X-ray emission 
and Auger emission. 
Most frequently technetium-99m is chosen as the radionuclide because of the 
convenient availability from a generator system, at low cost, and the favourable decay 
characteristics, exhibited by the radionuclide. The isomeric transition has an emission 
(140keV) well suited to the thallium doped, sodium iodide scintillant employed to 
detect it. 
Positron Emission Tomography 
The decay of a neutron deficient nucleus may result in positron emission, p + . Positrons 
are anti-electrons, possessing identical mass, but opposite charge to electrons. Anti-
neutrinos accompany positron emission, but are not considered here as they have no 
impact in imaging. 
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For p + : p n + e + 
A X - A Y + ° e 
Z Z-1 +1 
P + particles themselves are not suitable for imaging. Positrons only exist until 
combining with an electron. The two annihilate, with their mass being converted to 
energy, in the form of two 51 IkeV y-rays, 180° apart. This sequence of events is 
depicted in figure 1.5., below. The positron and electron form a short-lived positronium 
which annihilates producing the two y-rays. 
Unstable, proton rich, neutron 
deficient nucleus. 
r 
V 
...decays, liberating a positron 
and a neutrino. 
0 The positron collides with an electron to form a 
f positronium which 
annihilates to give two 
511keV y-rays. 
hv hv 
Figure 1.5. A radionuclide decays by positron emission. Kinetic energy is lost by 
molecular collisions, before the positron annihilates with an electron. 
This produces two almost collinear y-rays. 
The advent of cameras, to detect both y-rays coincidentally, made positron emission 
tomography (PET) a feasible diagnostic technique in nuclear medicine. The bulk of this 
thesis concerns the development of radiometal complexes for use in PET imaging. 
The detection of both these photons, using a coincident circuit, defines the line in which 
the annihilation event took place (figure 1.6., below). 
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Datectere 
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Figure 1.6. The coincident detection of both photons defines the line along which 
the annihilation occurred. Reproduced from reference 11. 
Sets of such lines intersect at the locations of high concentrations of annihilations. As 
the positron only travels a short distance (l-8mm), depending on the kinetic energy of 
the positron, the location of the radionuclides which emitted the positrons are 
effectively located also. The simultaneous detection results in an increase in sensitivity, 
as more of the random background disintegrations can be discounted. PET cameras are 
not infallible, however. Scattering and background disintegations do still create signals 
which are incorrectly interpreted. 
The technique of PET allows in vivo study of biochemical processes, by providing 
cross-sectional images of the body that quantitatively map the distribution of positron 
emitting radionuclides. The development of the technique has been based primarily on 
the "organic" radionuclides carbon-11, oxygen-15, nitrogen-13 and fluorine-18, all of 
which decay by positron emission. By incorporation of these radionuclides into known 
metabolites, for example, sugars or amino acids, it is possible to follow the path taken 
by the compound when administered to the body. Therefore, information about the 
location of various receptors in the body can be gleaned from such a technique, and, 
indeed, this is possible to a range of a few millimetres. Although the greatest clinical 
impact of PET has been in metabolism studies of the brain and heart, there is a 
continued interest in studies of other organs and in applications such as tumour biology. 
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Summary of Imaging Techniques 
The sensitivity and specificity of the different imaging modalities are illustrated in 
figure 1.7. below.7 The range of sensitivity spans from millimolar concentrations for 
MRI to sub-nanomolar concentrations, for tomographic techniques employing 
radionuclides. An indication of the information obtained from the techniques 
demonstrates the complementarity of the various modes used for imaging 
X-ray CT Physiology 
MRI 
Ultrasound 
Drug 
Distnbutio 
PET, SPET 
Figure 1.7. The spectrum of medical imaging, illustrating the level of information 
attained from various imaging modalities. Reproduced from ref. 7. 
The technique of MRI has the advantage of avoiding both the handling of radionuclides 
and any radiation dose to the patient. However, the sensitivity of techniques utilising 
radionuclides renders them useful for quantitative studies, and provides biochemical 
information which is not as easily accessible by MRI. An additional advantage of 
radionuclides is the occurrence of several nuclei of the same element (isotopes) being 
available, which emit different radiations. This opens the possibility of therapy with 
ionising radiations, following initial dosimetry measurements performed with low dose 
y-emitting isotopes. 
The advantages of PET over SPET are greater precision in measuring the amount of 
activity, and the increased resolution obtained by coincident detection. Also, the 
sensitivity of PET is much greater, as the collimation required for a SPET system results 
in a large reduction in the number of counts being detected. The availability of the 
radionuclides of carbon, nitrogen and oxygen also add to the attraction of PET - no such 
analogues are available for SPET. The detection equipment for commercially available 
SPET systems is optimised for the emissions of technetium-99m, and, thus, the transfer 
to another nuclide may not be trivial. Positron emitting nuclides all give rise to 51 IkeV 
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y-rays, and so the same detector and software are applicable for all PET studies. The 
major disadvantage of PET is the cost of the facility. The camera itself may be ten times 
more expensive than a gamma camera for SPET, but the major cost incurred is the 
maintenance of the cyclotron. The use of a cyclotron centre, providing a service to a 
collection of consumers, is quite feasible, and allows the burden of cost to be shared. 
As PET technology becomes more available, different nuclides will play a greater r61e 
in diagnostic nuclear medicine. 
Some nuclides used in SPET imaging have a sister isotope which decays by positron 
emission, such as technetium-99m/94m, which should facilitate a smooth transition 
from one imaging modality to the other. 
1.3. Radionuclides Used for Imaging 
The characteristic qualities of a suitable candidate radionuclide for imaging applications 
are the possession of an emission (or range of emissions) which give a detectable signal 
outside of the body, and a half-life appropriate to the time frame of the study. These 
criteria arise from the desire to minimise the radiation dose to the patient, whilst giving 
a respectable signal to noise quotient. Low energy y-emitters8 (100-200keV) and tracer 
amounts of P + emitters are suitable candidates. Fortunately, a range of radionuclides, of 
differing half-lives, is available offering a choice to suit each application. 
Short lived radionuclides are used for studying properties such as blood flow, where the 
short half-life results in a smaller dose to the patient. Also, a clinical advantage is 
gained, as the study can be repeated after a short time period, to monitor a change with 
time, or under different physiological conditions. Longer lived radionuclides are useful 
for prolonged tracer kinetics, for example, studies using antibodies, which often localise 
much more slowly. 
Radionuclides for Imaging - y-Emitters 
The most commonly used nuclides for SPET applications are listed in table 1.1., 
below.9-10 
12 
Radionuclide Halflife/hr Principle yEmissions/keV 
6 7Ga 78 93, 184 
9 9 m T c 6 141 
m i n 68 171,247 
123j 13 159 
131j 193 364, 367 
Table 1.1. Radionuclides used for SPET. 
Of these radionuclides 9 9 m T c and 1 2 3 I are most suitable due to their mono-energetic 
emissions, which lead to a lower radiation dose to the patient, and provide an enhanced 
image quality, due to the reduced amount of background and scatter. 
Radionuclides for Imaging - Emitters 
A representative, but not exhaustive, list of positron emitting radionuclides is given in 
table 1.2., below.1 1'1 2 As can be seen, a range of half-lives up to 100 hours is available. 
This variation of decay characteristics and chemical properties allows a choice based 
not only on physical half-life, but also permits some consideration to be given to the 
ease and flexibility with which a particular radionuclide can be tailored to fit specific 
applications. 
Radionuclide Half-life Positron Yield/% Radionuclide Half-life Positron Yield/% 
" C 20 min >99 6 6Ga 9.5 hr 57 
1 3 N 10 min >99 7 2 As 26 hr 88 
1 5 Q 2 min >99 7 5 Br 1.6 hr 76 
18p 110 min 97 7 6 B r 16 hr 57 
52p e 8hr 57 83 S r 33 hr 24 
5 5Co 18 hr 77 89Zr 78 hr 23 
5 7 N i 36 hr 40 9 4 g T c 5hr 11 
^Cu 23 min 92 9401^ 54 min 72 
6 1 Cu 3.5 hr 61 120j 1.4 hr 46 
64CU 13 hr 18 124j 101 hr 22 
Table 1.2. Positron emitting radionuclides. 
An important practical consideration, when choosing a radionuclide, is the speed at 
which the radionuclide, or compound derived from it, can be delivered from the source 
to the patient. Applications involving radionuclides with half-lives of the order of 
minutes cannot be considered, unless a cyclotron is available at the hospital where the 
study is to take place. 
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An alternative strategy, which does permit the use of short lived nuclides at centres 
removed from a cyclotron, is to use generator produced nuclides. 
Generators 
A generator is a method of producing a shorter lived radionuclide from one of longer 
half-life. The parent radionuclide can be produced at a remote site and transported to 
the clinic. The parent decays to the shorter lived daughter, which is withdrawn from the 
generator by a physical or chromatographic separation and administered to the patient. 
The parent radionuclide continues to decay and so the process may be repeated until the 
generator becomes inefficient, due to the eventual decay of the parent. 
Table 1.3., below lists some radionuclides which can be produced from generators. The 
half-life of the parent is clearly important. A reasonably short half-life is sought for 
large scale production of the daughter, but too short a half-life results in a poor "shelf-
life" and the inconvenience of having to repeatedly replenish the parent activity. 
Parent Half life Daughter Half-life Positron yield/% 
. 5 2Fe 8hr 5 2 M n 21 min 97 
6 2 Z n 9hr 6 2 Cu lOmin 97 
68 G e 27 Id 6 8Ga 68 min 89 
8 2 S r 25 d 8 2Rb 1 min 95 
8 6 Z r 16 hr 86y 15 hr 34 
1 1 0 Sn 4d n o I n 69 min 62 
1 2 2 Xe 20 hr 122j 4 min 77 
1 3 4Ce 3d 1 3 4 La 7 min 62 
Table 1.3. Generator produced positron emitting radionuclides. 
1.4. Perfusion Studies 
The behaviour of a tumour is significantly affected by the supply of blood.13 The 
nutrients and oxygen provided by the blood are necessary for the tumour cells to survive 
and divide. Similarly, the delivery of agents to destroy the tumour benefits from an 
increase in the local blood flow. In addition, the efficacy of conventional radiotherapy 
is compromised by hypoxia, a result of poor oxygen delivery. The manipulation of 
tumour blood supply clearly has potential as a means to affect the management and 
treatment of the disease, even though it may seem, intuitively, that an increase in 
perfusion would provide the tumour with better conditions in which to flourish. 
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Manipulation can be achieved by the use of various pharmacological agents, which 
constrict or dilate blood vessels. 
Two therapeutic scenarios can be envisaged. Increasing the blood flow results in more 
effective radiotherapy, and potentially, increases intra-tumoral uptake of chemical 
agents. Alternatively, a decrease in blood flow, which promotes hypoxia, may enable 
tumour targeting with compounds that possess bioreductive cytotoxicity. In both these 
situations, it is necessary to measure tumour blood flow, to gauge the success of efforts 
to affect blood flow, and also to monitor any physiological change adopted by the 
tumour to counter the alteration. 
The use of radionuclide techniques is clearly appropriate for perfusion studies. The 
sensitivity achievable with SPET or PET allows a tracer amount of a radionuclide to act 
as a marker of blood flow without perturbing the system under scrutiny. Several 
nuclides have been used to provide quantitative information in this way. Technetium-
99m is the most commonly used radionuclide for diagnostic purposes, accounting for 
well over 90% of studies, and dominating the £700M per annum market.14 Several 
factors have combined to enhance the popularity of the radionuclide. The physical 
characteristics of single photon emission (140keV) and a half life just over 6 hours, 
make the radionuclide amenable to SPET imaging, without exposing the patient to an 
excessively high radiation dose. The pertechnetate ion is readily produced in a 
generator, making it commercially attractive. 
Several complexes have found use in the clinic for measuring blood flow. The ligands 
are chosen to provide the necessary tailoring to suit the application in mind. Some 
commercially available Technetium imaging agents15 include Tc-MIBI 1 (Cardiolite) 
for imaging myocardial perfusion, Tc-HMPAO 2 (Ceretec) for cerebal perfusion and 
TC-MAG3 3 (TechneScan) for kidney function. The ligands are supplied in sealed vials 
containing the lyophilised ligand together with the necessary reducing agent, usually 
tin(II) chloride. The radioactive pertechnetate solution is added and, after an assessment 
of quality, the complex is administered to the patient. 
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In PET studies, use is made of the positron emitting nuclides of oxygen and nitrogen. 
150-water, 150-butanol and 13N-ammonia are used as blood flow imaging agents. The 
use of these short lived nuclides is attractive, as the study can be repeated at brief time 
intervals, to give information about the effect of modifying the blood flow, at several 
time points during the study. However, the use of these nuclides necessitates the 
provision of an on-site cyclotron, and, hence, most hospitals are unable to benefit from 
the increased sensitivity and resolution offered by PET. Attempts to overcome this 
shortcoming have centred around the need for generator produced positron emitting 
nuclides. One much studied example is the use of copper-62 (ti/2=9.7 mins), product of 
the 6 2 Zn/ 6 2 Cu generator.10 
There is a great deal of investigation into ligands which bind copper. Much work is 
centred around the PTSM 4 complex, a very lipophilic charge neutral copper complex, 
which is being closely examined in the clinic, to assess suitability for studies of blood 
perfusion.16 
The fate of copper PTSM is believed to be cellular reduction of the copper(II) ion to 
copper(I), with concomitant loss of complex stability, and trapping of the free reduced 
ion. 1 7 Because the extraction of the complex from the blood is essentially complete in 
the first pass, quantitative information is gained relating the regional uptake of activity 
with perfusion. A problem encountered in the use of copper-62 is the short shelf-life of 
the generator, resulting from the relatively short half-life of the zinc-62 parent. 
An attractive alternative generator is the 1 3 4 Ce/ 1 3 4 La generator, which has highly 
desirable decay characteristics for both the parent and daughter nuclides. Lanthanum-
134 has a 6.7minute half-life with high positron emission. The parent cerium-134 has a 
half-life of 3.2 days. This gives the generator a shelf-life of around two weeks, 
comparable to the " M o / 9 9 " 1 ^ generator, familiar to all radiopharmacies. 
Although the lanthanides exhibit similar co-ordination chemistry, little has been 
reported on the tailoring of lanthanum complexes for use in diagnostic medicine. The 
development of ligands to bind lanthanum for use in perfusion imaging forms the 
subject matter for chapter 2, below. 
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1.5. Imaging Receptor Sites on Tumours 
Tumour cells often display an increase (overexpression) or decrease (underexpression) 
of surface proteins, compared with normal healthy cells. Alternatively, a slight 
modification in the number, type or position of prosthetic groups, e.g. carbohydrates, 
may be observed. These subtle differences affect the way in which the cell interacts 
with the environment and, in particular, affects the ionic and molecular species the cell 
attracts and binds to - processes essential to the survival of the cell. The surface 
differences are also detected by the host's immune system and trigger a response, with 
the body's own defence mechanism releasing antibodies to try and expel the unwanted 
cell. 
Antibodies are high molecular weight proteins (M r -150 000 Da) which possess the 
ability to recognise surface features (antigens), differentiating between healthy and 
unhealthy cells. On binding to the tumour cell surface, a sequence of biochemical 
changes are invoked which result in cell death. 
Artificial antibodies can be raised against a known antigen, and produced in a large 
amount by the use of the hybridoma technology, developed by Kohler and Milstein.1 8 
The antibodies produced do not complete the process of destroying the cell, as they are 
not the host's own. By the incorporation of radionuclides into the antibodies, the cell 
surface and, hence, tumour, can be imaged. Detailed information on the location of the 
tumour and metastases can be gained by such an approach. The sensitivity of 
radionuclide imaging permits the detection of small secondary tumours. 
Choice of Radionuclide 
Several radionuclides warrant investigation for their applicability in targeted imaging of 
receptor sites. The choice is primarily limited by the half-life, which should ideally be 
comparable to the time frame of the study. For antibody based imaging protocols, the 
time taken for localisation is 24-48 hours for whole antibodies. However, the time may 
be considerably less for fragments of antibodies, or other low molecular weight 
targeting vectors. Inspection of the abbreviated list of nuclides (under paragraph 1.3.) 
suggests several suitable medium lived radionuclides. It was decided for this study to 
use copper-64. This radionuclide was chosen primarily because it has a half-life (12.8 
hours) suitable both for use with antibodies and, also, smaller targeting vehicles. Many 
stable complexing agents have been defined for copper, which may be elaborated for 
attachment to targeting modalities. In addition, copper-64 has a range of emissions, 
including potentially useful ionising radiations of various energies. The availability of 
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copper-67 as a therapeutic isotope may result in a smooth transition from imaging to 
targeted therapy, with the same antibodies. 
Conjugation to Low Molecular Weight Targeting Vehicles 
The use of radioactively labelled small molecules, which exhibit selectivity for tumour 
cells over healthy cells, has the significant advantage that localisation is much quicker 
than with antibodies. The result of this is a reduced dose to the non-target tissues. 
However, the specificity of these smaller molecules may not be as high as for the 
antibody approach. (The use of the term "small" is somewhat arbitrary. Attempts have 
been made to use fragments of antibodies (M r = 50 000 Da) where only the portion of 
the antibody required for antigen recognition is used. For the purpose of this section, 
molecules of mass < 1000 Da are considered "small." ) 
As mentioned previously, tumours express proteins which bind with some selectivity to 
various molecules in vivo. The molecules sought include hormones and small peptides. 
The realisation that tumours show an increased uptake of molecules such as these has 
inspired the synthesis, and testing, of labelled variants, including the examples below. 
The 18F-fluorinated steroid 5 is finding clinical application for imaging breast tumours 
using PET. The work has been extended to develop metal complexing agents, 
mimicking the structure of steroids, for both imaging and therapy of steroid positive 
tumours. For example, the progestin derivative 6, functionalised at the 1 lp position,19 
and the rather unusual dihydrotestosterone 7 mimic 8. 2 0 
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Octreotide, an octapeptide which binds selectively to the somatostatin receptor, has been 
labelled with indium via terminally conjugated DTP A. The conjugate 9 retained a very 
high affinity for the receptor.21 
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It seems likely that the incorporation of an unnatural prosthetic group to these small 
molecules will cause a large change in the three dimensional electron distribution that is 
recognised by the cell. This may account for the loss of specificity found with some 
low molecular weight targeting vehicles. With antibodies, such changes may be more 
tolerable, as only a fraction of the molecule is required for recognition. 
The prospect of pretargeting using an unlabelled antibody followed (after localisation at 
the tumour) by a low molecular weight tracer, which shows a specificity for the 
antibody, is an attractive idea. The method offers the prospect of excellent specificity, 
without the radiation dose being borne by the whole body. The tools to test the validity 
of this approach exist with the avidin bio tin system.22 
Biotin 10 (vitamin H) is a low molecular weight enzyme cofactor whose role in vivo is 
to activate acetate groups by addition of carbon dioxide to form malonyl derivatives. 
Biotin shows a remarkable affinity for the tetrameric protein avidin, extracted from egg 
white, and the similar protein streptavidin, extracted from Streptomyces bacteria. The 
value of the dissociation constant (K^ = 10"15 dm3 mol"1) is more akin to those of metal 
complexes than the non-covalent interactions between hosts and their guests, where the 
bonding involves principally hydrogen bonding and hydrophobic interactions. The 
driving force that keeps biotin and avidin bound, effectively non-reversibly, is both 
entropic and enthalpic in origin, with several poorly bonded water molecules being 
displaced from the binding site of avidin, on complexation with biotin. 
If a monoclonal antibody is conjugated with biotin, it may be coupled to avidin via one 
of the binding sites on the avidin. As avidin is tetrameric in nature, three binding sites 
are left vacant. A radiolabelled biotin conjugate, introduced after antibody localisation, 
would be expected to bind to the "avidinated" antibody at the site of the tumour. This 
hypothesis is presented schematically below (figure 1.8.) 
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Step 1 The antibody is derivatised at lysine 
by reaction with biotin active ester 
£3 
Step 2. The "biotinylated antibody 
is conjugated to the tetrameric 
V protein avidin 
Step 3. The hybrid protein is administered to the patient, and left for 24-48 hours to 
achieve a high degree of localisation 
C3 Cu 
Step 4. The copper-64 conjugate, Cu 
incorporating the biotin motif is 
administered, and rapidly forms a 
stable, non-covalent link with avidin 
anchored to a tumour cell via the antibody 
Legend: 
Cu 
Y Antibody 
Biotin 
£3 Avidin Cu 
Figure 1.8. A schematic diagram of the envisaged multi-step approach to tumour targeting. 
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This approach to tumour targeting is not particularly novel. Several conjugates have 
been defined, incorporating radionuclides suitable for SPET imaging. The DTPA 
derived ligand 11 has been reported for use with indium,23 however, the anionic 
complex might be expected to demetallate in vivo. A similar approach to targeting, 
using the technetium complex 12, has also been investigated.24 The half-life of copper-
64 is suitable for consideration for PET studies using this pretargeted approach. The 
synthesis and characterisation of copper complexes, incorporating the biotin moiety, for 
potential use in PET imaging are discussed in chapter 3 below. 
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Conjugation to Antibodies 
There are several criteria that a complexing agent must fulfil, to serve as a means of 
attaching a metal ion to a protein.25 The complexing agent has to be attached in a 
manner which does not compromise the immunoreactivity of the antibody, i.e. the point 
of attachment must be somewhat removed from the binding portion of the antibody. 
The linkage must be covalent and stable in vivo, as well as not provoking an immune 
response from the host. 
Points of Attachment 
Several amino acid residues provide a convenient point for attachment of the complex. 
The most reactive is the thiol group of cysteine, which reacts at physiological pH. 
However, most of the thiols are oxidised to form disulfide bridges, which play an 
important structural role, in the conformation of proteins. Additional thiol groups may 
be introduced, using the method developed by Traut26 and modified by Meares,27 where 
2-iminothiolane 13 is reacted with the e-amino group of the lysine residue. The free 
thiol may then be reacted quite selectively, with either a-halo carbonyl compounds or 
with Michael acceptors such as maleimides, as depicted in figure 1.9., below. 
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Figure 1.9. The conjugation of complexing agents with proteins, using 
2-iminothiolane. 
The terminal amine group on lysine residues reacts with activated esters of, for example, 
N-hydroxy succinimide or />-nitrophenol. A slightly elevated pH is required to render 
the amine a little more nucleophilic. The terminal amine can also react with the 
isothiocyanate group to form a stable thiourea linkage. These more direct conjugation 
reactions are shown below (figure 1.10.) 
'NH, 
Y N ^ N H H 
Figure 1.10. Direct conjugation at lysine. 
22 
Carboxylic acid groups on some residues have also been used, usually via a 
carbodiimide coupling reaction. The activated, aromatic group of tyrosine has seen use 
for conjugation, particularly with diazonium compounds. This is also the point where 
oxidised iodine species attack, in the direct halogenation of proteins. 
In this study the point of attachment is the lysine residue, either by direct reaction with 
active esters or through the free sulfurs introduced by the Traut method. The number of 
lysines does, of course, vary between proteins, but there is a tendency for hydrophilic 
residues to be disposed at the more accessible sites (i.e. the surface) of the protein. 
Therefore, it can be expected that the modification of the lysine residue can be 
accomplished without a change in protein conformation. This is clearly desirable, as the 
specificity of the antibody is totally dependent on the complementarity of shape 
between the antibody and the receptor site on the tumour surface. 
1.6. Towards Targeted Therapy with Radionuclides 
There is considerable potential for ionising emissions from decaying nuclides to be used 
therapeutically. The radionuclides most likely to find use are a, P and Auger emitters. 
Alpha emission - Heavy nuclides are able to lose energy by the emission of an oc-
particle, two neutrons and two protons. These relatively massive particles have a very 
short range in tissues (pim) and fail to escape the body. The strong ionising ability of a-
particles renders such nuclides suitable for therapeutic applications. 
A w ^ A - 4 X / 4 X " Y + a 
Z Z-2 2 
Beta emission - The decay of a proton deficient nucleus resulting in the release of an 
electron is termed beta decay P~. The ionising radiations are potentially useful in 
therapy. 
ForP": n - p + e" 
A X A Y + °e 
Z Z+1 -1 
Auger electrons, mentioned above, are also worthy of consideration. The short path 
length of Auger emissions (nm) effectively limits their dose to a single cell. This is in 
contrast to P" particles which may exhibit mean path lengths, in tissue, of up to 4mm. 
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Positron emitting nuclides could be used to provide the ionising radiation required for 
therapeutic applications, with simultaneous imaging. However, the number of high 
energy (511keV) y-rays which accompany positron emission could result in a 
prohibitively high radiation dose to the patient. The criteria a positron emitting 
radionuclide must satisfy to be considered for therapy are (i) a (3+ energy suited to the 
morphology of the tumour, (ii) a low positron emission. Sufficient annihilations must 
take place for imaging, but ideally, not too many, otherwise the whole body dose could 
become too high. Finally, (iii) the rest of the decay (usually by electron capture) should 
not lead to other y-rays, hence further enhancing the dose. Copper-64 is a quite unique 
radionuclide, combining P + , (5" and Auger emission, and is the positron emitting nuclide 
most suited to therapy. 
There are a number of elements possessing both a positron and a P" emitting isotope. 
Such radionuclide pairs include copper-64/67, yttrium-86/90, strontium-83/89, iodine-
124/131. The prospect of therapy using a cocktail of mixed isotopes of the same 
element appears quite attractive, and would permit the application of therapy with 
simultaneous imaging. 
For radiotherapy, it is essential to deliver as much ionising radiation to the tumour as 
possible, whilst the dose to healthy tissue is minimised. Conventional radiotherapy 
employs an externally located source which is focused on the tumour. For a deep seated 
tumour, the path of radiation is obscured by the presence of healthy tissue, which 
subsequently receives a high dose. Targeted radiotherapy offers the prospect of 
delivering the dose solely to the tumour. Monoclonal antibodies offer a means to 
deliver the radionuclide to the site of the tumour. However, the time taken for 
localisation results in a high radiation dose to the whole body. For lower energy, 
imaging protocols, this may not give rise to much concern, but the more harmful 
ionising radiations used in therapy may prohibit the use of full antibodies. The use of 
antibody fragments may improve matters, as may low molecular weight targeting 
vectors, introduced above. 
An alternative strategy may be to "implant" the source directly into the tumour. The 
poor vascularity of many tumours might be expected to result in a poor washout, 
effectively keeping the activity in the tumour. Some precedence for this type of therapy 
has been reported in the use of lipiodol 14,28 an iodinated ester of unsaturated fatty 
acids derived from poppy seed oil. Radioiodinated analogues show a remarkable uptake 
and retention in liver hepatoma. Conjugation to a complexing agent 15 has been 
achieved, which has enabled the use of nuclides more suited to therapy to be 
investigated.29 
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1.7. Ligands for Forming Metal Complexes 
It is well known that the stability of complexes formed between metal ions and electron 
donors, arranged in a macrocyclic array, far exceeds those complexes formed by several 
discrete ligands.30 When designing macrocyclic ligands, several parameters can be 
varied to affect stability. The primary factors to be considered are: 
1) donor groups 
2) ring size and conformation 
The choice of donor group is important to the thermodynamic stability of the complex, 
the rate of formation of the complex and, also, has an effect on the charge of the 
complex. The main atoms which are used as donors are 
nitrogen as either an amine or an imine (neither affect the charge of the complex), 
oxygen as an ether or carbonyl (no effect on charge) or an "ate" (derived from 
deprotonation of an acid or alcohol/phenol, resulting in a lowering of the complex 
charge.) 
sulfur. Analogous to oxygen, but, potentially, with further complications arising from 
the various oxidation states exhibited by sulfur. 
Some other atoms are also used e.g. phosphorus analogously to nitrogen 
The optimum ring size for forming stable complexes varies considerably, not only with 
the size of the relevant metal ion, but also depends on whether the metal sits in the plane 
or caps the faces described by the donor atoms. Generally, five membered chelate rings 
give the optimum stability, but it has been shown31 that more stable complexes are 
formed with some smaller ions, if six membered chelating groups, with a smaller bite 
angle, are used. The combination of 5 and 6 membered chelate rings can serve to 
provide complexes of optimal stability for the ion in question. 
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For use with radionuclides in vivo several criteria have to be satisfied by ligands. The 
complexing agent must bind the metal ion quickly, preferably with some selectivity. 
(Although radionuclides are isolated in a radiopure form, some cold metal ions are often 
present as chemical impurities. Some ligands, used to bind metal radionuclides, 
indiscriminately bind the first ion encountered, rather than the desired one, resulting in a 
drop in labelling yield.) The complex formed must be stable to metal loss in vivo. The 
physiological pH of 7.39 applies to serum, and does not nearly represent the range of 
pH the complex may be expected to encounter in the body, where the pH drops to below 
2 in the stomach and, most importantly as far as catabolism is concerned, the liver. The 
instability of some metal complexes at low pH has resulted in some compromised 
biological evaluation of conjugates, even though the known formation constants are 
deemed sufficiently high. 
Ligands to Bind Lanthanides 
There is considerable interest and synthetic effort in designing ligands to utilise the 
special effects that many lanthanide ions exhibit. For example, ligands to form stable 
complexes have been synthesised to bind toxic ions for use in vivo.32 Ligands 
incorporating chromophore antennae have been devised, which may find use as 
luminescent probes, on complexation with ions possessing long lived excited states.33 
The most commonly used ligands for binding lanthanides are polyaminocarboxylates, in 
particular DTPA 16 and DOTA 17. Both form complexes of high thermodynamic 
stability, but are not appropriate for all applications. An array of alternatives is under 
continual development to tune complexes for specific uses.34 
For use in perfusion studies, it is desirable that the nuclide be rapidly cleared from the 
blood, preferably on the first pass of the circulation. This necessitates the uptake and 
retention of the radionuclide by cells for the duration of the study. The short half-life of 
lanthanum-134 reduces the need for the complex to be excreted intact, as the radio 
tracer rapidly decays to present no long term risk. This concession to stability allows 
more flexibility in the design of ligands to bind lanthanum. An increased effort can be 
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invested towards producing complexes which are trapped quickly, rather than ensuring 
that the complex integrity is preserved. 
The primary factors which affect the cellular uptake of complexes are the charge, 
molecular weight and lipophilicity. These observations point towards membrane 
permeability as the major factor determining whether a complex is taken up or not. All 
cells have a phospholipid bilayer, hence, it might be expected that lipophilic species are 
more adept at entering cells. 
The ligands DTPA and DOTA form anionic hydrophilic complexes which are not 
suitable for use as perfusion agents. The basic geometry of these ligands does provide 
complexes sufficiently stable for in vivo use, and provides a framework to be built upon. 
A modification to these ligands is sought, which will increase the lipophilicity of 
complexes formed with lanthanides. 
The use of complexing agents incorporating amides as ligating groups in the place of 
the carboxylates results in the formation of complexes with an increased positive 
charge. By substitution of the appropiate number of carboxylates, illustrated by the 
generalised structures, of figure 1.11., ligands can be produced which will form charge 
neutral complexes, on incorporation of a cation. Such complexes might be expected to 
enter cells more easily than charged ones. 
Figure 1.11. Generalised structures of ligands capable of forming charge neutral 
In addition to reducing the charge on the complex, incorporation of the amide provides 
a handle for convenient control of the complex's properties, and for conjugation to 
targeting vehicles, such as monoclonal antibodies.35 
An alternative donor group to the carboxylate is the phosphinate. The change of acid 
moiety introduces the possibility of elaboration at the phosphorus atom, and, indeed, 
this has been realised36 with, for example, the ligand 18. Some control of lipophilicity is 
gained by the designer, which has an effect on the biodistribution and clearance rate of 
the complex. Also, the change to a more acidic group results in complexes more able to 
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complexes on binding to lanthanide ions. 
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resist protonation. This may be important in applications where stability under acidic 
conditions is paramount. The increase in lengths of bonds to phosphorus over carbon 
manifests itself as a larger bite angle being displayed to the complexed metal ion. 
Possibly, this may result in increased stability of complexes of larger ions, and a 
tolerance of geometry prohibited by carboxylate analogues. 
A comparison of complexes of DOTA with those of the analogous phosphinic acid 
reveal a difference in the co-ordination number of the metal. The crystal structures of 
the yttrium complexes have been determined.37'38 It is quite clear that, whilst an 
approximately square anti-prismatic structure is adopted by both, the [Y(DOTA)]" 
complex exhibits 9 co-ordination of the metal centre with one face capped with a water 
molecule. This water molecule is absent from the phosphinic acid derived complex. 
The structural curiosity demonstrated by the yttrium complexes clearly has implications 
for the prospects of gadolinium complexes of these ligands. The relaxivity of a 
paramagnetic complex is primarily a function of the number of bound water molecules 
and the correlation time. As the ionic radius of yttrium and gadolinium are quite 
similar, it may be expected that gadolinium complexes will be isostructural with the 
corresponding yttrium complexes. The potential for use of both complexes as contrast 
agents has been investigated.39 The [Gd(DOTA)]" complex behaves as an inner sphere 
contrast agent, whereas the phosphinic acid derived complex behaves as an outer sphere 
contrast agent, consistent with the absence of metal bound water. 
Ligands to Bind Copper 
There are two common oxidation states of copper. The preferred co-ordination 
geometry changes with oxidation state. Copper(I) forms tetrahedral complexes, 
whereas copper(II) opts for distorted octahedral geometry. This distortion (Jahn-Teller 
effect) is a result of the degeneracy of the t2g and e g energy levels, present in true 
octahedral complexes, arising from the d 9 configuration of the ion. The distortion is 
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manifested to such an extent, that the complexes formed are more accurately described 
as square planar. 
This change of geometry with oxidation state necessitates the need for ligands to be 
designed for the specific ion to be used, if complexes of high stability are sought. The 
change in complex stability on reduction has been exploited, however, with the copper 
PTSM complex [Cu(4)]. Bifunctional complexing agents based on the PTSM 
framework 19 for protein conjugation have been defined.40 
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However, the applications to be developed herein, require copper complexes of high 
stability in vivo. Several potential complexing moieties have been defined and their 
stability constants, determined at 298K, are listed in table 1.4.,below.9 
It is, however, important to remember that the body is not at equilibrium, and, although 
serum pH may be very mild, many metabolically important organs offer highly acidic 
environments to vulnerable metal complexes. Hence, it is necessary to consider the 
stability of the complex (and any conjugate derived from it) at a range of acidity. The 
charge of a complex may provide useful clues to the stability of the complexes listed in 
the table below. It may be expected that cationic complexes will electrostatically repel 
advancing protons which could lead to the extradition of the metal. The acid catalysed 
dissociation has been investigated,41 and it was found that protonation, rather than 
donor group displacment, was the factor most important in the dissociation pathway. 
On the contrary, anionic complexes will attract protons, and other cations, which may 
lead to an increased susceptibility to metal loss. For example, the stability constants of 
the respective monoprotonated complexes of TETA, DOTA and NOTA (log K ^ ^ ) are 
14.6, 14.4 and 12.7, representing a drop of ten orders of magnitude over the 
unprotonated complexes. The complexes have pKa values42 between 2.7 and 4.3, 
which indicates that the complexes should be fairly stable with respect to acid catalysed 
dissociation, and much work has been done on the carboxylates. An advantage of the 
negatively charged polyaminocarboxylates is that they would be expected to form 
complexes more rapidly than the dicationic (under labelling conditions) tetraamines. 
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Ligand logKML Charge 
14N4 20 27.2 +2 
13N421 29.1 +2 
TETA 22 21.6 -2 
DOTA 17 22.2 -2 
NOT A 23 21.6 -1 
DTPA 15 21.4 -3 
EDTA 23 18.9 -2 
Table 1.4. The stability constants of some representative copper complexes. 
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All of the ligands above have been investigated, to an extent, for use in antibody based 
imaging. The ease of incorporating DTPA and EDTA on to proteins by the use of their 
respective anhydrides e.g. 25 makes rapid conjugation feasible (figure 1.12). However, 
the conjugates produced showed a propensity to demetallate in vivo.43 
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Figure 1.12. The reaction of an antibody lysine residue with DTPAA 25 allows 
rapid metal conjugation, albeit at the sacrifice of stability. 
The macrocyclic complexes offer greater stability and many conjugates have been 
defined and tested with a variety of radionuclides. Much work with copper has centted 
around the use of the TETA ligand, coupling to thiolated antibodies by a-halo amides 
26. The tetraamine ligands have also been used, with Michael type acceptors 27,28 
being employed in the conjugation step.44 
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A synthetically simpler method for conjugation of cyclam, by N-alkylation rather than 
C-alkylation, has also been used. An example of this approach45 gave conjugates which 
were slow to label, and resulted in some, potentially problematic, non specific binding. 
Ligands based on the NOTA framework, including 29 and 30, have been synthesised46 
and evaluated for use with small trivalent metal ions such as gallium and indium. These 
ligands should be suitable for use with copper. Copper NOTA complexes would, of 
course, be anionic, hence susceptible to acid promoted metal loss. The replacement of 
one of the carboxylic acid groups with an amide to counter such dissociation is 
investigated in chapter 3. 
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1.8. Scope of the Work 
This thesis is concerned with methods for the detection of tumours, monitoring the 
behaviour and treatment of tumours, and the therapy of tumours. 
Chapter 2 considers the development of complexes for use as blood flow imaging 
agents, with the short lived lanthanum-134 nuclide. Such complexes would permit 
investigation of factors affecting tumour blood supply, by repeated measurements made 
under different physiological conditions. The generator used to produce the 
radionuclide has a convenient shelf-life for use at centres not possessing a cyclotron. 
Discourse is introduced, illustrating the suitability of gadolinium, terbium and europium 
complexes of the ligands, developed for lanthanum, in other imaging applications. 
Chapter 3 looks towards the use of the avidin-biotin system as a method for achieving 
high tumour to background ratios of activity, at time intervals shorter than those 
accessible with conventional antibody based approaches. The potential therapeutic use 
of low molecular weight lipophilic complexes to target hepatoma is also outlined. 
Chapter 4 concerns the use of radiolabeled antibodies for tumour targeting, and further 
elaboration by the incorporation of intercalators to target the nuclear DNA of the tumour 
cell. Antibodies developed by the Department of Immunology at the Institute of Cancer 
Research are labelled with ^Cu macrocycles, and investigated for their use in imaging 
and, potentially, therapy of solid tumours. 
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Chapter Two 
Lanthanide Complexes 
Perfusion Imaging 
2. Lanthanide Complexes for Perfusion Imaging 
An overview of lanthanide co-ordination chemistry, (2.1.) defining the requirements of 
ligands to bind lanthanides, is followed by ligand synthesis, (2.2) and the 
characterisation of lanthanide complexes. (2.3.) The potential for lanthanum-134 to be 
used for perfusion studies is introduced.(2.4) The radiolabelling of the ligands is 
investigated, (2.5.) followed by an evaluation of the complexes synthesised, for potential 
use as imaging agents. (2.6.) 
2.1. Co-ordination Chemistry of the Lanthanides 
The lanthanides usually display similar physical properties and possess a preference for 
the +3 oxidation state. These similarities proved problematic historically in the 
isolation of the metals in pure form, a feat which was not realised until the 1950's 
following the advent of ion exchange methods of chromatography.1 The similarity in 
size and bonding mode of the ions permits the usage of ligands common to all 
lanthanides. 
A slight decrease in ionic radius is observed as the series is traversed from lanthanum to 
ytterbium, termed the lanthanide contraction. A high co-ordination number is 
characteristic of lanthanide compounds, with the lighter, larger ions exhibiting co-
ordination numbers up to 12. A co-ordination number of 8-9 is commonplace. 
Complexes tend to adopt a square anti-prismatic geometry, with faces capped to 
complete the ligand field. This geometry is enforced more by the steric constraints of 
the ligands rather than the position of metal orbitals. This is a consequence of the non-
participation of 4/electrons in bonding - the lanthanide(III) ions possess an almost 
spherical electronic distribution. This indifference to directional bonding is being 
exploited in the use of lanthanides as calcium mimics, to probe cellular biochemistry.2 
Lanthanide(UI) ions have a similar size to Ca 2 + and so can be accommodated at active 
sites of metalloproteins, without perturbing the geometry. Europium (IE) and 
terbium(IJI) are finding use as luminescent probes3 whereas gadolinium (III) has found 
use as an EPR probe.4 
The lanthanides are "hard" acids and hence prefer to bind with "hard" bases, i.e. 
electronegative donor ligands such as oxygen and fluorine. 
Macrocyclic vs Acyclic Ligands 
The additional stability imparted by arranging donor atoms in a macrocycle is highly 
desirable for in vivo use of radionuclides, which emit ionising radiations. However, for 
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perfusion studies using minute amounts of lanthanum with a short half-life, the need for 
stability is not quite as acute. Indeed, copper PTSM [Cu(4)], an acyclic copper(II) 
complex, has attracted considerable attention because the complex is rather unstable. 
Decomplexation is initiated by intracellular reduction by a tripeptide (glutathione) to 
give a copper(I) complex of moderate stability which then dissociates, trapping the 
copper, and allowing quantitative measurements to be made. 
NHMe 
H 
>V 
N=< 
NHMe 
[Cu(4)] 
It was decided to synthesise both acyclic and macrocyclic ligands for use as lanthanide 
complexing agents, and investigate the properties of selected lanthanide complexes, 
both in vitro and in vivo. 
Metal Ions of Interest 
Complexes of lanthanum are of particular interest because of the potential diagnostic 
use of the lanthanum-134 isotope, which decays by positron emission. Also of interest 
are the related terbium and europium complexes because of their interesting 
luminescence properties, and the corresponding gadolinium complexes because of the 
potential application as contrast agents in MRI. The common co-ordination chemistry 
of these ions necessitates no modification of the ligands for use with different metals of 
the lanthanide series. 
.2. Ligand Syntheses 
Acyclic Ligands 
Acyclic ligands based on the DTPA backbone, in which two of the acid groups have 
been replaced by amide functionality, were chosen as synthetic targets. The 
commercially available ligand DTPA 16 forms thermodynamically stable complexes 
(log -20-23) with lanthanides,5 but is not sufficiently lipophilic to be of use for 
perfusion studies. Also, as lanthanide complexes are dianionic, such complexes 
electrostatically attract cations. This renders the complex too unstable in vivo for many 
applications as the principle dissociation pathway is likely to be either proton or cation 
mediated.6 
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The amide groups co-ordinate to the metal via the harder oxygen, but do not affect the 
overall charge of the complex, on co-ordination to the metal ion. (Some charge 
delocalisation may occur however, as depicted in the scheme below (figure 2.1.) Thus, 
the acyclic complexes with two amides are charge neutral overall. In addition, the 
incorporation of the amides allows structural variation, through modification of the 
amide N-substituent. This in turn influences the lipophilicity of the complexes, which 
in turn is a prime consideration in the biodistribution of the complex. A low molecular 
weight is preferable, as smaller compounds may passively diffuse through biological 
membranes more easily, which should increase the amount of radiotracer extracted by 
cells on the first pass (i.e. the complex is removed from the circulation on the first 
encounter with tissues.) 
Figure 2.1. The charge on the metal ion may delocalise on co-ordination. 
The acyclic diamide ligands 31-34 were easily synthesised (figure 2.2.) by addition of 
slightly over two equivalents of the appropriate primary amine, to a stirred solution of 
diethylenetriamine pentaacetic acid dianhydride 25 in pyridine. The three amines 
employed were chosen to give a range of lipophilicities. N,N-Dimethylaminopyridine 
(DMAP) was used as an acyl transfer catalyst. The groups of Geraldes7 and Bligh8 
have simultaneously synthesised several similar ligands with a view to examining the 
charge neutral gadolinium complexes as MRI contrast agents. 
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Figure 2.2. The reaction of an amine with the dianhydride 25 afforded the acyclic 
ligands 31-34 
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A larger excess of 3,5-bis(trifluoromethyl)benzylamine was required to make the 
tetratrifluoromethyl ligand 34. The use of 2.2 equivalents of amine resulted in the 
formation of the monoamide 33. This would be expected to form monoanionic 
complexes with trivalent lanthanide ions. 
Macrocyclic Ligands 
The ligand, DOTA 17, is known to form stable complexes (log K j ^ - 23-29)with 
lanthanide ions.9 As with DTP A, the derived complexes are very hydrophilic, anionic 
and are rapidly excreted by the kidneys. The replacement of the carboxylic acid donors 
with the isosteric phosphinic acid moiety, allows the lipophilicity of the complex to be 
controlled. An alternative modification to the DOTA skeleton is the replacement of one 
carboxylic acid group with an amide. Complexes produced from these ligands would 
be charge neutral. The replacement of all four acid groups with amides affords 
tripositive complexes on incorporation of lanthanide ions. 
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The ligands 18, 35-40, based on the tetraazacyclododecane macrocycle 41 (cyclen), 
were synthesised using synthetic procedures10 established within the group. 
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The tetrabenzylphosphinate ligand 18 was synthesised by Miss Emma Smart, following 
the published procedure.10 The substituted tetraarylphosphinate ligands 35-38 were 
synthesised using a modification of the route, depicted in the scheme below for ligand 
36 (figure 2.3.) The Grignard reagent was made from the commercially available 
chloroaryl compound, except for the ortho derivative, for which only the benzyl alcohol 
compound is available. Functional group inter-conversion was achieved with thionyl 
chloride. The ligands 35 and 37 were synthesised by Dr Timothy Norman and Dr 
Stephen Faulkner respectively. The synthesis of the Grignard reagents for the ortho and 
para methoxy substituted benzyl phosphinates, had to be performed in tetrahydofuran, 
and the magnesium salts removed, by precipitation from benzene, before the Mannich 
reaction was attempted. 
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Figure 2.3. The synthetic scheme followed to produce ligand 36. 
The ligands comprising amides 39 and 40, were synthesised by Gareth Williams and Dr 
Timothy Norman. The monoalkylation of cyclen 41 is realised by the use of 
molybdenum hexacarbonyl. Three of the four nitrogens co-ordinate to the metal centre, 
permitting a nucleophilic reaction by the one left vacant (figure 2.4.) The synthesis is 
completed by alkylation of the remaining nitrogens. 
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Figure 2.4. The protection of three of the nitrogens of 41 leads to mono-
alkylation. 
The 13 membered cycle tetraazacyclotridecane (TRITA, 44), the homologue of DOT A 
was synthesised as a model cycle for developing C-functionalised complexing agents, 
which may be accessible more quickly than the C-functionalised DOTA ligands.11 
However, subsequent work within the group12 has resulted in a much abbreviated 
synthesis to bifunctional complexing agents, based on the tetraazacyclododecane 
skeleton. Lanthanide complexes based upon the DOTA framework possess greater 
42 
stability than the TRITA analogues, and so would be chosen in preference for in vivo 
targeting. 
The carboxymethylation of 1,4,7,10-tetraazacyclotridecane 21 was effected (figure 2.5.) 
by the addition of chloroacetic acid, in aqueous lithium hydroxide solution, whilst 
controlling the pH of the reaction. 
Figure 2.5. The synthesis of TRITA 44. 
2.3. Solution and Solid State Characterisation of Macrocyclic Complexes 
Complexes were formed by reaction of the ligand in aqueous solution with one 
equivalent of lanthanide salt, except for complexes made with the oxide (L^C^), where 
0.5 equivalents were added. 
The complexation gives rise to racemic chiral complexes, with all of the ligands. For 
the acyclic complexes the loss of symmetry results in the non-equivalance of the 
resonances of geminal protons, observed in NMR spectra. In principle, the macrocyclic 
complexes, derived from the tetraphosphinic acid ligands, could adopt any one of a 
large selection of stereoisomers. On binding a metal ion, a new stereogenic centre at 
phosphorus is created. Eight distinct combinations of phosphorus configuration are 
possible (i.e. RRRR, RRRS, RRSS, RSRS and their corresponding enantiomers). Also, 
the macrocyclic ring may adopt one of two conformations and the array of pendent arms 
may define a left or right handed helix. There are thus 32 possible stereoisomers. Of 
course, not all isomers will have the same conformational energy, and so certain 
diastereomers may be expected to dominate. 
The "cold" lanthanum complexes formed with the tetrabenzylphosphinic acid 18 and 
meta methoxy substituted ligand 36 gave two resonances in the proton decoupled 
phosphorus NMR spectrum, as shown in figure 2.6., below. This indicates the presence 
of phosphorus in two environments, in the ratio of approximately 8:1. 
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Figure 2.6. The 3 1 P{ 1H} NMR spectrum of [La(18)]", acquired at 25°C. 
On first inspection, it appeared as though further recrystallisation was required. The 
nature of isomerism in DOTA and related complexes of lanthanides has been 
investigated.13 As figure 2.7., below illustrates, two co-ordination modes are possible. 
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Figure 2.7. The diastereomeric relationships of DOTA complexes. 
Structures A and D are enantiomers, as are B and C. Enantiomers are indistinguishable 
by solution state NMR in achiral media, but it is possible to observe different spectra 
for diastereomers. As the topology of the chelating portions of the phosphinates is 
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identical to that of the carboxylates, it would seem reasonable to suggest that the two 
resonances observed by 3 1 P NMR have arisen from the presence of both diastereomers 
in the sample, rather than as a result of an impurity. 
The solid state structure of the corresponding yttrium phosphinate complex has been 
determined14 (figure 2.8.) and demonstrates the distorted inverted square anti-prismatic 
structure, illustrated by B and C in the scheme above. This is in contrast to the known 
structures of DOTA complexes (figure 2.8.), which all display the distorted square anti-
prismatic geometry, as in A and D above. Also, the complexes of DOTA are known to 
be nine co-ordinate, with a water molecule capping the face of the O4 donor set. The 
metal sits almost in the plane of the four hard acetate oxygens. The yttrium phosphinate 
complex has no metal bound water. This change in geometry between phosphinates 
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Figure 2.8. The structures of [Y(18)]"H30+ and [Y(17)]-Na+.2H20 obtained in 
the crystal. 
and carboxylates may be a result of the increased "bite size" (illustrated in figure 2.9., 
below) of the phosphinate chelates, enabling the pendent arms to bisect the corners of 
the square described by the twelve membered ring, rather than the sides. The exclusion 
of the water molecule from the inner co-ordination sphere of the metal for the 
phosphinate class of ligands is a result of steric crowding around the phosphorus atom, 
rather than the presence of the aromatic groups. This is inferred by comparison with the 
P-methyl complexes, which also display a marked decrease in metal hydration. 
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Figure 2.9. The phosphinic acid ligands offer a large "bite angle" to the metal ion. 
An X-ray analysis of crystals of the lanthanum tetrabenzylphosphinic acid complex 
[La(18)]" was performed by Miss Janet Maloney. The diffraction data obtained proved 
difficult to refine, but the metal geometry was determined with a high degree of 
confidence. A water molecule is clearly seen (figure 2.10.) occupying a ninth co-
ordination site on the lanthanum ion. The distorted inverted square anti-prism 
characteristic of the yttrium complex is retained, however. 
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Figure 2.10. The structure, in the crystal, of [La(18)]" 
The occurrence of the two resonances in the phosphorus NMR spectrum is not 
explained by the crystal structure result alone. It seems quite plausible that the complex 
may convert between the two geometries. At elevated temperature, one shaip resonance 
is observed by NMR, consistent with higher C 4 symmetry. On cooling, the same 
sample shows the original spectrum. This clearly indicates a reversible process. Two 
possible changes in structure can be envisaged i) the water molecule is in slow 
exchange with the metal centre or ii) the complex is twisting, converting from square 
anti-prismatic to the inverted square anti-prismatic geometry. This second explanation 
is much more likely. Oxygen-17 NMR experiments with macrocyclic gadolinium 
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complexes have demonstrated,15 by measuring relaxivities of nuclei, that the exchange 
of water molecules is far too fast (>107s_1) to be observed by NMR. Additional support 
for the idea of a reversible change in geometry is presented by the proton NMR spectra 
acquired at 25° and 80°C, which show (figure 2.11.) that the diastereotopic N C H 2 P 
methylene protons coalesce at high temperature. 
r 
J 
Figure 2.11. *H NMR spectra of [La(18)]" acquired at 25°C (bottom) and 80°C 
(top). 
A variable temperature experiment was performed on the complex La[18]", to probe the 
kinetics of the change in co-ordination geometry of the metal centre. A Phosphorus-31 
spectrum was acquired at 10° intervals between 0 and 80°C. 
30°C 
40°C 
50°C 
60°C 
70°C 
80°C 
70°C 
60°C 
50°C 
40°C 
30°C 
18°C 
Figure 2.12. Overlaid 3 1 P { 1 H } spectra of [La(18)]", acquired at 10° intevals. 
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From the spectra (figure 2.12.), an approximate coalescence temperature (T c) of 333K 
(60°C) was determined. The rate constant, k p can be calculated from the full width, at 
half height (Av), of the converged peaks, thus: 
k r = 7iAv/V2 = 179.9Hz 2.1. 
This value was entered into the Eyring equation (2.2) after rearranging (2.3) to give the 
activation energy AG*. 
k c = (kBT/h).exp(-AG*/RT) 2.2. 
AG* = RTc(ln ke/h + In V k r ) = 67.5 kJ mol"1 2.3. 
(where kg = Boltzmann Constant, R = molar gas constant, h = Plancks constant) 
Of course, this represents only an estimate, as the analysis is based upon the assumption 
that the two interconverting forms are of the same energy. One isomer is clearly present 
in ah 8:1 excess at room temperature. However, the value obtained is reasonable and 
shows the barrier to the twisting motion is comparable to the hindered rotation of the 
DOTA complex, [Nd(17)]". The published 1 3 C variable temperature spectra16 exhibit a 
lower coalescence temperature of 45°C, and by the above calculation, AG* is found to 
be -60 kJ mol - 1 . 
A more rigorous analysis is difficult to achieve with this system, due to the poor 
separation of the resonances. The rate constant can be calculated from equation 2.4.,16 
where 8v is the difference in frequency between the resonances of A and B, the 
interchanging structures, k^ is the rate constant of the conversion of A to B and k B is 
the rate constant of the reverse process. The fractional populations of the two structures 
are represented by p^ and p B . 
Av = 47TpApB(§V)2 
k A + k B 2 4 
The determination of the average rate constant at several temperatures permits the 
graphical determination of the activation energy. To achieve a reasonable value with 
this complex would require the aquisition of several lower temperature spectra, to give 
the enhanced separation necessary for an accurate determination of the population of 
each structure. 
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Assignment of Proton NMR Spectra 
9 9-H t OMe H 
C r ^ O H Or OH OH u H Lb 
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Figure 2.13. The atom labelling scheme used for [La(18)]~ and [La(36)]" 
A detailed assignment of the proton spectra for the [La(18)]" and [La(36)]" complexes 
has been made. The lH NMR spectra of the two lanthanum complexes display a 
marked similarity (Figure 2.14.). This behaviour can be contrasted with that observed 
for the related yttrium complex,10 [Y(18)]\ A doublet of doublets (appears to be a 
triplet) at &h = 2.72ppm in the *H spectrum of the yttrium complex, has no 
7VXJ 1 
4.0 3 .B 3 .6 3.4 3 .2 3 .0 2 .8 2 .6 2.4 2 .2 2.0 l . B ppm 
Figure 2.14. Partial lH NMR spectra of macrocytic phosphinate complexes. 
[La(18)]", top, [La(36)]- and [Y(18)]", bottom. 
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corresponding peak of similar shift in the spectra of the lanthanum complexes. This 
peak is attributed to one of the diastereotopic N C H 2 P protons w and x (letters 
correspond to the labelling scheme of figure 2.13.), the other resonating at ~2.4ppm in 
complexes of both cations. The corresponding methylene proton can be identified in 
the lanthanum complex by acquiring a proton spectrum, whilst irradiating the sample at 
the frequency corresponding to the phosphorus signal. This phosphorus decoupled 
spectrum, ^ H f ^ P } , below) has lost all coupling information to phosphorus. The 
hydrogens nearest to the phosphorus atoms are noted by inspection of the two spectra. 
The NCH2P protons, w and x, are found at 2.5 and 3.6ppm. This represents a change 
J 
7 6 5 4 3 2 ppm 
Figure 2.15. Proton spectrum of [La(36)]", top, and the spectrum acquired with 
phosphorus decoupling. (The difference in chemical shift, is an effect 
of the different concentration of ammonium acetate in the samples.) 
in chemical shift of 0.9ppm for one of the protons, as a result of changing the metal ion. 
The benzylic protons, y and z, are isochronous, resonating at 3.3ppm. The four 
remaining resonances, of the ethylene bridges, in the cycle can be assigned partially. 
The lower frequency doublets at 2.1 and 2.3ppm are the resonances of the 
pseudoequatorial protons, t and u. The 2.1 resonance is coupled, as determined by a 
correlation experiment, to the multiplet at 3.5ppm. Similarly, the resonance at 
2.3ppm is coupled to the resonance at 3.6ppm. 
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Clearly, the presence of the water molecule, observed in the crystal, is having a 
substantial effect on the rest of the complex, as illustrated by the contrasting spectra for 
the lanthanum and yttrium complexes. 
Solution Structure of the [La(TRITA)]' Complex 
The structure of the lanthanum DOTA complex, determined by solution state NMR has 
been reported.17 The incorporation of the methylene bridge into the 13 membered cycle 
destroys the fourfold symmetry of the complex, and hence renders all 26 protons non-
equivalent. The assignment of the peaks in the proton NMR spectrum is, thus, a much 
more difficult task. For the DOTA complex only 6 resonances are observed, as 
depicted in the projection, figure 2.16. below. The chemical shifts of the protons are 
given in parts per million, relative to tertiary butanol, SJJ ( D 2 O ) = 0.90. 
2.70 
2.20 
y r 
1 * 
H 
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3.15 
H 2.78 
o 3.45 
Figure 2.16. Assignment of the proton resonances in [La(DOTA)]" 
To simplify the problem of assigning the peaks for the [La(TRITA)]" complex, it was 
assumed that the three five membered chelate rings adopt similar conformations to the 
four five membered chelates oflhe DOTA complex. The six membered chelate must 
adopt a twisted boat conformation, rather than the symmetric chair, otherwise the five 
membered rings would be forced to adopt high energy conformations, with eclipsing 
interactions. The atom labelling scheme used is defined in figure 2.17. 
g H 
H N H 
H N J N H La 
H H 
> l j m H 
H n 
d 
Figure 2.17. The atomic labelling scheme used for [La(TRITA)] 
51 
The COSY spectrum ^ H ^ H correlation) is shown in figure 2.18. The methylene 
protons resonate at 1.73 and 1.80ppm. It is difficult to attribute the peaks to either a or 
b as both are in a somewhat intermediate position between axial and equatorial. A 
crosspeak is observed between the methylene 1.73 and the two pseudoequatorial 
protons, c and/, at 2.5ppm. Geminal couplings are detected to resonances at 3.0 and 
3.2ppm - thus identifying the pseudoaxial d and e. i 
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Figure 2.18. 1 H- 1 H correlation spectrum of [La(TRITA)]" 
The study by Aime et al reported a 16.6Hz coupling between the acetate protons, 
resonating at 2.78 and 3.45 ppm.17 However, no coupling is seen between the two 
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resonances at 2.8 and 3.4ppm, which are attributed here for the TRITA complex to the 
resonances of the corresponding acetate protons. The temperatures of acquisition of the 
two spectra were different. The DOTA complex was analysed at -3°C, whereas the 
TRITA complex was acquired at room temperature. The acetate arms of DOTA are 
known to concertedly slide over the surface of the metal ion in a reversible process, a 
conversion which is facilitated at elevated temperatures. Such an exchange process 
removes the non-equivalence of the acetate protons, hence the signals coalesce, but does 
not affect the ring conformation. Thus, the lack of geminal coupling is consistent with 
the presence of a fast exchange process on the NMR timescale. The resonances at 2.8 
and 3.4ppm can thus be assigned to the two sets of acetate protons. 
The remaining resonances of the three sets of four ethylenic protons can be found at 
2.4-2.6, 2.9, 3.2 and 3.4ppm, corresponding to g, h,j and k. It was not possible to 
assign each of these resonances from the COSY spectrum, although, by analogy to the 
DOTA assignments of figure 2.16., it might be expected that the higher frequency 
signals arise from the pseudoaxial protons. 
NMR Dispersion Studies of Gadolinium Complexes 
As mentioned in the introductory chapter (paragraph 1.2., page 6.), stable gadolinium 
complexes are clinically useful as contrast agents in MRI imaging. On co-ordination to 
gadolinium, a decrease in the water proton longitudinal relaxation time of the order 106 
is observed.15 The change in relaxation rate affects the intensity of the signal. Most 
often, a T j weighted image is obtained (Tj is the longitudinal relaxation time, as 
opposed to T 2 , the transverse relaxation time.) The longitudinal relaxivity of the 
complex is the difference between Tj" 1 , when measured both in the presence and in the 
absence of the complex. There are two components to the longitudinal relaxivity, Rj , 
namely the inner and outer sphere mechanisms (is and os respectively). Ligands in 
contact with the paramagnetic centre are said to be in the inner sphere. Longer range 
interactions fall into the outer sphere category. The total relaxivity is the sum of both 
components. 
R l = R l i s + Rlos 2-5-
The inner sphere contribution, R^ , is proportional to the number of water bound 
molecules, q. Hence, for the gadolinium tetraarylphosphinate complexes, this term 
approaches zero. The outer sphere contribution can be described by Freed's equation:18 
R l o s = k . (C / aD). /(T s, t D , con, U) s) 2.6. 
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Where k is a collection of constants, C is the molar concentration of complex, a is the 
distance of closest approach between the water molecules and the paramagnetic 
gadolinium centre. The constant D is a measure of the relative translational diffusion of 
solvent and solute, and G>H and are, respectively, the proton and electron Larmor 
frequencies. The remaining parameters t j ) and %$ are defined by: 
x D = a 2 / D 2.7. and 
V 1 = _L 1 
1 + U ) S 2 T V 2 1 + 4C0STV^ 2.8. 
where x^o is m e electronic relaxation time at zero field and x v is the correlation time of 
the interaction. 
A plot of relaxivity against the proton Larmor frequency (which is field dependent) is 
called a nuclear magnetic resonance dispersion profile (NMRD). Analysis of such plots 
facilitates the determination of the parameters ?$q and T v , above. 
A representative profile, obtained by the group of Professor Silvio Aime in Turin, for 
the complex [Gd(36)]" is shown below in figure 2.19. The profile is similar to that 
obtained for the tetrabenzylphosphinate [Gd(18)]" complex, also shown. An imaging 
study with the [Gd(18)]" has been performed showing promise as a contrast agent for 
imaging the gastrointestinal tract. Biliary clearance of the intact complex has been 
demonstated in the rat.19 
R l 5.0 
n n 
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Figure 2.19. The NMR dispersion profile of [Gd(36)]", solid line and [Gd(18)]' 
dashed line. 
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The parameters derived from such plots for [Gd(18)]~,14 [Gd(35-36)]", acquired by the 
Turin group, are reproduced in table 2.1., below. The data show that the complexes 
have quite similar properties, with respect to application as MRI agents. The presence 
of the methoxy groups has no influence on the distance of closest approach between 
water molecules and the metal centre. 
Complex T s o /ps T v/ps a/A DxlO 5 / cmV 1 
[Gd(18)]- 71.0 11.5 4.25 2.0 
[Gd(35)r 102 16.4 4.25 2.4 
[Gd(36)]- 115 10.3 4.25 2.4 
[Gd(37)]" 146 13.3 4.25 2.4 
Table 2.1. Parameters obtained from NMRD measurements to give the best fit to 
Freed's equation (2.5.) 
Luminescence Studies of Terbium Complexes 
In principle, the use of luminescent markers appended to biological molecules enables 
the monitoring, in real time, of cellular events by fluorescence microscopy. 
Luminescence, the absorption of light followed by emission at a lower energy, may be 
divided into two main processes, illustrated on the diagram, figure 2.20. below. 
l 
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8 Radiative decay 
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Figure 2.20. Energy level diagram showing some luminescent decay pathways 
Fluorescence - Energy is absorbed by the sample, which populates an excited state, Sj. 
Energy is rapidly lost, by molecular vibrations, until the lowest energy level of the 
manifold is reached. The radiative decay from this level, is termed fluorescence and is 
"allowed" by the selection rules governing transitions. 
Phosphorescence - If a molecule has a triplet state energy level, similar in energy to that 
of the excited singlet state, intersystem crossing can occur. Energy is then lost until the 
lowest level of the triplet state, T j , manifold is achieved. The radiative loss of energy 
from a triplet state, to the ground (singlet) state is a "forbidden" process, and, hence, 
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occurs slowly. This process is termed phosphorescence. The lifetime of an excited 
state which decays by phosphorescence may be several orders of magnitude longer than 
one decaying by fluorescence. 
Other radiationless decay pathways exist, such as molecular collisions and energy 
transfer to proximate energy matched OH, NH and CH oscillators.20 These processes 
are not illustrated on the above diagram. The parameters which characterise the 
luminescent behaviour of molecules are the lifetime, x, wavelengths of excitation, X e x , 
and emission, X, e m , and the quantum yields, 0, of each process. 
For use in immunoassay procedures, it is essential that the light emitted by the marker 
molecule is distinguishable from the emissions of other chromophores in the system 
under study. In particular, proteins exhibit fluorescent behaviour. Therefore, the use of 
phosphorescent marker molecules, possessing extended lifetimes, allows a time-gated 
approach to be used. For example, excitation of a sample, containing both fluorescent 
and phosphorescent molecules, with light of 254nm wavelength, causes chromophores 
to achieve a state of higher energy. Those decaying by fluorescence emit energy 
rapidly (lO^-lO^s) whereas excited states, decaying by phosphorescence, emit light 
over a longer period (10"6-10"3s). Thus, i f measurement of emitted light is not 
commenced until a few microseconds after excitation, only phosphorescent decay is 
observed, free from all contaminating fluorescence decay. 
Many lanthanides, in particular, europium and terbium, feature the overlap of energy 
levels of different spins. This enables efficient intersystem crossing, and 
phosphorescence is commonly observed for lanthanide ions. However, the presence of 
water molecules provides a non-radiative decay pathway for quenching the excited 
state. Incorporation of the lanthanide ion in a complex offers a means to exclude water 
molecules, and, hence, reduce the radiationless decay. In addition, the presence of 
chromophore antennae has been shown 2 1 to increase the luminescence observed by the 
efficient transfer of energy from the chromophore to the metal ion. As detailed above, 
the yttrium complex of the tetrabenzylphosphinic acid ligand, possesses no metal bound 
water. The ionic radius of the yttrium(III) ion is similar to that of europium(III) and 
terbium(III) and so these complexes too might be expected to have no metal bound 
water, and, hence, long lifetimes. 
The rate constant of luminescence decay has additive components from all of the 
relaxation modes. By comparing the lifetimes of complexes in both water and 
deuterium oxide, the effect of relaxation by the solvent can be estimated and the number 
of inner sphere water molecules inferred. The stretching vibration of the O-H bond 
provides a quenching mechanism for the non-radiative decay of the excited ion because 
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of the similarity in energy of the two processes. This process is reduced on isotopic 
substitution of water, as the O-D stretch is of a different energy. Simply substitution 
into the expression, equation 2.9., provides the estimate. 
q = A L n - ( T : H 2 0 " 1 - ^ D 2 0 " 1 ) 2-9-
Where A L n is a proportionality constant, derived empirically for each lanthanide 
(Ajb=4.2ms, AE u=1.05ms) and x is the lifetime determined in the particular solvent. 
The luminescence properties of the terbium complexes formed by the methoxy 
substituted ligands, Tb[35-37]" were measured, in both protiated and deuterated water, 
by Gareth Williams, and the results tabulated below. The data, acquired at 298K, are 
similar in nature with those obtained with the tetrabenzyl complex Tb[18]", and are 
HOoC 
2 HO,C 
C J 
C0 2 H ' 
COoH 
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consistent with the absence of a water molecule in the inner co-ordination sphere. In 
comparison, the [Tb(45)]" complex has approximately one metal bound water molecule. 
The data for the five complexes are tabulated in table 2.2., below 
Complex x(D 20)/ms T(H20)/ms <t>(D20) <KH 20) q 
[Tb(45)]- 2.03 1.4 0.9 
[Tb(18)]- 4.44 4.13 0.49 0.44 0.07 
[Tb(35)]" 4.33 4.08 0.52 0.44 0.09 
[Tb(36)]- 4.42 4.08 0.46 0.40 0.08 
[Tb(37)]" 4.32 4.00 0.08 0.07 0.07 
Table 2.2. Luminescence properties of terbium complexes. T = 298K, 
X e x = 250nm for [Tb(45)]' and [Tb(18)]\ Xex = 278nm for methoxy 
substituted complexes [Tb(35-37)]", X e m = 545nm. 
The phosphinate complexes, except [Tb(37)]", have very high quantum yields - for 
every five photons absorbed by the aromatic groups of the complex, two lower energy 
photons are returned. Indeed, [Tb(35)]" has the highest quantum yield reported to date. 
The lifetimes of over four milliseconds are also very high, and should permit their 
application to time resolved photoimmunoassay studies. The poor solubility of the 
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complexes (and of the corresponding europium complexes) may, however, limit their 
application. 
2.4. Lanthanum-134 for PET Studies 
The characteristics of lanthanum-134 fu l f i l the requirements necessary for use in 
perfusion studies. The mean circulation time in man is approximately two minutes. 
The half-life, of 6.7 minutes, is thus appropriate to the time frame of the study 
proposed, and is also short enough for repeated measurements to be taken, at brief time 
intervals. Lanthanum-134 has a high positron yield (62%), and can be produced in a 
no-carrier added form, loosely termed "carrier-free," from a generator. The electron 
capture decay of 1 3 4 L a does not lead to additional frays and so the image quality and 
quantitation is not compromised. 
Synthesis and Isolation of Lanthanum Radioisotopes 134La and 140La. 
For use as a blood flow tracer, it is important that as little complex is administered to 
the patient as possible. This is to eradicate any influence the complex may have on the 
system under scrutiny. It is, therefore, essential that the radionuclide to be used is 
available in high specific activity (i.e. a large amount of activity per unit mass.) A 
radionuclide, which is found in the absence of any other atoms of the same element is 
described as "carrier free" and has a very high specific activity. This is the optimum 
purity achievable for a radionuclide, and can be attained, only i f the nuclide is produced 
from another element. This then allows a chemical separation to remove the 
radionuclide from the sample it was produced from. (A process of enrichment can be 
used, whereby isotopes may be separated by a physical process such as diffusion, but 
this is a slow process, and only applicable to long lived or stable isotopes.) The 
preferred method for separating metal ions is by the use of chromatography. 
Lanthanum-134 is produced from the unstable parent cerium-134 by an electron capture 
decay process. Cerium-134 (ty2=3-2 days, E.C., X-ray=33-38keV) decays, to produce 
the desired lanthanum-134 (tj/2=6.7 minutes, P+, 7^ =51 IkeV, 62%). This generator is 
convenient because the generator has a shelf-life of around two weeks, which is 
acceptable to the clinic. The low energy emissions of the parent cerium reduce the 
amount of shielding necessary and lower the radiation dose to personnel. This is 
important as the short half-life may necessitate portability of the generator, for bedside 
delivery of the radionuclide. 
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Cerium-134 can be produced by several methods. Two methods involve bombardment 
of enriched barium targets with ot-particles, viz. 1 3 2 B a (oc, 2n) 1 3 4 Ce and 1 3 4 B a (a, 4n) 
1 3 4 Ce. These reactions require expensive, enriched targets and rare, high energy a-
particle beams. An alternative approach is the 1 3 9 L a (p, 6n) 1 3 4 Ce reaction. The target, 
lanthanum oxide in natural isotopic abundance, is much cheaper, avoiding the 
inconvenience and expense of recycling precious enriched targets. A slight 
disadvantage of this production route is the necessity of a high energy (>60MeV) proton 
source. However, the sufficiently long half-life of 1 3 4 Ce allows production and 
delivery from a remote site. The cerium-134 is isolated by chromatography, after 
dissolving the target in nitric acid. The cerium decays as depicted in the scheme below. 
1 3 4 Ce ^ - 1 3 4 L a ^ — ^ 1 3 4 B a 
Ai A 2 
The lanthanum-134 is removed from the generator, as required, by chomatography on 
manganese dioxide, eluting with a 0.9 mol dm"3 sodium chloride solution. The 
cerium(IV) is retained on the column and continues to decay to the daughter lanthanum, 
whilst the lanthanum(IH) ion is eluted. The delivery of the radionuclide in salted water 
is attractive for potential kit formulation. 
The amount of lanthanum-134 activity, A2, can be calculated from the initial cerium 
activity, A j , and the decay constants X\ 2 ° f t n e t w o decay steps, at time, t, using the 
equation (2.10.) below. 
A 2 = Xl AjfexpC-Xjt) - exp(-A,2t)} 
^ 2 - ^ 1 _ ^2.10. 
The short half-life of lanthanum-134 makes it difficult to do development work. For 
this reason lanthanum-140 (tj/2=40 hours) was chosen for experiments to evaluate the 
potential of the lanthanum complexes synthesised. Lanthanum-140 is produced by 
irradiating natural lanthanum-139 oxide with a neutron beam. The excess energy is 
liberated as y-radiation. The reaction may be described therefore as 1 3 9 L a (n, y) 1 4 0 L a . 
The lanthanum produced is described as "carrier added" as there are atoms of 1 3 9 L a as 
well as 1 4 0 L a in the sample. The ratio of isotopes found varies with the parameters 
used for the irradiation, but typically there will be a 106-109 fold excess of cold 
lanthanum-139. 
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.5. Radiolabelling Studies 
The labelling efficacy of the ligands was determined using carrier added lanthanum-
140. Radiolabelling was attempted for twelve ligands, by adding a ligand solution 
(O.Olmol dm"3) to an equimolar lanthanum-140 chloride solution. The pH was 
modified by addition of sodium hydroxide. The solutions were mixed with a vortex 
shaker, and then analysed by HPLC with radiometric detection. The results of the 
radiolabelling are summarised in table 2.3., below. 
Ligand PH temp /°C time /min yield /% 
17 7.0 25 10 70 
18 8.0 25 30 100 
31 6.6 25 60 <10 
32 7.6 25 10 90 
33 5.6 25 10 100 
34* 6.0 25 10 100 
35 6.6 25 30 60 
36 9.4 25 60 60 
37 0 
38 0 
40 9.1 25 30 70 
Table 2.3. Radiolabelling yields obtained for the acyclic ligands 31-34 (page 40) 
and macrocyclic ligands 17,18,35-38 and 40 (page 41). Ligand 
concentration = 0.01 mol dm"3. pH was controlled by addition of 0.1 
mol dm"3 sodium hydroxide solution. The optimum yields are 
reported. 
*The solution of ligand 34 was prepared using a 50% aqueous ethanol 
solution, as the ligand was insoluble in water. 
The insolubility of ligands 37 and 38 may explain the poor labelling yields obtained. 
The macrocyclic ligands 17,18,35,36 and 40 labelled well. Ideally, quantitative 
labelling, within one half-life, would be sought for ligands to bind lanthanum-134. 
Some of the ligands above take a good deal longer than this, but it should be 
remembered that when carrier-free quantities of activity are used (10" 9-10' 1 2 mol dm"3) 
a great excess of ligand (10"6mol dm"3) is used and a faster rate of labelling might be 
expected. 
The acyclic diamide ligands labelled very well except for the tertiary butyl amide 31. 
This poor labelling is difficult to explain from a steric point of view, as the bulky 
groups are able to move out of the path of the incoming metal ion. An assumption was 
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made that this particular ligand crystallised as a triammonium salt, but a satisfactory 
microanalysis has not been obtained. 
.6. Evaluation of Lanthanum Complexes as Perfusion Tracers Using PET 
The need for determining blood flow in patients for therapeutic gain, was outlined in 
paragraph 1.4. above. There are a number of methods which are used to measure 
perfusion.2 2 A brief outline of the methods follows: 
Laser Doppler Flowmetry (LDF) - This method is an invasive technique, which 
provides a direct measure of blood flow. Coherent light from a helium-neon laser 
(A,=633nm) is delivered to tissues, via an optical fibre, introduced through a plastic 
cannula. LDF measures the mean velocity of erythrocytes, by measuring the Doppler 
shift. This is used to calculate perfusion, by comparison with measurements under 
different physiological conditions, within a specific tissue type. 
Thermodynamic Methods - Heat flux to a constant temperature heat sink, provides a 
means to determine perfusion. The flow of heat is measured and related to the oral and 
surface temperature of the patient. The method is subject to large errors, and although 
not invasive, the technique can influence the blood flow, as the tissue under 
investigation is either heated or cooled, depending on the temperature of the heat sink. 
Magnetic Resonance Imaging (MRI) - The high spatial resolution, attainable with MRI, 
allows a detailed study of the heterogeneity of tumour blood flow. To achieve good 
images, a fairly large dose (0.2 mmol kg"1) of a contrast agent, such as [Gd(DTPA)]2", 
is administered to the patient The presence of the complex, however, may affect the 
flow. 
Radionuclide Techniques - The washout of xenon-133, injected interstitially into 
tumours, can be followed by a scintillation detector, and correlated with perfusion. 
However, the resolution obtained is poor, and the trauma of injection may deem the 
assumption of a steady state redundant. The use of 9 9 m Tc-HMPAO and radiolabeled 
microspheres have been used to evaluate tumour perfusion with SPET. The use of 1 5 0 -
water has allowed the use of PET to study blood flow. It is hoped that the lanthanum-
134 complexes studied herein may be useful for providing similar information, for sites 
remote from a cyclotron. 
It would be clinically desirable to be able to determine the relative blood flow, in any 
region of the body, directly from the computer, processing the information, from the 
PET scanner. In principle this is almost possible, i f we assume the complex is extracted 
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into tissues on the first pass through the circulation. The model below 2 3 describes an 
estimate of blood flow, in tissues of low to moderate flow, by a single measurement of 
tissue uptake and an arterial blood sample. 
The model assumes that the tracer becomes trapped after tissue extraction, i.e. does not 
re-enter the circulation. 
The uptake of tracer, Q, over a period of time is given by: 
Qtissue = t^issue • ^ tissue • J -^arterial (t) dt 2.11. 
where Qtissue * s t n e tissue uptake, in cpm g"1, F t i s s u e is the flow through the tissue, in ml 
min"1 g"1, E t i s s u e is the tissue extraction, and is the blood concentration of the 
tracer, in cpm ml" 1 . Similarly, for the whole body, wb: 
Qwb = F wb • Ewb • J Carterial (0 dt 2.12. 
F w b , the whole body flow, is, of course, equivalent to the cardiac output. The whole 
body uptake of tracer, Q w b , can be expressed in terms of the activity administered, Q^j: 
Qwb = Q i n j ( l - B ) 2.13. 
where B is the activity which is retained in the circulation. By combining the above 
equations, an expression relating tissue blood flow, F t j S S u e to cardiac output, F w b , can be 
derived: 
Fwb = t^issue • ^ tissue • Qinj • (1 * ^ ) / Qtissue • ^ wb 2.14. 
A reference organ is provided by an arterial blood sample, for which the extraction, 
E , . e f , is unity. Substitution gives: 
Fwb = F r e f - Q i n j - ( l - B ) / Q r e f . E w b 2 - 1 5 -
Combining 2.11. and 2.12.: 
Ftissue = Qtissue • Fwb • F\vb ^ Qwb • ^ tissue 2.16. 
and substituting equation 2.15. gives: 
Ftissue = Fref • Qtissue ^ Qref • ^ tissue 2.17. 
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I f we apply the assumption that the tracer is extracted on the first pass, then the term 
^tissue * s u m t v > leaving the desired relation: 
tissue - Ffef • Qtissue ^ Qref 2.18. 
The reference arterial flow, F r e f , and the uptake by the reference, Q-ef, are given by the 
arterial blood sample. (The radiotracer must be extracted from the blood sample, prior 
to counting, otherwise protein bound and free radioactivity from dissociation of the 
complex wil l be counted, as well as the intact complex. This would give an 
overestimate of the amount of complex left in the blood. As lipophilic complexes are to 
be used, a simple extraction into n-octanol permits easy counting of the complex 
activity.) The tissue uptake, Qtissuc * s determined by the PET study, to give the 
required tissue blood flow, F^^g. The assumption that the extraction is first pass, is 
not applicable to high flow organs, and so the simplification of equation 2.17 cannot be 
justified. However, there is evidence that the relationship models perfusion in moderate 
to low flow organs, as determined by comparison with other perfusion methods. 
To produce an accurate representation of blood flow, for the whole body, it is required 
that the complex shows little specificity for one tissue over another. This is a very 
difficult ideal to achieve. The charge, molecular weight and lipophilicity affect the 
biodistribution profile exhibited by agents introduced to the body. For example, 
lipophilic cationic complexes show a propensity to localise in the heart, whereas 
hydrophilic anionic complexes are rapidly excreted by extraction into the kidneys. The 
best (most promising) perfusion imaging agents are small, lipophilic charge neutral or 
cationic complexes, as exemplified by 1 and [Cu(4)]. 
CNR 
RNC'.„ 1 CNR 
RNC*"~ | °^*CNR 
CNR 
OMe 
1 
Me. ,
N=< 
NHMe 
| Cu 
N=< 
NHMe 
[Cu(4)] 
The ligands used to form lanthanum complexes allow a systematic study of the effect of 
variation of lipophilicity, mass, and charge. The variation in the number of amide and 
acid donor groups permits control over the charge. The pendent amis confer differing 
lipophilicities upon the complexes. However, the incorporation of hydrophobic groups, 
results in an increase in the molecular mass of the complex. A compromise has to be 
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made, between the low mass required for efficient uptake into some organs, in 
particular the brain, 2 4 and a high lipophilicity for extraction into cells. 
Partition Coefficient Measurements of Lanthanum Complexes 
The lipophilicities of the radiolabeled complexes were determined by partitioning the 
complex between an aqueous phase (0.15mol dm"3 sodium chloride) and an organic 
phase (n-octanol). The amount of radioactivity associated with each phase is counted 
and the lipophilicity is quoted as a log P value, where: 
P = (activity in organic phase) / (activity in aqueous phase) 2.17. 
The lipophilicities of the complexes are tabulated below (table 2.4.) 
La Complex log P La Complex log P 
31 -4.13 32 -1.51 
39 -3.28 33 -1.06 
17 -2.51 18 0.08 
40 -2.35 36 0.08 
LaCl 3 -1.72 35 0.49 
34 1.62 
Table 2.4. The partition coefficients of lanthanum complexes. 
As expected, the phosphinate and fluorine containing complexes show a higher 
propenisty to accumulate in the organic phase. The difference between the tertiarybutyl 
31 and isobutyl amide 32 ligands was unexpected - as was their differenUabelling 
abilities. A crystal structure of the yttrium complex of a DTPA bis amide has been 
determined25 showing that the amides co-ordinte datively to the metal, rather than 
ionically. An argument that the amides may cleave could be constructed, based on a 
potential relief of steric strain, but no evidence of this was detected by mass 
spectrometry of the "cold" complexes. 
In Vitro Studies of Lanthanum Complexes 
The behaviour of the acyclic lanthanum complexes with human sarcoma cells was 
investigated in vitro, to determine the level of cellular uptake compared with lanthanum 
chloride. The time points of 5 and 30 minutes were chosen as they are most appropriate 
to the time frame of the perfusion experiment. The complexes were incubated with the 
cells in the cell growth medium at 37°C. The suspension was then centrifuged to 
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separate the cells from the supernatant, the cells were then washed twice. The amount 
of radioactivity associated with the cells was compared to that measured in the 
combined supernatant (table 2.5.). No attempt was made to determine whether the 
complex had entered the cell, or was attached to the cell surface. 
La Complex %in pellet 5mins %in pellet 30mins 
LaCl 3 98 98 
31 4 20 
32 1 12 
33 52 58 
34 16 72 
Table 2.5. Cell uptake measurements for the acyclic [1 4 0La(31-34)] complexes, 
compared with 1 4 0LaCl3 
The results show that the most lipophilic complexes are indeed taken up by the cells 
more quickly than their hydrophilic counterparts. The increase in uptake with time 
suggests that a more subtle mechanism than merely an electrostatic interaction, may be 
involved. A purely electrostatic interaction would be diffusion controlled, and certainly 
complete by the first time point. The uptake value for the [La(34)] complex is very 
encouraging. The complex becomes associated with the cells fairly quickly and 
continues to be extracted until almost all activity is bound to cells. The free 
lanthanum(III) aquo ion becomes bound rather quickly. Again this could be the result 
of an electrostatic attraction to the acidic residues found in gangliosides in the cell 
membrane. It is also possible that channels for the active uptake of calcium, are 
providing a cellular uptake pathway. This hypothesis could be tested by repeating the 
measurement after blocking such channels. 
In Vivo Profile of Some Lanthanum Complexes 
The biodistribution profile of three of the complexes was determined, in adult hooded 
rats. The [La(18)]\ [La(35)]" and [La(34)] complexes were selected on the basis of 
their high lipophilicities, and the interesting high uptake of [La(34)] with the cells in 
vitro. The choice of timepoints was made as they are the most relevant to the half life 
of lanthanum-134, and the time frame of perfusion studies. Unfortunately, the lack of 
availability of suitable animals negated the evaluation of the [La(34)] complex at 15 
minutes. 
Rats weighing 160-280g were anaesthetised, by Dr P. Carnochan, with a 1% mixture of 
halothane and oxygen, delivered using a commercial vaporiser system. The complexes 
were administered by rapid intravenous infusion, to the surgically exposed right jugular 
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vein. Animals were killed, whilst under anaesthesia, by cervical dislocation. Organs 
were removed by dissection, weighed and then counted in an autogamma counter. The 
data from the tissue dissections are given in table 2.6., as percentage of injected activity 
(%i.a.) per gram of organ, after normalisation to a 250g rat. The results represent an 
average from three animals, except for the [La(18)]", where only two were available for 
the 15 minute timepoint. 
%i.a/g-1 of tissue 
LaCl 3 [La(34)J [La(18)]- [La(35)]" 
organ \time 5 min 5 min 5 min 15 min 5 min 15 min 
Blood 0.09+D.01 0.49+0.01 0.35±0.05 0.09+0.00 0.3110.07 0.0910.02 
Heart 0.4310.06 0.65+0.14 0.25+0.01 0.11+0.03 0.1610.03 0.0810.01 
Brain 0.16+0.02 0.23±0.13 0.09±0.00 0.10±0.02 0.0610.01 0.06+0.00 
Liver 2.31±0.80 8.86±2.89 2.39±0.01 0.96+0.04 3.1310.58 1.3910.15 
Kidney 0.68+0.07 1.39+0.54 1.21±0.35 0.18±0.01 0.7310.29 0.1710.02 
Muscle 0.04±0.03 0.16+0.06 0.10+0.02 0.0310.00 0.1010.02 0.0310.01 
Spleen 3.57±1.87 7.06+1.00 0.18±0.01 0.1610.01 0.5110.15 0.4310.08 
Skin 0.47+0.12 0.38±0.04 0.3810.10 0.3010.02 
Intestine* 0.09±0.03 0.83±0.81 4.06+0.25 4.34+0.50 2.5711.21 4.7612.84 
Lungs 45.8±16.1 16.0±9.07 1.33±0.34 0.73+0.15 0.6610.11 0.3110.05 
Stomach 0.27±0.37 0.27+0.03 1.1010.09 0.1210.02 
Table 2.6. The biodistributions of lanthanum complexes. *The contents of the 
intestine were removed for the macrocyclic complexes [La(18)]" and 
[La(35)]" but not for LaCl3 and the complex [La(34)]. 
The macrocyclic complexes show a rapid clearance via fhebiliary_system. This is 
characterised by high and increasing liver and intestine uptake at the early timepoints. 
This behaviour is very similar to that of the corresponding gadolinium complexes.19 
However, whereas imaging of the gastrointestinal tract is sought after in MRI, the rapid 
biliary clearance observed here is not suitable for application to perfusion studies, 
where it is hoped the complex might become trapped in a quantitatively useful manner. 
The in vivo profile of [La(34)] is very interesting and appears to show behaviour very 
much akin to that observed with microspheres. The first capillary bed that a 
microsphere encounters following intravenous injection is the lungs, where the particle 
becomes mechanically trapped. This behaviour pattern could prove attractive 
particularly as there is some concern over the potentially harmful effects of occluding 
capillaries with particulates. The behaviour of the complex seems to mirror that of the 
lanthanum ion, administered as the chloride. This may be indicative of some in vivo 
instability of the complex, hence the behaviour of the lanthanum ion, released from the 
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ligand may have been observed rather than the complex. Further studies are needed to 
probe the kinetics of dissociation. The quantification of bone uptake may have been 
useful in this respect, as it would be expected, that even at the short timepoints taken, 
free L a 3 + would have been deposited. 
2.7. Conclusions 
The complexes defined herein have properties which may permit their application in 
various imaging techniques, and could provide clinically relevant information at a range 
of levels. Physiological data may be accrued from the use of gadolinium complexes in 
MRI. Cellular events can potentially be followed by the use of phosphorescent 
markers. The two levels can be combined with radionuclide imaging, using positron 
emitting complexes. 
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Chapter Three 
Tumour Targeting with 
Low Molecular Weight 
Conjugates 
3. Tumour Targeting with Low Molecular Weight Conjugates 
The first half of this chapter (3.1.-3.6.) concerns the synthesis and evaluation of a 
lipophilic copper complex for potential therapeutic use. The motivation (3.1.) is drawn 
from the reported hepatoma retention oflipiodol. The synthetic efforts towards suitable 
ligands are described (3.2.), followed by the preparation of the radionuclide copper-64 
(3.3.). The ability of the ligand to form complexes is evaluated (3.4.) before comparing 
the cell uptake of the copper complex with radioiodinated lipiodol (3.5.). The first part 
concludes with the in vivo evaluation of the complex (3.6.). 
The second half of the chapter (3.7.-3.11.) investigates the potential for using the 
affinity of the low molecular weight compound biotinfor the tetrameric protein avidin. 
After outlining the possible clinical advantages of this approach (3.7.), the synthesis of 
ligands incorporating biotin is reported (3.8.). An assessment of the ligands binding to 
both copper-64 (3.9.) and avidin (3.10.) is made before evaluating the complex in vivo, 
with a rat bearing a tumour model (3.11.) 
. 1 . Towards Therapy with Lipophilic Copper Complexes 
It was mentioned in the introduction (paragraph 1.6., page 23), that the radiation dose 
delivered to a patient in conventional radiotherapy, may be hazardous to health and may 
even give rise to new tumours. A means of reducing the dose to non-target organs may 
be to physically place the radiation source inside the tumour. 
The mode of therapy envisaged is to regionally administer radiolabelled complexes, via 
an intra-arterial cannula directly into a tumour of the liver. The method of targeting, 
although lacking elegance, wi l l obviously lead to very high initial tumour uptake. As 
copper-64 has a half-life of 12.8 hours, it was deemed desirable for a complex to 
maintain a high tumounnon tumour ratio for several days, to minimise the dose given to 
healthy tissues. 
There have been several reports of remarkable hepatoma retention by lipiodol 14.1 This 
formulation is a mixture of iodinated ethyl esters of long chain fatty acids, derived from 
poppy seed oil. The reports conclude that the iodine content of these molecules is 
essential to the retention of the molecule in the liver tumour, but no reason is offered as 
to why this may be so. 
o 
X 
BO C 1 7H3^ nl n 
14 
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One might expect that all fatty molecules would remain in the liver after injection and, 
as the poor vascularity would lead to a poor washout from the tumour, it seems 
reasonable that the clearance may be quicker from healthy tissues than from the tumour. 
However, it may be argued that the electrophilic alkyl iodide moieties render the 
compound susceptible to nucleophilic attack, which may provide an "anchoring 
mechanism" to keep the molecule at the point of injection. It must be remembered that 
the method of tracing the iodinated ester in vivo is to use radioisotopes of iodine. Loss 
of iodine wil l almost certainly complicate the situation and any postulate offered to try 
and explain it. Not only must the fate of the labelled lipiodol be considered, but also the 
fate of any free iodide ions. 
The need for increased chemical stability is obvious i f a mode of therapy such as this is 
to be contemplated. One approach is to use a metal complexing agent. This has been 
attempted, albeit with the rather poor ligand 46 derived from the reaction of EDTA 24 
with 1,2-diaminobenzene 47, figure 3.1., below. The group describe the ligands 
application as a complexing agent for yttrium-90, which may covalently conjugated to 
lipiodol via nucleophilic substitution of iodine.2 As might be expected, the 
biodistribution showed an increasing uptake into bones with time, indicative of poor 
complex stability. 
Q -
CO,H H,N 
NH CO,H 
N C H,N N 47 H 
N N 
H0 2 C < H 
N CO,H 
HN 
24 
46 
Figure 3.1. The synthesis of a complexing agent which forms both a covalent 
linkage to lipiodol and a complex with 9 0 Y . 
One could envisage using this strategy to attach more appropriate ligating moieties to 
lipiodol, which offer greater stability. However, the approach is not particularly 
satisfying, as lipiodol is a mixture of poorly defined compounds, i.e. the number and 
position of iodine atoms and double bonds varies within a sample. 
It was decided to prepare and evaluate well defined compounds, incorporating 
macrocyclic complexing agents as well as long alkyl chains to enhance the lipophilicity 
of the complexes. Attempts were made to synthesise iodine free molecules and 
iodinated analogues. However, the synthesis of the iodine containing ligands was not 
achieved. 
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3.2. Synthesis of Ligands to Bind Copper, Which Incorporate Lipophilic Moieties 
Several ligands to bind copper have been defined, indeed seven are mentioned in the 
introduction to the thesis. It was initially anticipated that the incorporation of aliphatic 
chains into macrocycles designed for conjugation to other targeting vehicles, would 
facilitate the rapid synthesis of ligands, which would form very lipophilic complexes 
with copper. 
The first method involved selective acylation of the known pentaamine 48 at the 
exocyclic nitrogen. The pentaamine was synthesised by the published route,3 depicted 
in the scheme, figure 3.2., below. 
o o 
XX 
EtO OEt CN 
OEt EtO 
NaOEt, EtOH 
C N 4 9 
NH NH 
C J 
\ ft H 
EtOH, 14 days 
C N 
NH 
5 x 
BHo.THF 
H H H H 
C 5 ..N Nu N  H H H H 
4 8 5 0 
Figure 3.2. The synthesis of pentaamine 48. 
The copper binding of this cycle is compromised if the secondary ring nitrogens are 
acylated. The lone pair from the amide nitrogen becomes delocalised over the carbonyl 
system, i.e. the canonical form, shown in figure 3.3. below, makes a significant 
contribution to the structure of the tertiary amide. The lone pair is thus, unavailable for 
binding to the copper, and the resultant complexes have lower stability. 
HN R 
H V ^ H 
Figure 3.3. The binding of the I3N4 macrocycle is compromised i f the nitrogens 
are acylated. 
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To effect the monoacylation at the primary amine, a pH control stategy was adopted. 
At a pH of 6.8, the ring is diprotonated (pK a values are 11.5, 10.2, 1.7, 1.04) and, hence, 
the nucleophilicity of the ring nitrogens is reduced to a greater extent than the primary 
amine (pK a -10-11). The difference in nucleophilicity is sufficient to ensure reaction 
selectively at the primary nitrogen. Analogous acylations have been achieved 
previously (and elsewhere in this work) using this pH control strategy, with 50% 1,4-
dioxane in 0.5 mol dm"3 PIPES buffer being the preferred conditions. 
In the attempted reaction of the protonated cycle 48 with an active ester 51 of stearic 
acid (figure 3.4.) a problem of immiscibility was encountered, which resulted in the 
abandonment of this approach. 
o 
11 
N H , <r^r~n C 1 7 H 3 5 XT 
T.N NTT pH=6.8 7;N NL 
H 
H \ _ J H 
4 8 
Figure 3.4. The acylation reaction could not be realised under the pH controlled, 
aqueous conditions. 
Clearly, it was necessary to use wholly organic media for the reaction. The pentaamine 
48 used above became unsuitable as other protection strategies for the secondary amines 
were based on the use of metal ions, which have been found in the past to be rather 
stubborn when the removal step was required. 
An alternative complexing agent was sought. The ligand 1,4,7-triazacyclononane-
1,4,7-triacetate (NOTA, 23 ) is known to form stable complexes with copper (log 
K ML = 2 1 - 6 ) and, as there is an absence of any nucleophilic amines, provides an 
attractive parent ligating moiety for incorporating into the ligand design. 
C 0 2 H 
H 0 2 C ' ^ ' ^ 
C 0 2 H 
23 
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Several functionalised analogues of NOTA have been synthesised by our group,5 using 
both N and C-alkylation approaches. The quickest route to a bifunctional complexing 
agent bearing a pendant amine, is achieved by N-alkylation of triazacyclononane. This 
compound 52 was chosen as a precursor to the target lipophilic ligands. As before, it 
was envisaged that the amines would react cleanly with active esters or acid chlorides to 
afford the desired ligands and, because organic solvents were available for use, no 
problems of solubility were expected. Although the compounds did go into solution, 
the desired acylation did not occur, figure 3.5. 
NO 
I—V rr^co,H N ^ C O 2 H HO,C N HOoC N 
V - N - / 
H EUN, DMF 
NH N 
T HO,C HO 
5 2 
Figure 3.5. The acylation reaction of 52 failed with both the acid chloride and the 
active ester. 
The reason for the failure of the reaction is uncertain, although the large difference in 
the polarity of the reactants may provide an explanation. It seems likely that the very 
polar amino acid and the relatively non-polar acylating agent, would have little affinity 
for each other, and hence the contact time between the reacting groups may not be 
sufficient. 
Another ligand system, again based on the triazacyclononane macrocycle, but with two 
pendant carboxylic acids and one pendant amide, was investigated to ascertain whether 
it bound copper and whether it could be used to form conjugates, including linkage to 
fatty acids. This ligand system would form charge neutral complexes with copper, a 
feature which would reduce the electrostatic attraction of the complex to cations, 
including protons, and hence reasonably high stability in acidic media might be 
expected. 
A model ligand 57 was made by the synthetic route shown in figure 3.6. 1,4,7-
triazacyclononane 53 was used in excess to increase the amount of monoalkylation with 
the chloroacetamide 54. 
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Figure 3.6. The synthetic scheme followed to give ligand 57. 
The alkylation of the two remaining nitrogens of the ring was realised by both the 
reaction with ethylbromoacetate followed by base hydrolysis and by reaction with 
chloroacetic acid under slightly basic conditions. The pH of the latter reaction was 
monitored during the reaction and kept to -10 to reduce the competing hydrolysis. 
A cold copper complex was made by addition of copper perchlorate to a solution of the 
ligand 57 under slightly acidic conditions pH~5.5, figure 3.7. An excess of copper was 
used and the uncomplexed copper was precipitated as the sulfide, on bubbling hydrogen 
sulfide through the reaction mixture. 
0£) COM HO,C N 1. Cu(CI0 4) 2 
X Cu 2. H,S N 
H 
O 
5 7 [Cu(57)] 
Figure 3.7. The formation of the model complex [Cu(57)] 
Analysis by infra red spectroscopy illustrated the participation of the amide carbonyl in 
binding to the metal centre, as well as the two acetates (table 3.1., below). Electrospray 
mass spectroscopy of a solution of the complex showed the molecular ions expected for 
the complex in their natural abundance. Unfortunately, attempts to obtain crystals 
suitable for X-ray analysis were unfruitful. 
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Carbonyl Stretch /cm"1 
Ligand 57 [Cu(57)] 
Amide Carbonyl 1672 1633 
Acetate Carbonyl 1727 1682 
Table 3.1. Infra red stretching frequencies of carbonyl groups before and after 
complexation. 
An indication of the stability of the complex under acidic conditions was obtained by 
monitoring the demetallation of the complex by visible spectroscopy. No change in the 
absorption intensity or wavelength (705nm) of a solution at pH 1.5, was detected at 3, 6, 
24 or 72 hours. This suggests that the copper complex should have sufficient kinetic 
stability for use in vivo. 
The ligand system defined above was elaborated to include a pendant amine 58 (the 
synthesis is described in the following chapter) and it was hoped that the exocyclic 
acylation reaction attempted for the NOTA derived systems above, might work on this 
slightly less polar molecule. 
N f ^ C O o H N HO,C 
O 
H 
N NH 3 +Br 
58 
The coupling reaction failed, so, a decision to abandon the convergent approach to the 
ligands wastaken, andinsteada repetitive approach of synthesising the...target ligands 
from stearic acid and linolenic acid was initialiated. The synthesis of the saturated 
ligand proceeded smoothly, figure 3.8., until the final step - the introduction of the 
carboxylic acids. The reaction with ethyl bromoacetate appeared to have gone to 
completion, indeed a molecular ion was visible in the mass spectrum, but the compound 
could not be purified by gravity chromatography on silica. 
Four different fractions were collected and each hydrolysed with base. The desired 
compound was not identified. Ions seen in the mass spectra of the hydrolysed ester are 
consistent with the cleavage of one or both of the amides in the side chain. The reaction 
sequence was halted and the analogous synthesis, using the unsaturated linolenic acid, 
was not attempted. 
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Figure 3.8. This stepwise synthesis of the ligands incorporating lipophilic chains 
failed to produce the desired product 
The final approach towards the synthesis of lipophilic ligands was to N-alkylate the 14-
membered cycle, cyclam 20. As mentioned above, acylation of the nitrogens would 
result in poorer complex stability, and so the acylation step was followed with an amide 
reduction. The 14-membered cycle was chosen over the 13-membered homologue 
because the higher symmetry would result in a single compound being made, rather 
than the two which would result from the 13 membered cycle. Additionally, it was 
decided that the purification would be simplified i f the triprotected cyclam 62, prepared 
by Dr I . Helps,6 was used as the starting material, as it was expected that the protected 
amines would behave more predictably under column chromatography conditions. The 
sulfonamide protecting groups were removed easily, at the end of the reaction sequence, 
to give the cycle 65, which required no further purification. The sequence used is 
illustrated in figure 3.9. 
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Figure 3.9. The synthesis of ligand 65. 
The synthetic route to be attempted for the unsaturated analogue necessitated 
modification. The presence of the double bonds prohibited the use of borane to reduce 
the amide. (This may, however, have offered a simple method to introduce iodine into 
the molecule). Also the harsh deprotection conditions employed for the saturated 
compound were incompatible with the alkene functionality. 
In the search for alternative procedures for reduction, two potentiaLsolutions were 
attempted, figure 3.10. A reduction of the amide 66 using lithium aluminium hydride 
was tried but resulted mainly in cleavage of the amide bond to give linolenol and the 
starting material 62. This reaction was attempted at both room temperature and -78°C, 
with little difference being seen in the ratio of products obtained, as estimated by proton 
NMR analysis of the crude reaction mixture. To remove the protecting groups a 
dissolving metal reduction was attempted, using lithium in liquid ammonia, however, 
the reaction did not proceed cleanly and the final product could not be isolated by 
chromatography. It was thought that the amide might also be reduced under the radical 
conditions, and indeed this did happen - again to the extent that the amide was cleaved. 
The tertiary amide is quite crowded and it is thought the driving force for cleavage 
rather than partial reduction to the amine may be the accompanying relief of crowding. 
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Figure 3.10. The reductive detosylation reactions failed to give the desired ligand. 
The introduction of iodine into the unsaturated ligands could well present problems, in 
particular it might be expected that salts of the amine with iodide may be formed rather 
than covalent bonds formed by electrophilic addition to the double bonds. The 
approach intended was to utilise the surfactant properties of these ligands to perform the 
iodinations at the interface between water and a solution of iodine in a halogenated 
solvent. The-reaetion could be monitored by the decoloration of the organic phase. 
3.3. Production of Copper-647 
The potential of copper-64 for use for both imaging and therapy was introduced in 
chapter 1. The radionuclide was obtained from irradiation of enriched nickel-64 targets. 
The reaction used was the bombardment of a disc of compressed powdered nickel-64 
metal with a beam of deuterons ^NiCd, 2n) 6 4Cu. The target was dissolved in a small 
volume of 7 mol dm"3 hydrochloric acid solution, with a few drops of aqueous 
hydrogen peroxide, to ensure complete oxidation to ^ N i 2 * and ^Cu2"1". The solvent 
was evaporated at ~60°C to near dryness. The caked solid was taken up with fresh 7 
mol dm"3 HC1 solution and loaded on to a AG-1X8 anion exchange column (3cm x 
1.1cm diameter) which was preconditioned with 7 mol dm"3 acid. The nickel(II) and 
the trace amounts of cobalt(III), produced as a by-product of the nuclear reaction were 
eluted with acid, whilst the copper(IT) remained on the column. The copper was then 
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eluted with deionised (18MQ cm) water. The copper-64 solution was concentrated 
using a rotary evaporator. 
The high cost (~£20 per milligram, which equates to -£2000 per target) of the enriched 
nickel-64, necessitates recycling of the target material. The ^ N i C ^ solution from the 
column was stored, to allow the radioactivity of 5 5 Co and 5 7 N i to decay. The eluent 
from the column was then concentrated and then neutralised with 5 mol dm"3 sodium 
hydroxide solution, to give a green precipitate of nickel hydroxide. The precipitate was 
collected by centriguation, and washed twice with deionised water. (The supernatants 
were retained from several "runs" to be combined and concentrated, to ensure 
quantitative recovery.) The wet, salt free 6 4Ni(OH)2 was heated to 40°C overnight in an 
oven, to remove the majority of the water. The hydroxide was then reduced to metallic 
nickel by heating to 650°C in a furnace, under a stream of hydrogen gas, for 5 hours. 
The powdered metal was pressed into a pellet, which formed the recycled target. 
3.4. Radiolabelling Studies 
The radiolabelling efficacy of the N-octadecyl cyclam ligand 65 was assessed using 
copper-64. As might be expected the ligand is only sparingly soluble in water, but the 
addition of 20% ethanol as a cosolvent enabled a solution to be formed. On standing, 
however, the ligand was seen to form droplets. These were dispersed quite easily by the 
use of a vortex mixer, but it is quite possible that the ensuing solution was not as 
uniform it appeared, and may have resulted in the compounds forming smaller 
aggregates such as micelles. Radiolabelling yields, table 3.2., were determined at 
ligand to metal ion ratios over 3 orders of magnitude. The labelling reactions were 
performed at pH 5.5 in Q.5_mol dm"3 ammonium acetate buffer, at 25°C Thin layer 
chromatography with radiometric detection was employed to determine the amount of 
complex formed, after challenging with a large excess of EDTA. The amount of copper 
was calculated from the specific activity, assuming that on receipt of the 
chromatographically purified copper, there was no cold copper and an absence of other 
interferring ions. 
Ratio eS-^Cu 
30mins 
% Radiolabelling 
120mins 18hours 
10:1 0.5 
100:1 9.4 
1000:1 51 68 98 
Table 3.2. Radiolabelling yields at various molar excesses of ligand over 
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As might be expected the uptake of copper increases with time. However, the rate of 
binding is somewhat lower than hoped for, with over one half-life required to ensure 
complete complexation. The quality control of the complex is rapid and the complex 
requires no further purification. 
.5. Cell Uptake Studies 
The extraction of the lipophilic copper complex [ 6 4 Cu(6S)] 2 + was investigated, in three 
cell lines, and compared with the extraction of 1 2 5 I- l ipiodol . The cell lines used were 
primary liver tumour cells (hepatocellular carcinoma, HepG2), liver metasteses cells 
from colorectal carcinoma ( L 0 V 0 ) , and normal human umbilical endothelial cells 
(HaVeo). 
Measurements were made in triplicate at three timepoints, for each type of cell, and 
with both compounds. The radiolabelled lipophilic compound was added to -2.5X104 
cells, suspended in 250|iL of Dulbecco cell growth medium, and incubated at 37°C, 
with occasional stirring. Three timepoints, of 1, 5 and 24 hours were chosen, and at 
each, the 18 (2 compounds x 3 cell types x triplicate =18) samples were centrifuged 
briefly. The supernatant was removed and the pellet was washed with 250|iL of cell 
growth medium. The percentage of the radioactivity found in the cellular pellet is 
tabulated below, table 3.3. 
^ C u complex 125j lipiodol 
lhr 5hr 24hr lhr 5hr 24hr 
HepG2 30.1 30.4 30.3 14.3 24.4 6.50 
L 0 V 0 25.4 32.9 33.9 31.9 26.8 23.6 
H V 
n a veo 
20.7 18.8 21.6 17.9 13.4 11.8 
Table 3.3. The amount of radioactivity taken up by cells at three timepoints. 
The results for the copper complex suggest little time dependence for the primary and 
normal cells. The 50% greater uptake by the tumour cells compared to the normal cells 
could indicate quicker metabolism of these cells or may simply be a reflection of the 
number of cells, which was uncertain, rather than an indication of higher uptake in these 
cells. (All three cell lines were believed to be of similar concentration.) The increase 
with time for the uptake of [ 6 4 Cu(65)] 2 + complex in the secondary tumour cells is quite 
interesting and suggests there may be an uptake mechanism. 
The collection of results for the lipiodol show less consistency. This scatter is likely to 
have arisen from the poor experimental procedure. The specific activity of the 
iodinated analogue was far lower than that of the copper complex. Consequently, a 
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larger amount of the compound, 30|iL, was administered to the cells. The lipiodol was, 
of course, immiscible with the cell medium, and so formed a bolus, at the bottom of the 
Eppendorf tube. After centifuging, there was subsequently three phases, the 
supernatant, the oil and the cells. The cell pellet was not distinguishable (it was visible 
for the corresponding copper samples) and so separation was not easy, and a large error 
may have occurred. The uptake of lipiodol by human hepatoma cells (HepG2) has been 
investigated by others, using electron microscopy and neutron activation analysis.13 
Both of these techniques may affect the integrity of the cells, as they are subjected to 
either chemical fixing agents for electron microscopy, or a beam of neutrons for the 
neutron activation analysis. Hence the results obtained aren't directly comparable to 
those presented here. 
3.6. In Vivo Evaluation of the Copper Complex 
The biodistribution of the copper complex [ 6 4 Cu(65)] 2 + was determined in adult 
hooded rats. The complex was administered, in 5% aqueous ethanol, by Mr M . Davies, 
intravenously to six rats (210-290g) via the surgically exposed right jugular vein, whilst 
under halothane anaesthesia. Three animals were sacrificed at each timepoint, by 
carbon dioxide asphyxiation. The animals were then dissected and the amount of 
radioactivity located in the weighed organs determined with a y-counter. The 
distributions obtained at 3 and 24 hours are shown, after normalisation to a 250g rat, in 
table 3.4., below. 
Tissue 
%injected activity g"1 
3 hours 24 hours 
Blood 1.30±0.09 0.57±£>.10 
Kidney 2.88±0.12 1.90±0.18 
Spleen 4.00±0.16 1.8410.30 
Liver 3.47±0.09 3.16±0.55 
Lungs 3.21±0.09 1.72±0.10 
Heart 1.04±0.06 0.3810.05 
Muscle 0.47±0.13 0.1610.02 
Brain 0.1110.01 0.071O.01 
Intestines 1.25±0.12 0.6710.06 
Table 3.4. The biodistribution profile of [ 6 4 Cu (65 ) ] 2 + at 3 and 8 hours post-
injection 
The data show clearance over time from all organs except for the liver. Of course, i f the 
complex had been infused directly into the hepatic artery, as is anticipated for the 
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application to hepatoma therapy, the liver uptake at both timepoints would be much 
greater. 
The difference between the liver and intestines is interesting, and suggests that the 
complex is not being effectively cleared by the biliary system (as was seen, at much 
earlier timepoints, for the lipophilic anionic lanthanum complexes of chapter 2.) It 
appeal's as though a substantial amount of the radioactivity (-30%) is actually trapped 
in the target organ. 
An experiment in a tumoured animal would be desirable, to determine whether the 
distribution in the liver is uniform, or whether, as the cell uptake measurements suggest, 
there may be a preferential uptake in the tumour cells over normal cells. 
3.7. Targeting Exploiting the Affinity of Biotin for Avidin 
Antibodies can show remarkable selectivities for tumour cells. However, they are very 
large and hence localise slowly (whole antibodies have molecular weights of 100-150 
kDa.) In applications involving the use of radionuclides this represents a significant 
drawback, as the whole body experiences a dose of radiation. For therapeutic 
applications, the high background dose may limit the administered dose. The lethargic 
localisation is inconvenient for imaging applications, as the imaging study has to be 
postponed until the background radiation, from the circulating activity, has reduced to 
an acceptable level. 
The low molecular weight (Mj=244 Da) compound biotin 8 10 has a remarkable affinity 
for the tetrameric protein, avidin. The dissociation constant (K<j=10"15 mol" 1 dm 3) is so 
small the binding, though non-covalent, can almost be considered irreversible, and is 
only a few orders of magnitude higher than the constants determined for some "stable" 
metal complexes. The use of the avidin-biotin system may enhance the quality and 
speed of images obtained by antibody/radionuclide methods, and may improve the 
efficacy of therapy with antibodies. 
NH HN H 
HO,C 
10 
In conventional antibody based imaging procedures, a radiolabeled antibody is 
administered to a patient, which then localises by binding to an antigen on the tumour 
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cell, after recognising a complementary molecular surface. Of course, on each pass of 
the circulation, only a fraction (0.0001-0.005% injected activity per gram, depending 
upon the local perfusion) of the administered antibody "sees" the antigen binding site, 
and, so, the majority of the radiolabeled antibody remains in the circulation. I f a clear 
image is to be obtained, with a sharp contrast between the tumour and healthy tissue the 
tumounblood ratio must be sufficiently high. In time, the radiolabeled antibody wil l all 
become associated with the tumour, or be metabolised by the body. The time taken for 
localisation may be too long, however, for some radionuclides, due to physical decay. 
The use of the avidin/biotin system may be useful for improving the quality of images 
at shorter post-administration time intervals. 
I f the antibody is labelled with both a radionuclide and biotin, it can be administered to 
a patient with little change in the immunoreactivity of the antibody. After a time of a 
few hours, some of the activity will have localised in the tumour, whilst most would be 
expected to remain in the circulation. An injection of the tetrameric protein avidin wil l 
then bind to the biotinylated antibodies in the blood, causing protein aggregation. Such 
aggregates ( M r -450-650 kDa), would be rapidly trapped and catabolised by the liver, 
hence removing the radionuclide from the circulation, and providing much enhanced 
tumounblood radioactivity levels.9 Imaging can be performed earlier, with better 
contrast. 
A reduction in radiation dose to healthy tissue is potentially attainable, i f avidin could 
be selectively concentrated at a tumour site, by attachment to a tumour seeking 
antibody. A radiolabeled biotin tracer, administered after localisation of the antibody 
avidin conjugate, should also concentrate at the site of the tumour, via "molecular 
recognition" of the avidin binding site. The smaller biotin conjugate, would localise 
much more rapidly than a whole antibody, hence, reducing the radiation dose given to 
the rest of the body. Strategies have been proposed for this mode of therapy.10 
The purpose of our work in this area was to investigate the possibility of using biotin as 
a vehicle for transporting the positron emitting copper-64 to the tumours for imaging. 
The possibility of using copper-64/67 as therapeutic radionuclides, adds further impetus 
to the enquiry. As only the cis-fused ring system of biotin is required for recognition, 
the carboxylic acid group is free to provide a covalent linkage to the complexing agent, 
with little effect on the binding with avidin. 
.8. Synthesis of the Macrocycle-Biotin Conjugate 
It was decided that it would be prudent to synthesise ligands capable of forming copper 
complexes of differing charges. The binding between avidin and biotin may be 
84 
compromised i f the charge on the complex is incompatible with amino acid residues 
close to the binding site of the protein, certainly one might expect to see a kinetic 
difference if, for example, a positively charged complex is compared with a charge 
neutral one. A ligand 11 expected to form an anionic copper complex, based on DTP A, 
is commercially available. The ligand has been studied11 for a similar application to 
that presented here, using indium- 111. 
HN 
COoH 0 
N 
N N H C H COoH 
HO,C CO,H H 
O 
H N N 
N 
CO,H O 
HN 
H 
11 
Complexes formed between 11 and copper would be expected to show poor kinetic 
stability. The copper complex also showed a very poor solubility in water, indeed a 
molecular ion was not obtained in an attempt to probe the speciation of the copper 
complex by electrospray mass spectrometry. A ligand based on the NOTA framework 
was designed (figure 3.11.) which would also form a negatively charged copper 
o 
A NH HoN HN HN I M I sequiv. NH H NH I INI 
<~f> 
H H"" H H N 
H2N 
o 
6 8 NO 
H O o C ^ N N ^ C O o H 
o 
H 
N 
HO,C 
2 9 /—v CO,H N N HO,C NH HN 
O H O 
.H 
HO 
Figure 3.11. The aborted synthesis of a ligand incorporating the bio tin 
functionality and a copper complexing moiety. 
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complex. The coupling reaction between the amine 68 and active ester 2 9 did not take 
place. This was somewhat surprising as analogous acylations have been achieved. It is 
believed the ester hydrolysed under the reaction conditions, as 4-nitrophenol was 
identified in the reaction mixture. 
The synthesis of a ligand 69 to form a cationic copper complex proceeded cleanly, 
figure 3.12., below. The tetraamine macrocycle 48 was acylated at the primary 
nitrogen with the biotin modality, pH control being used to protect the four secondary 
amines. 
o 
A XT*.^ NH HN NH H H 
H XX H H H H 
C 5 NO H H PIPES buffer, pH=6.8 
Dioxane 
6 9 48 
Figure 3.12. The synthesis of ligand 69. 
The lU NMR (figure 3.13.) and electrospray mass spectra (figure 3.14.) provide 
convincing evidence of the formation of the desired conjugate. 
n I in 
7 6 5 4 3 2 1 ppm 
Figure 3.13. 1 H NMR spectrum of 69. 
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Figure 3.14. Electrospray mass spectra of 69 left and [Cu(69)] 2 + right. 
3.9. Radiolabelling Studies 
A high specific activity is desirable for radio metal complexes as there are a finite 
number of binding sites at the biochemical target which is being pursued. The presence 
of a large excess of complexing agent with no bound copper would result in 
competition for the available receptors. Radiolabelling was attempted at a range of 
ligand to macrocycle ratios, to try and maximise the specific activity obtained. The 
amount of copper was calculated from the measured radioactivity. Complexation 
reactions were performed at pH 5 in 0.5 mol dm"3 ammonium acetate, 30 minutes, 
37°C. Radiolabelling yields .were determined by thin layerxhromatography, after 
challenging the complex with EDTA, which sequestered any free copper ions. The 
eluent system used for chromatography was 50% ammonium acetate (0.15 mol 
dm"3):50% methanol. With this solvent system, the dianionic [ 6 4 Cu(EDTA)] 2 ' complex 
eluted at the solvent front, whereas the dicationic [ 6 4 Cu(69)] 2 + remained at the baseline 
when adsorbed on to silica impregnated glass fibre sheets. The labelling yields 
obtained are tabulated below (table 3.5.) at various ligand ratios. 
Ratio o f 6 9 : 6 4 C u 2 + 
10:1 
100:1 
1000:1 
Radiolabelling yield /% 
4 
81 
84 
Table 3.5. The radiolabelling of ligand 69 at 30 minutes. 
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The radiolabelling yield of 80%, obtained at a 100 fold ligand excess represents a very 
high specific activity. Furthermore the copper EDTA complex can be easily removed 
by the use of a solid phase extraction cartridge (SAX Isolute, International Sorbent 
Technology). Elution with 0.15 mol dm"3 ammonium acetate provides the pure 
conjugate, with no breakthrough of the anionic EDTA complex. 
3.10. Binding Studies 
An experiment was conducted to assess the affinity of the radiolabeled copper 
conjugate for avidin. A sample of the labelled complex was incubated with avidin at 
different stoichiometries, and for different periods of time. The binding was assessed 
by elution through a gel filtration column (PD10) collecting fractions. Large species 
elute first, enabling a comparison to be made between protein bound conjugate and the 
unbound conjugate. The experiment was also performed with tritiated biotin T2(10), 
obtained commercially, and the indium complex of the DTPA-lys2-biotin2 complexing 
agent 11. 
, H 
HN 
CO,H.O 
CM H N N N H C NH H HN CO,H MIN I 
\ 3 ) H»" HO,C COoH H 
O H . 
HO,C H N N 
N 
CO,H O 
HN 
H 
o H T2(10) 11 
The experiments were conducted on both chromatographically and affinity purified 
avidin. The more expensive chromatographically treated protein resulted in a greater 
uptake of complex. It is thought that the affinity purification step may have introduced 
some blocking of binding sites. Table 3.6. below shows the amount of radioactivity 
which became bound to avidin on incubation of avidin with the two complexes and the 
tritiated biotin, for 30 minutes. A four fold excess of complex over avidin was used, as 
avidin and biotin are known to form a 4:1 complex.12 
Complex % Bound to protein 
[ 6 4 Cu(69)] 2 + 90 
[ m I n ( l l ) ] - 50 
T2(10) 95 
Table 3.6. The amount of biotinylated complex bound to avidin after 30 minutes, 
pH 7.4, 37°C 
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The results obtained suggest that the binding of the conjugate has not been significantly 
compromised by the incorporation of the macrocyclic copper complex, and that binding 
is almost instantaneous. Interestingly the indium complex, which has two biotinyl 
groups per complex binds only half as well. This leads one to speculate that the 
complex is acting as a bridge, between two binding sites, preventing access of another 
complex from binding. Intuitively this seems unlikely, due to the sheer bulk of the 
protein molecules, but spacer groups of similar size have been shown to be long enough 
for three antibody fragments to be attached to one complexing agent, in previous 
work. 1 3 Of course it may be possible that the complex is binding to two of the four 
sites on avidin, with the tethering of one half of the complex predisposing the complex 
in the vicinity of the other. 
Competition Experiment 
Although the binding experiments show that the complex binds to avidin, it offers no 
information on the strength of the binding. Such detail was investigated by challenging 
the protein-conjugate complex with biotin. No release of the conjugate was detectable, 
with up to 1000 fold excess of biotin, over 1 hour. It can be stated with confidence that 
the binding is essentially irreversible. 
11. In vivo Evaluation 
The biodistribution profile of the copper biotin complex [ 6 4 Cu(69)] 2 + was determined 
in a rat model, and compared with the profile obtained using the parent I3N4 complex 
[ 6 4Cu(21)] 2 +. Eight rats were anaesthetised by Dr I . Rowland with 2.8ml kg" 1 
Hypnorm and Hypnovel. Each then received an intramuscular injection of polymer 
supported streptavidin (0.1-0.2 mg on 6% beaded agarose, Pierce) into the right thigh. 
After 24 hours, a time chosen arbitrarily to represent the time taken for localisation of 
an antibody administered intravenously, each complex was administered via the tail 
vein to four animals, under anaesthetic. Two animals from each set were killed at 2 and 
8 hours by cervical dislocation, whilst under anaesthesia. Selected organs were 
removed and the amount of radioactivity in the tissues determined with a y-counter. 
The biodistribution data is tabulated below (table 3.7.), as the %injected activity per 
gram of tissue. 
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%injected activity g" 
[ 6 4 Cu(21)] 2 + 
2 Hours 8 Hours 
[ 6 4 Cu(69)] 2 + 
2 Hours 8 Hours 
Blood 0.38+0.21 0.17±0.02 0.2410.08 0.3310.06 
Kidney 7.51±0.81 2.47±0.03 4.6211.30 2.4611.14 
Liver 3.30±0.18 1.67±0.22 1.8610.04 1.3010.36 
Spleen 0.40±0.01 0.2710.01 1.0510.02 0.6910.12 
Lungs 0.53±0.04 0.1810.07 1.2110.23 0.6110.20 
Left Thigh 0.07±0.01 0.0610.01 0.0910.00 0.1010.01 
Right Thigh 0.09±0.01 0.1110.04 0.1510.05 0.2110.08 
Intestine 0.81+0.01 0.2610.13 1.3810.45 0.7010.29 
Heart 0.19±0.01 0.2510.05 0.2110.01 0.3510.07 
Table 3.7. The biodistribution profile of [ 6 4 Cu(69)] 2 + compared with 
[ ^ C u ^ l ) ] 2 4 " in rats bearing an intramuscular deposit of polymer 
supported streptavidin. 
The data shows a similar pattern for both complexes, with a large amount of the 
complex rapidly excreted, as expected for hydrophilic cations such as these, primarily 
via the kidney. Analysis of a urine sample by HPLC showed a retention time 
characteristic of the administered complex, but little of the radioactivity in the urine 
bound to avidin, perhaps suggesting some modification (e.g. amide cleavage or N-
carboxylation) of the pendent biotin functionality. The avidinated beads were 
administered to the right thigh, and so the left thigh can be used as a reference organ. 
The tissue counts for the left thigh show a high level of consistency, with a small error. 
The results from the right thigh muscle are more irregular, which suggests that the 
intramuscular injection of the previous day has had a negative effect on the quality of 
the results obtained. An approximately two-fold difference between the biotinylated 
complex and the parent complex can be seen from the data. However, one has to be 
careful in interpreting the data as the fairly large error on some measurements suggests 
there is little difference between the two compounds, i f an assumption of the worst case 
scenario is made. (Throughout this work biodistribution data are presented in the 
format "mean 1 error." The error quoted is the sample standard deviation, a n _i, rather 
than the population standard deviation, o n . The value of the error obtained is larger 
with the sample standard deviation than the population standard deviation, especially 
when small sample sizes (here n=2) are used.) I f the average values are taken as "real" 
then the result is quite encouraging. The difference between the left and right muscles 
is the few milligrammes of beads, however when processing the tissue counts the 
weight of the whole muscle is considered and hence the difference in uptake is diluted 
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throughout the whole tissue. I f the beads themselves were separable from the rest of the 
muscle and were able to be counted as an organ in their own right, as for xenografted 
tumours, the high activity concentrated in the low mass would give a very high 
%injected activity per gram of tissue. 
In conclusion, a further experiment is required with tumour bearing animals. The 
model nature of the in vivo experiment doesn't tackle the potentially problematic 
antibody-avidin localisation, but it does suggest that the approach may be useful, to 
reduce the dose to non-target tissues, due to the rapid clearance from the circulation. 
Also the stability of the complex in vivo has been demonstrated. 
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Chapter Four 
Targeting with Monoclonal Antibodies 
4. Targeting with Monoclonal Antibodies 
The possibility of antibody based targeted imaging and therapy with copper-64 labelled 
ICR-12 is introduced (4.1.). The synthesis ofbifunctional complexing agents is detailed 
(4.2.) and the radiolabelling (4.3.) and antibody conjugation (4.4.) described. Damage 
caused to the antibody is assessed (4.5.) and the conjugates are evaluated in vivo (4.6.). 
. 1 . Introduction 
The potential use of monoclonal antibodies as targeting vectors for tumour imaging and 
therapy was introduced in chapter 1. The high specificity of monoclonal antibodies 
makes their application to targeting attractive. In principle, the administration of a 
monoclonal antibody, radiolabeled with an appropriate nuclide, wil l result in the 
localisation of radioactivity at the site of tumours. The tumours may then be visualised 
by one of several radionuclide based imaging modalities, or i f appropriate radiations are 
liberated in the physical decay, one can envisage using the radiolabeled antibodies to 
cause cell death. 
The monoclonal antibody ICR-12, binds to the external domain of a transmembrane 
glycoprotein, produced by the human c-erbB2 proto-oncogene.1 It is believed that the 
protein functions as an autocrine receptor in breast cancer. The gene that codes the 
protein is also over expressed in adenocarcinomas of the lung, endometrium, ovary and 
possibly the bladder. ICR-12 does not bind significantly to normal cells and, thus, the 
antibody represents a versatile targeting vehicle for the detection and treatment of a 
number of important tumours, when labelled with radionuclides. 
Copper-64 is a unique radionuclide because the radioactive decay gives rise to three 
different, potentially useful types of emission. The y-rays arising from the annihilation 
of positrons are useful for PET imaging, both diagnostically and as a mode to monitor 
therapy. The positron and beta emissions are useful therapeutically as ionising 
radiations. As the pathlengths of the emissions are greater than cellular dimensions, a 
degree of "crossfire" may be expected which could cause cell damage, even though the 
ionising radiation is delivered from a nuclide bound to a different cell. This is crucial i f 
therapy is to be effective, as some cells are inaccessible to the antibody conjugate 
because of poor perfusion. It is important that the radiation pathlength is large enough 
to deliver a sterilising dose to these cells. The third useful decay process of copper-64 is 
electron capture, which leads to the emission of Auger electrons. Although Auger 
electrons have a short pathlength, they may be useful for causing the critical DNA 
double strand cleavage, required for cell death. The range of Auger electrons, from the 
decay of copper-64 is 1.3^im-38nm, hence the radionuclide must be bound to the DNA 
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double helix, i f damage is to be effective. To target the DNA of tumour cells, a means 
of locating the target cell and then finding the DNA is required. The use of a 
monoclonal antibody promises an answer to localisation at the tumour cell, but i f 
damage is to be caused to the nuclear DNA, the radiolabel must then become 
internalised in the cell, and localise at the nucleus. Several antibodies are known to 
internalise, and may be useful for nucleic acid targeting. 
.2. Synthesis 
Bifunctional complexing agents for use in antibody based targeting require a set of 
ligating groups to bind the radionuclide, and a linking group which allows conjugation 
to the antibody. The nature of the complex (e.g. the charge, size and shape) may affect 
the ability of the antibody to bind with the receptor site on the tumour cell. The three 
ligand systems 21, 23 and 57 are known to form complexes of different charges on 
binding copper. 
COoH CO,H 
H N N N HO,C N HO,C 
c t ; uO 
o 
N 
H 
COoH 
O 
21 23 57 
Kinetic stability in vivo has been demonstrated for the [Cu(21)] 2 + complex.2 The 
complexes derived from 23 and 57 should also be kinetically stable in vivo. To 
facilitate the linkage to the antibody, a pendent reactive group is necessary. It is 
convenient to use an exocyclic amine for derivatisation, as there are several methods for 
forming stable amide linkages. 
NH 
NH 
H H H H CO,H CO,H N N N N N HO,C HOoC N N N 
\ I 
C J 
o 
H 
H NH N 
HO,C 
O
48 70 52 58 
The four ligands 48, 52,58 and 70, bearing pendent amines were selected for synthesis. 
The synthesis of 48, was described in the previous chapter. Whilst the aromatic group 
of 48 provides a useful chromophore for analysis of conjugates, it was thought that the 
95 
group may exhibit a degree of immunogenicity, hence the aliphatic ligand 70 was also 
prepared. The synthetic sequence depicted below (figure 4.1.) afforded the ligand in 
three steps. 
o o CN 
OEt 
CN 
71 
NH NH 
C J 
H N N H 
EtO OEt EtO 
NaOEt, EtOH 
EtOH, 14 days 
NH 
H H 
C 5 
H H 
2. HCI 
LBH3.THF H H 
C 5 H H 
CN 
70 72 
Figure 4.1. The synthesis of the aliphatic ligand 70. 
Ligand 52 was prepared by Fiona Smith following the published route.3 NOTA 23 was 
prepared as a model compound (figure 4.2.) to investigate the radiolabelling efficacy of 
52, by alkylation of 53 with chloroacetic acid. 
Figure 4.2. The synthesis of NOTA. 
The ligand 58, was prepared using the reaction sequence illustrated in figure 4.3., 
below. The alkylation of 1,4,7-triazacyclononane 53 with the N-protected amide 74 was 
performed with the cyclic amine present in an excess, to reduce the amount of 
dialkylated material produced. The alkylation of the remaining two nitrogens was 
achieved by two methods. The first method tried was the reaction with ethyl 
bromoacetate in DMF. This procedure resulted in the formation of a substantial amount 
of the alkylated sulfonamide product 79. The second method used was the aqueous 
alkylation with chloroacetic acid, under carefully controlled pH conditions, using 
lithium hydroxide to maintain a slightly basic pH, and minimise glycolic acid formation. 
Although some alkylation of the sulfonamide was seen, preparative HPLC 
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Figure 4.3. The synthesis of ligand 58. 
N H 3 + B r 
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under anion exchange conditions provided an easier purification than the gravity 
chromatography used to purify the diester. Detosylation proceeded cleanly to give the 
desired ligand 58. 
A sample of 80 was isolated by HPLC. This compound is a potentially useful 
intermediate for introducing three different substituents on the nine membered cycle. 
The remaining secondary nitrogen was alkylated (figure 4.4.) with the a-bromo 
diprotected 5-aminovaleric acid 81. The compound 82 has two protected pendent 
amines, which can be made available selectively by the choice of deprotection 
sequence. The use of a BOC protecting group for one nitrogen would be more versatile, 
as the difference in reactivity between the two amides of 82 may not be sufficient for an 
efficient deprotection. 
JO H N 5^ 
CO,Et 
N 
N ^ C O a H H H N 
N f ^ C 0 2 H 81 B r N HO,C 
O 
H 
O 
CsoCO,, DMF H N 
N N 
H N 
H OMe 
80 82 OMe 
Figure 3.4. The synthesis of 82. 
It is important that the complexing agent is conjugated rapidly to the antibody, under 
mild conditions, to ensure minimal damage to the protein. A simple coupling is 
achievable by either Michael type addition to an electron deficient double bond, or by 
substitution of an active ester, figure 4.5. Thus, the protein behaves as a nucleophile. 
The most nucleophilic groups of antibodies are the thiols on the cysteine residues, and 
the free amines of lysine residues. The maleimide group reacts rapidly, in aqueous 
media (pH ~7), with thiols to form a stable linkage (the analagous reaction with amines 
is slower). 
V Nuc Y N - R 
0 , N 
1 N - R 
Nuc R 
Figure 4.5. Coupling reactions for derivatising monoclonal antibodies. 
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Active esters such as N-hydrroxysuccinimidyl and para-nitrophenyl react rapidly in 
slightly basic media (pH -7.5) with the terminal amine of lysine. The three active esters 
85-87 were synthesised (figure 4.6.), as a means of introducing maleimides and active 
esters to the ligands 48, 52,70 and 58. 
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\ o p HO,C 
88 
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J O OH DCC.THF 0 , N 
87 
Figure 4.6. The synthesis of active esters 85-87. 
None of the desired product was identified in the coupling reaction (figure 4.7.) between 
the aliphatic pentaamine and the active esters 85 and 86. The absence of a suitable UV 
active chromophore in the amine should not have caused a problem, as the transferred 
maleimide exhibits an absorption (Xm a x=305nm). The reaction was performed using the 
same mixed solvent system used for the selective acylation of the primary amine in the 
preparation of the biotin conjugate 69, in the previous chapter. The reaction was 
followed by HPLC, but no compound with the characteristic absorbance and retention 
time was detected. The use of the commercially available ester 90 also failed to 
produce the desired conjugate. 
99 
o 
H NH R N 
T 
PIPES, Dioxane 
pH=6.8 H H H H 
C 5 ,,N Nu R = CH NO N H H H or(CH2) 4 H 
70 86 
° 85 0 90 0 
Figure 4.7. The attempted synthesis of a Afunctional complexing agent. 
The synthesis of the conjugate 91 proceeded smoothly with the ester 90, and was 
purified by preparative HPLC (figure 4.8.). It appears as though the subtle difference in 
the solubility of the two pentaamines may account for the unsuccessful synthesis of 
conjugates of 70. 
o 
NH 
O 0 0 
^ o so r H H H H 
PIPES, Dioxane 
H H pH=6.8 
48 91 
Figure 4.8. The synthesis of 91. 
Similarly, the monoamide ligand 58 was used to form the bifunctional complexing 
agent 92, incorporating the maleimide group (figure 4.9.) 
T O 
I—V N ^ C O , H COoH N HOoC N HOoC N 
V-N—/ 
l^,H . ^ J k . — 
n H o o 
H 
N PIPES buffer pH 6.8 
NHi*Br Dbxane 
58 92 
Figure 4.9. The synthesis of 92. 
The use of paranitrophenyl active esters is not compatible with the secondary amines of 
the pentaamine ligands 48 and 70. However, the ligands 52 and 58, in which all 
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nitrogens are tertiary are useful for preparing active esters. The reaction of the ligands 
with the bis-ester proceeded cleanly (figure 4.10.), and the presence of the strong 
chromophore facilitated HPLC purification. The reaction of the NOTA derived ligand 
52 proceeded in higher yield than the with monoamide ligand, 58. 
N N T " C 0 2 H CO,H HO,C HO,C 
O 
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NH N 
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58 52 NO XX EtaN 
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N N: C O 2 H N ^ C 0 2 H HOoC N HOoC 
^ - N > - / NO 
O 
| H 9 H 
N 
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29 93 
Figure 4.10. The synthesis of bifunctional complexing agents 29 and 93. 
The potential utility of the Auger emission from copper-64 wan-ants the synthesis of 
bifunctional compounds, which could both bind with the polyanionic DNA molecules, 
and also allow conjugation to the radionuclide or protein targeting vehicle. Two types 
of conjugate can be envisaged. One can modify the protein to possess both a 
complexing agent and an intercalating moiety. Alternatively, the protein can be 
conjugated to a Afunctional molecule, where both the intercalating and radionuclide 
complexing groups are attached via one linkage. These two situations are illustrated in 
figure 4.11., below. 
Intercalator . . 
| Radiolabel V -Radiolabel I 
Intercalator 
Figure 4.11. Possible antibody-intercalator-radionuclide conjugates. 
The simpler approach is to attach both groups individually. The intercalating acridine 
group has been incorporated into an agent 95 suitable for protein derivatisation.4 The 
synthesis (figure 4.12.) from the triamine 96 incorporates one tertiary amine, which 
^ < A 101 
should be protonated at cellular pH, thus providing an electrostatic attraction between 
the intercalating group and the anionic DNA. Two other compounds 98 and 99 were 
synthesised (figure 4.13.) which incorporate maleimide linking groups. The asymmetric 
amine 98 bears a free amine for attaching the complexing agent, and hence provides a 
potential route to the trifunctional complexing agent 100 described above. The final 
coupling was attempted, but the trifunctional conjugate was not identified by 
electrospray mass spectrometry. 
The dimaleimide compound 99 could be used as a non-specific protein modification 
reagent, by employing 2-iminothiolane as a linking molecule. The compound could 
also be further elaborated to provide an alternative synthesis a of trifunctional conjugate, 
figure 4.14. 
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Me 
N 95 
Figure 4.12. The synthesis of the bifunctional intercalating agent 95. 
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Figure 4.13. The synthesis of 98 and 99, precursors to trifunctional complexing 
agents such as 100. 
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4.3. Radiolabelling 
The radiolabelling of the parent ligands 21, 23 and 57 was investigated using carrier 
added copper-64. This nuclide was prepared from a natural abundance copper foil, 
using the reaction 6 3 , 6 5 C u (n, y) ^-^Cu. The copper-66 produced decays rapidly 
(tj/2= 5.1 minutes). The complexation reactions were performed in a 0.2 mol dm"3 
ammonium acetate buffer pH=5.5, at 25°C, with equimolar amounts of copper and 
ligand. The reactions went to completion within 20 minutes. The optimum 
radiolabelling yields, determined by HPLC after challenging the complex with EDTA, 
are tabulated below (table 4.1.). 
Radiolabelling Yield / % 
Ligand 20 mins 60 mins 
21 100 100 
23 100 100 
57 60 60 
Table 4.1. Radiolabelling of parent ligands with ^Cu. 
The radiolabelling of 21 and 23 is very good. The 60% labelling shown by the 
monoamide ligand 57 is a little disappointing, as it would be expected that the anionic 
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ligand would electrostatically attract the cationic copper ions. The EDTA challenging 
step could result in some trans complexation, but the radiolabelling was not affected 
when a greater excess of EDTA was added. At the no carrier added concentration, it 
would be expected that a higher labelling yield would be obtained, as there would be an 
excess of ligand over copper. 
.4. Conjugation to Antibody 
There are two distinct methods for attaching the complex to the antibody.5 In the post-
labelling approach the ligand is attached to the antibody, and then the conjugate is 
radiolabeled. The pre-labelled strategy involves the formation of the copper complex, 
followed by attachment of the complex to the antibody. The post-labelling method is 
clearly more efficient for short lived radionuclides, but the labelling conditions used for 
some metals, in particular the reductive methods used with technetium-99m, may be 
incompatible with the vulnerable protein. Also, the post-labelling strategy can result in 
a large amount of non-specific binding to certain amino acid sequences on the protein, 
which may dissociate in vivo leading to loss of the radionuclide. This is minimised for 
copper by labelling under mildly acidic conditions (pH 4-5.5).2 The pre-labelling 
approach has the advantages that the protein is not subject to the labelling conditions, 
and, if the complex is purified before conjugation, does not result in non-specific 
binding. 
The approach employed in this work depended on the particular conjugate. In all cases 
carrier free copper-64 was used. The maleimide ligands 91 and 92 were pre-labelled. 
The complexes were made by incubating the ligand with the ^CuC^ solution for 30 
minutes at pH 6, 25°C. Any free ^ Cu 2 * ions were then sequestered by the addition of 
DTPA. Analysis by TLC indicated 60-80% labelling for both conjugates. The mixture 
of the maleimide complex and the DTPA complex were added to a solution of ICR-12 
(1 mg ml"1) followed by the addition of 2-iminothiolane.6 The reaction mixture was 
incubated at 37 °C for 1 hour, with periodic mixing. In contrast, the NOTA derived 
ligand 29 was conjugated to the protein, by incubation at 37°C. The excess ligand was 
removed by the use of a gel filtration column (PD10). The copper solution was then 
added and the mixture incubated for 1 hour at 37°C, before adding EDTA. All three 
conjugates were then purified by chromatography on pre-packed PD10 columns. 
5. Immunoreactivity 
It is important to monitor the effect of introducing the unnatural prosthetic groups to the 
antibody. Ideally, the labelled antibody will show a similar affinity for the antigen 
binding site as the untreated antibody. In practice this is seldom achieved, but usually 
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most of the activity is retained. The immunoreactivity of the conjugate is a measure of 
retained binding capability. For example, if three-quarters of the modified protein still 
binds, the conjugate is said to have an immunoreactivity of 75%. 
The measurement is made in vitro, and thus provides information solely on the relative 
ability of the modified protein to bind with the receptor. No indication is gained about 
the stability of the conjugate in the presence of the broad spectrum of enzymes, which 
will attempt to metabolise the conjugate. 
The determination of the immunoreactivity is made with nanogrammes of antibody, and 
so a sensitive method of detection is required. Colorimetric methods are often used to 
determine such low concentrations of analytes, but here radionuclides were employed. 
Two simple protocols can be envisaged for determining the amount of protein bound. 
As the conjugates to be evaluated are radiolabeled, a simple measure of the amount of 
radioactivity bound to the antigen can be made. Alternatively, the ability of the 
conjugate to block the binding of another radiolabeled conjugate, which is known to 
have a high specificity for the antigen, can be measured. The method used for 
determining the immunoreactivity of the three conjugates is based on the method 
developed by Lindmo.7 
The antigen was coupled to sepharose beads by Dr Christopher Dean. The absolute 
amount of antigen is not known, but by measuring the binding at several concentration 
ratios, the amount of binding at infinite antigen concentration can be determined 
graphically by extrapolation. Each conjugate (~2ng) was added to Eppendorf tubes 
containing 1, 2 and 3 units of antigen coated beads. The Eppendorf s were gently 
rotated at 4°C for 4 hours. The tubes were centrifuged and the supernatant removed. 
The pellet was washed and recentrifuged. The pellets, supernatants and washes were all 
counted in a y-counter, enabling the amount of radioactivity bound to be determined. 
A double inverse plot of (activity bound)"1 against (antigen units)"1 gives a straight line. 
Extrapolation to (antigen units)"1 = 0 (i.e. the y-axis) gives the (activity bound)"1 at 
infinite antigen concentration. Thus, simply taking the reciprocal of the intercept on the 
y-axis gives the immunoreactivity. The graph below (figure 4.15.) illustrates the type of 
plot obtained. 
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Figure 4.15. A Lindmo plot for the determination of immunoreactivity. 
The immunoreactivities obtained by this method are tabulated below (table 4.2.). The 
data obtained showed some scatter as indicated by the rather poor correlation. 
Conjugate Immunoreactivity Correlation 
64Cu-91-ICR12 79 0.84 
64Cu-92-ICR12 40 0.70 
64Cu-29-ICR12 15 0.83 
Table 4.2. The immunoreactivities of conjugates. 
The values indicate that some specificity has been retained by all three conjugates. The 
amount of antigen on the beads is very much lower than the amount of antigen present 
on tumour cells. It is, therefore, possible that more of the 64Cu-29-ICR12 conjugate 
may become bound in the presence of a higher concentration of antigen found in a real 
tumour. 
4.6. In Vivo Evaluation 
The biodistribution profiles of the three conjugates were determined in nude mice, 
bearing bilateral MDA MB 361 tumours. The tumours were initiated by Dr Suzanne 
Eccles from trocar fragments. Each mouse received two fragments, located at the 
midpoint of each flank. The tumours were allowed to mature for three weeks. At this 
time all mice exhibited at least one good tumour, i.e. one with a visible increase in size 
and an indication of the formation of blood vessels. The conjugates were administered, 
by Dr Suzanne Eccles, to fifteen mice whilst under anaesthetic (halothane). Six mice 
received the ^Cu^l- ICRH conjugate, six received the 64Cu-92-ICR12 conjugate and 
three received the ^Cu-^-ICR^ conjugate. Three mice from each of the ^C\x-9\-
ICR12 and ^ C u ^ - I C R ^ groups were sacrificed at 5 hours, by cervical dislocation. 
The remaining nine were killed at 24 hours. Organs of interest were removed by 
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dissection, weighed and the radioactivity measured in a y-counter. The amount of 
radioactivity in the tissues are tabulated below (table 4.3.), expressed as the percentage 
injected activity per gram of tissue. 
%injected activity g" 
^u-JH-ICRU ^ C u ^ - o m ^ C u ^ - I C R H 
5 hours 24 hours 5 hours 24 hours 24 hours 
Blood 2.07+0.94 2.1810.56 1.2210.06 0.9810.21 1.4010.21 
Kidney 5.65+0.14 5.4610.29 3.4310.22 2.4310.29 4.8610.15 
Heart 3.30±0.02 3.3110.57 1.8910.07 1.8310.40 3.8510.87 
Spleen 6.3210.60 4.7811.11 2.7110.58 2.1610.69 4.6311.34 
Liver 11.8±1.61 9.3711.81 5.1010.70 3.5710.35 7.2010.69 
Lungs 38.0+6.92 19.914.36 8.7013.28 6.4412.76 5.3910.57 
Tumour 6.0812.85 3.4511.31 2.6810.79 2.58+0.37 12.916.02 
Intestines 5.6011.90 3.2310.41 2.6210.34 1.8210.15 3.271X).13 
Table 4.3. The biodistribution profile of three radiolabeled ICR12 conjugates. 
The data show a rapid clearance from the blood in the first five hours, followed by a 
much slower clearance phase. Whilst the low blood background level of radioactivity is 
desirable, it suggests that the conjugates were not as pure as believed, indicative of 
some low molecular weight free complex or antibody fragments. A figure of ~10%i.d. 
g"1 would be more consistent with other results. The very high uptake in the lungs with 
the 64Cu-91-ICR12 group suggests that some particulates may be present in the sample, 
and that the conjugate is being mechanically trapped in the first capillary bed 
encountered. The nature of a colloidal species is not known, but the aggregation of 
proteins is clearly possible. The high uptake in the liver compared to the blood suggests 
some denaturation of the protein has occurred, consistent with the observed loss of some 
immunoreactivity. (Ideally the liver uptake should be about one third of the blood, as 
approximately 30% of the the liver's weight is blood.) 
The tumour uptake is quite high, particularly when the rapid clearance of most activity 
is taken into consideration. The tumour to blood ratios are very encouraging. At 24 
hours the ratios are 1.6:1,2.6:1 and 9.2:1 for the three conjugates, which compare 
favourably with the tumounblood ratio of 1.2:1 obtained in the biodistribution of the 
same antibody labelled with iodine-124.1 However, the iodinated antibody shows little 
sign of protein damage, with a very low amount of activity in the liver, blood:liver ratio 
-4:1. The longer half-life (100 hours) of 1 2 4 I permits the study over a longer time 
period. At five days the tumounblood ratio had risen to 2:1 
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4.7. Conclusions 
The high tumour to blood ratio obtained with the conjugates are promising. However, 
further work is required to ensure more of the conjugate stays in the circulation for 
longer. In particular an improved purification procedure is desirable. The use of a 
chromatographical separation by the use of an HPLC gel filtration column would result 
in a reduction of protein aggregates, and perhaps also reduce the breakthrough of any 
low molecular weight fragments. 
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Chapter Five 
Synthetic Procedures 
5. Synthetic Procedures 
The methods and instrumentation employed for the purification and characterisation of 
compounds are detailed. (5.1.) The synthetic procedure used for each compound 
synthesised (5.2.) is reported, in order of appearance in the text of chapters two to four. 
.1. Instrumentation and Chemicals 
Chromatography 
Column chromatography was carried out using either neutral alumina (Merck Art 1077), 
which had previously been treated with ethyl acetate, or "gravity" silica (Merck Art 7734) 
using the eluent specified. Rf values refer to either alumina TLC (Merck Art 5550) or silica 
gel TLC (Merck Art 5554.) HPLC analyses were performed on a Varian 9010 / 9065 
Polychrom system using either reverse phase, anion exchange or cation exchange column 
with a flow rate of 1.4ml min"1. Semi-preparative HPLC was achieved using either the 
above system or a Varian Vista 5500 / 9050 system equipped with a reverse phase or anion 
exchange column, operating at a flow rate of 5.0ml min"1. A larger reverse phase column, 
operating at 10ml min"1, was also employed on the Vista. "TFA" refers to 0.1% 
trifluoroacetic acid added to the solvent. The specific solvent system used for each 
purification is stated individually. 
Spectroscopy 
Several spectrometers were used for acquiring NMR spectra. *H NMR were recorded on 
either a BrukerAC250, Varian Gemini-200, XL-200, VXR-200 or VXR-400. 1 3 CNMR 
were obtained on the Gemini, and 3 1 P NMR on the Briiker. Variable temperature NMR 
spectra were obtained on a Briiker AMX500. The NMR solvent used is stated in brackets, 
followed by the chemical shifts, in parts per million, to high frequency of TMS for lH and 
1 3 C or H3PO4 / H2O for 3 1P NMR. Peaks are referenced to known solvent peaks, except 
for phosphorus spectra, which are referenced externally to 85% phosphoric acid. Coupling 
constants are given in Hertz. For spectra acquired in deuterated water, an approximate 
acidity is given. 
Infra-red spectra were recorded with a Perkin-Elmer 1600 FTIR spectrometer. Samples 
were prepared either as a KBr disc or as a thin film on NaCl plates. Frequencies are quoted 
in cm' 1. 
Ultra-violet / visible spectra were obtained on either a Kontron Instruments Uvikon 930 or 
Unicam UV2. Absorption maxima are quoted in nanometres. 
I l l 
Luminescence measurements were made with a Perkin-Elmer LS50B spectrometer, in both 
protiated and perdeuteriated solvents. Lifetimes and quantum yields of luminescent 
complexes were determined by monitoring the decay in phosphorescence after excitation at 
277nm. The number of bound water molecules (q) was estimated according to the method 
of Horrocks.1 
Mass spectra were recorded with a VG 7070E spectrometer, operating in CI, DCI or FAB 
modes, with DCI samples presented as dilute methanol or dichloromethane solutions, 
ammonia being used as the impingent gas. A glycerol matrix was used for the FAB 
spectra. A VG Platform electrospray mass spectrometer was also used, both in negative 
and positive modes. Typically, samples were analaysed with a cone voltage of 110 volts, 
presented as aqueous methanol or acetonitrile solutions (~10~-5mol dm"^). 
Analysis 
Elemental analyses were determined on a Carlo ERBA 1106. 
Melting points were determined on a Reichert Kofler Block and are uncorrected. 
Reagents and Solvents 
Reagents were used as received, unless otherwise stated. Solvents were dried from an 
appropiate drying agent: methanol and ethanol from the corresponding magnesium 
alkoxide, dichloromethane and acetonitrile from calcium hydride, chloroform from 
phosphorus pentoxide, pyridine from potassium hydroxide, tetrahydrofuran from 
potassium, and ether from sodium. Benzophenone was used as an indicator when drying 
ethereal solvents. Dimethylformamide and dimethylsulfoxide were used directly from 
"sure-seal" bottles, and water was purified by the "Purite" system. 
.2 Syntheses 
The characterisation of compounds is reported, after the synthetic procedure, in the order 
chromatography, NMR data, IR data, UV/visible spectra, luminescence data, mass spectra, 
elemental analysis and melting point. 
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5.2.1. Chapter 2 
N,N"-bis(tertiarybutylcarbamoylmethyl) diethylenetriamine-N,N',N"-triacetic acid 31 
HO2C 
r 
— N 
C02H O 
N ^ 
N H - t " 
CO,H 0 
To a stirred solution of diethylenetriamine pentaacetic acid dianhydride (DTPAA, 25) 
(357mg, lmmol) in pyridine (5ml) was added tertiary butylamine (315jiL, 219mg, 3mmol) 
and N,N-dimethylamino-pyridine (DMAP, 5mg.) The solution was heated to 50°C and 
stirring continued for 36 hours, under argon. The reaction mixture was then cooled and the 
pyridine removed under reduced pressure. Water (1ml) was added and the pH lowered to 2 
(HC1). Ethanol was added and the precipitated DTPA filtered off. The remaining solution 
was basified (pH=13) with 1.0 mol dm"3 NH4OH and washed with chloroform (10ml). 
Concentration afforded the triammonium salt as a white solid. (123mg, 24%) 
lU NMR(D 20, pD ~7) 1.20(18H, s, Me), 3.06(4H, br t, NCH2CH2N), 3.37(4H, br t, 
NCH2CH2N), 3.49(2H, s, NCH2CO), 3.91(4H, s, NCH2CO), 3.92(4H, s, NCH2CO) 
1 3 C NMR (D 20) 27.6(CH3), 49.3, 53.6,55.2,56.5(CH2N), 164.2 & 169.4(2C+2C, 
CONH+C02"), 173.4(1C, C02") IR(KBr disc) 3246 (v br), 3066,1733 (acetate), 1677 
(amide), 1567,1457,1406,1222 MS(ES-) 502.59 (M-l) ( C 2 2 H 4 1 N 5 0 8 requires 502.29) 
A satisfactory elemental analysis could not be obtained m.p. 163-170°C 
N,N"-bis(isobutylcarbamoylmethyl) diethylenetriamine-N,N',N"-triacetic acid 32 
HO2C 
r 
C0 2H ,0 
(M 
N N-
H 
— N 
^-N N-
C0 2H O 
The reaction was carried out as above. DTPAA 25 (227mg, 0.636mmol) was reacted with 
isobutylamine (189jiL, 139mg, 1.91mmol) for 24 hours, to give a white solid ammonium 
salt. (215mg, 61.0%) 
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lH NMR(D 20, pD ~7) 0.86(12H, d (J=6.6Hz), Me), 1.78(2H, m, CH2CHMe2), 3.04(4H, d 
(J=6.7Hz), NCH2CH), 3.20(8H, s br, CH 2N (backbone)), 3.55(4H, s, NCH2CO), 3.67(2H, 
NCH 2C0 2H), 3.73(4H, s, NCH2CO) 1 3 C NMR (D 20) 19.3(CH3), 27.7(CH), 46.6, 51.1, 
51.6, 57.3, 57.5, 57.5(CH2N), 169.7(2C), 171.9(1C, C 0 2 ) , 174.4(2C) IR(KBr disc) 3154 
(br), 2963,1634,1401 MS(ES-) 502.53 (M-l) ( C 2 2 H 4 1 N 5 0 8 requires 502.29) Found 
C=46.65 H=8.48 N=15.16 C 2 2 H 4 1 N 5 0 8 .NH 3 .2 .5H 2 0 requires C=46.71 H=8.73 N=14.86 
m.p. 96-98°C 
N-(3,5-bistrifluoromethylbenzylcarbamoylmethyl) diethylenetriamine-N,N',N",N"-
tetraacetic acid 33 
DTPAA 25 (71mg, 0.198mmol) and 3,5-bistrifluoromethylbenzylamine (106mg, 
0.436mraol, 2.2 equiv.) were stirred in pyridine (5ml). DMAP (2mg) was then added, and 
the temperature of the solution raised to 60°C Stirring was continued for a further 18 hours. 
Preparative HPLC afforded the trifluoroacetate salt. (23mg, 19%). 
HPLC: Dynamax 60A (10ml min"1); elution A=MeCN/TFA; B=H20/TFA; from 10% A, 
90% B, to 75% A, 25% B in 20 minutes A,=254nm R t= 15.3 minutes 1 HNMR(D 2 0,pD 
~4) 3.12(8H, m, CH 2N (backbone)), 3.41(4H, s, NCH2CO+NCH.2C02H), 3.68(4H, s, 
NCH 2C0 2H), 3.71(2H, s, NCH 2C0 2H) 4.42(2H, s, benzylic), 7.72(2H, s, ArH), 7.85(1H, 
s, ArH) 1 9 F NMR(D20) -63.1 IR(film) 3196, 3072,1669 (with shoulder to low 
frequency), 1401,1282,1203,1183,1132 MS(ES-) 617.46 (M-l) (C 2 3 H 2 7 N 4 09F 6 
requires 617.17) 
N,N"-bis(3,5-bistrifluoromethylbenzylcarbamoylmethyl) diethylenetriamine-N,N',N"-
triacetic acid 34 
The reaction was performed as above, using DTPAA 25 (310mg, 0.86mmol) and 3 
equivalents of 3,5-bis-trifluoromethylbenzylamine (633mg, 2.61mmol). HPLC afforded a 
flocculent white hygroscopic solid (141mg, 19%). 
COoH.O CF 
<7^ 
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HPLC: Dynamax 60A (10ml min' 1); elution A=MeCN/TFA; B=H20/TFA; from 10% A, 
90% B, to 75% A, 25% B in 20 minutes X=254nm Rt=19.8 minutes X H NMR(CD3OD) 
3.23 & 3.48(4H+4H, 2xbr s, CH 2N (backbone)), 3.61 & 3.65(4H+4H, 2x s, 
NCH2CO+NCH2C02H), 4.22(2H, s, NCH2C02H), 4.51(4H, s, benzylic), 7.80(2H, s, 
ArH), 7.84(4H, s, ArH), 1 3 C NMR (CD3OD) 43.2,51.0,54.5, 56.1,58.0(CH2N), 
122.0(2C), 124.8 (q, JCF=270Hz, CF3), 129.1(4C), 132.8 (q, JC C F=33Hz, CCF3), 
143.3(quaternarycarbon), 169.3(1C,C02), 173.6 & 174.2(2C+2C,CONH+C02) 
1 9 F NMR(CD3OD) -63.2 IR(film) 3292,2936,1668,1552, 1390,1286, 1178, 1136 
MS(ES-) 842.35 (M-1) + (C 3 2 H 3 2 N 5 0 8 F 1 2 requires 842.21) a reliable melting point could 
not be determined because of the hygroscopic nature of the ligand. 
3-methoxybenzylmagnesiunichloride 
3-Methoxybenzylchloride (6.42g, 41mmol) was added to a stirred suspension of 
magnesium (2g, excess) in THF (40ml), with a crystal of iodine. After an incubation period 
a vigorous reaction commenced. The reaction was stirred for 1 hour, and boiled gently due 
to the exothermic reaction. The quality of the Grignard reagent was assessed by quenching 
a sample in D 2 0. NMR intensities show almost quantitative conversion. The reaction was 
found to proceed equally well in dry ether. Integration of the two singlets to low frequency 
of the isotopically labelled 3-methoxy-[2H]-toluene indicated near quantitative conversion. 
lH NMR 2.9(2H, s, CH2D), 3.8 (3H, s, OMe), 6.7-7.4 (4H, m, ArH) 
(3-methoxybenzyl)diethoxyphosphine 42 
OEt 
6. EtO OMe 
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An ethereal solution of the Grignard reagent, prepared above (ca. 24mmol) was filtered, via 
a steel cannula, to remove unreacted magnesium. Diethyl chlorophosphite (3.6ml, 3.88g, 
24mmol) was added at a temperature of -20°C. The product was not isolated in a pure form 
as the compound exhibits a propensity to decompose when distilled. A 72% conversion 
was estimated from NMR analysis of 3 1 P intensities, by comparison of the product's 
resonance, with that of the oxidised material (8p=26ppm). 
lH NMR (CDCI3) 1.23 (6H, t, CH 3), 2.95 (2H, d (J=3.9Hz), CH2P), 3.81 (3H, s, OMe), 
3.89 (4H, qd (J=1.4Hz), OCH2), 6.8 (3H, m, ArH), 7.2 (1H, t, ArH) 1 3 C NMR 16.9(CH3), 
42.7 (d ( J C P ~80Hz), ArCH2) 54.8(OCH3), 62.9(d (JC 0 P=21Hz), OCH2), 111.2,112.4 , 
114.8, 121.8, 130.0(Ar), 159(£OMe) 3 1 PNMR (CDCI3) 176.8 (s) IR (film) 2974,1600, 
1490, 1198,1163 MS (DCI) 243 (M++1) 
Tetraethyl-1,4,7,10-tetrakis( methylenetetra(3-methoxybenzylphosphinate))-l,4,7,10-
tetraazacyclododecane 43 
-9 
MeO 
OEt OEt 
N N ' - ^ I on 
^-6 
OMe 
MeO 
EtO E O 
6-X OMe 
To a stirred solution of 1,4,7,10-tetraazacyclododecane 41 (475mg, 2.76mmol) and 
paraformaldehyde (414mg, 13.8mmol), boiling under reflux, over 4A molecular sieves, in 
THF, under an argon atmosphere, was added crude (3-methoxybenzyl)diethoxyphosphine 
42 (assumed to be 80% pure, 13.8mmol.) An orange precipitate was formed almost 
immediately, and the remaining solution became orange and turbid. The reaction mixture 
was allowed to cool after 6 hours, and solvent was removed under reduced pressure. 
Column chromatography (alumina EtOH:CH2Cl2 gradient elution from 0-5% ethanol) of 
the residue afforded the ester as a pale yellow glass. (528mg, 18%) 
TLC (5% EtOH:CH2Cl2) Rf=0.4 HPLC: Spherisorb 50DS2 (1.4ml min"1); elution 
A=MeCN/TFA; B=H20/TFA from 5% A, 95% B to 95% A, 5% B over 30 minutes; 
observed X=278nm; Rt=24.8minutes (Very broad); *H NMR (CDC13) 1.15Q2H, t, CH3), 
2.8(24H, m, CH2N), ~3.2(8H, m, ArCH2P), 3.75(12H, s, OMe), 3.8-4.2(8H, m, OCH2), 
6.84(12H, m, ArH), 7.17(4H, t, ArH) 1 3 C NMR (CDC13) 16.5(CH3), 35.8(d (JCP=81Hz), 
116 
Ar£H 2P), 52.6(d (JCP=107Hz), PCH2N), 53.5(CH2N), 55.1(00%), 60.8(OCH2), 112.1, 
115.5, 122.2, 129.4(Ar), 132.9(quaternary Ar), 159.5(£OMe) 3 1P NMR (CDC13) 49.3 
IR(film) 2980, 2835,1663,1600, 1498,1452,1298,1268,1213, 1151 MS(CI) 
1077(M++1), 215 (100%) MS(FAB, NOBA) 1077(M++1) 1099(M++Na) MS (FAB, PEG) 
found 1077.4801 C 5 2 H 8 1 N 4 0 1 2 P 4 requires 1077.4801 
1,4,7\10-tetrakis(methylenetetra(3-methoxybenzylphosphinic acid))-l,4,7,10-
tetraazacyclododecane 36 
The ester 43 was hydrolysed with potassium hydroxide solution (lmol dm"3), and the 
potassium salt was used to form lanthanide complexes without isolating the tetraphosphinic 
acid 36. A small amount of the 3-methoxy substituted ligand was purified by HPLC for the 
purpose of characterisation. 
HPLC: Synchropak AX100 (5ml min"1); elution A=MeCN; B=H 20; C=NH4OAc pH=5.6 
from 20% A, 70% B, 10% C to 20% A, 0% B, 80% C in 20 minutes Rt=13.1 minutes 
*H NMR(D 20, pD ~6) 2.8-3.2(32H, m (maxima at 2.82,2.91, 3.09), CH2N+ArCH2), 
3.65(12H, s, OMe), 6.76(12H, br s, ArH), 7.16(4H, t, ArH) 1 3 C NMR (D 20) 41.2 (d 
(JCP=87Hz), ArCH2P), 54.1 (CH2N ring), 54.1 (d (JCP=93Hz), NCH2P), 58.1 (OMe), 
115.1(4JCP=2.8Hz), 118.2(3JCP=5.4Hz), 125.5(3JCP=5.3Hz), 132.8(5JCP=2.6Hz), 
137.7(2JCP=8.0Hz), 161.8(4JCP=2.8Hz) 3 1 P NMR (D 20) 31.9 (br) IR(film) 3326(br), 
1682, 1595, 1486,1448,1266,1164, 1039 MS(ES-) 1016.4(100%) (M++52) 507.9(100%) 
(M+52) 2 + 
l,4,7,10-tetraazacyclotridecane-l,4,7,10-tetraacetic acid 2 44 
3 
MeO 
r " 0 
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CO,H 
5 HO,C N N N CO,H 
CO,H 
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1,4,7,10-tetraazacyclotridecane 21 (183mg, 0.984mmol) prepared by J.R.Morphy was 
stirred in water (15ml). Chloroacetic acid (560mg, 6 equiv.) was then added and the pH 
modified to 10 using lithium hydroxide. The mixture was stirred at 80°C for 18 hours. The 
reaction was then acidified and concentrated. The product was recrystallised from ethanol 
to give a white solid (174mg, 42%) 
lH NMR(D 20, pD ~3) 2.07(2H, p, CH2), 3.3(16H, m, CH2N), 3.83(8H, br s, NCH2CO) 
m.p. 160-165°C (dec.) (lit. 3 185°C) 
Lanthanide Complexes 
[La(31)] 
The complex of the tertiarybutylamine derived ligand 31 was prepared in the same manner 
as for the isobutylamine complex [La(32)], but, during the reaction, the complex 
precipitated out, as a white solid. The ligand 31 (66mg, 131|0,mol) was reacted with 
lanthanum acetate (42mg, 131p,mol). The complex (54mg, 64%) was found to be soluble in 
dilute hydrochloric acid (O.lmol dm"3). 
lH NMR(D 20, pD ~1) 1.11(18H, s, CH3), 3.08(4H, br t, CH2N), 3.43(4H, br t, CH2N), 
3.54(2H, s, NCH2CO), 3.97(4H, s, NCH2CO), 4.11(4H, s, NCH2CO) 1 3 C NMR (D 20) 
30.2(CH3), 51.7, 54.7, 56.0,56.3, 58.0,59.3(CH2N), 166.2,170.9,176.2(CO) IR(KBr 
disc) 3100 (v br), 1740,1636 (br), 1402,1250 MS(ES+) 320.8 (100%) (M+2) 2 + , 639.88 
(55%) (M+l) + ( C 2 2 H 3 9 N 5 0 8 requires 640.19), 640.7 (90%) (M+2)+ A satisfactory 
elemental analysis was not obtained m.p. >250°C 
[La(32)] 
A solution of ligand 32 (26mg, 52|imol) and lanthanum acetate (16mg, 52p.mol) was stirred 
at 80°C for 16 hours, pH=6. The solvent was removed, and the complex purified by 
chromatography on alumina (25% MeOHiCF^Cl^ to give a white solid. (9mg, 27%) 
TLC(10%MeOH:CH2Cl2) Rf=0.9 lH NMR(D 20, pD ~7) 0.74(12H, d, CH 3), 1.6(2H, m, 
CH), 2.2-3.7(22H, br m, CH2N) 1 3 C NMR(D20) 17.4(CH3), 25.7 & 25.9(CH+CH), 45.2, 
45.6, 54.0, 55.3, 58.6, 60.1, 60.5(CH2N), 172.6, 173.3, 177.9, 178.0, 178.7(CO) IR(KBr 
disc) 3416, 3250, 3092, 2960, 1620 (br), 1403,1331,1257, 1159,1098 MS(ES+) 640.61 
(M+l) + (C 2 2 H 3 9 N 5 0 8 La requires 640.19) A satisfactory analysis could not be obtained 
m.p. 205-210°C (dec.) 
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[La(34)] 
The fluorinated ligand 34 (33mg, 38.9|j.mol) was taken up in methanol (0.5ml) and water 
(5ml). Lanthanum acetate (12.3mg, 1 equiv.) was then added, and the reaction mixture was 
stirred at 80°C for 16 hours. The complex (7mg, 17%) was isolated by preparative HPLC. 
HPLC: Dynamax 60A (10ml min"1); elution A=MeCN; B=H 20; from 10% A, 90% B, to 
75% A, 25% B in 20 minutes X=254nm Rt=18.8 minutes *H NMR(CD3OD) 2.3-3.7(18H, 
m (symmetry of ligand lowered by complexation), CH2N), 4.7(4H, m, benzylic), 7.95(6H, 
s, ArH) 1 9 F NMR(CD3OD) -63.3 (s) IR(film) 2932, 1624, 1394, 1282, 1178, 1132 
MS(ES+) 1019.45 (M+K+l)(C 3 2 H 3 1 N 5 0 8 F 1 2 KLa requires 1019.06) m.p. >250°C 
[Eu(34)] 
The europium complex was made by the same method as the lanthanum complex above, on 
a 21.9(imolar scale. The reaction was left stirring at 80°C for 36 hours. The complex was 
purified by HPLC, to give a white solid. (7mg, 32% yield) 
HPLC: Dynamax 60A (10ml min'1); elution A=MeCN; B=H 20; from 10% A, 90% B, to 
75% A, 25% B in 20 minutes X=254nm Rt=18.8 minutes lH NMR(CD3OD) -14.0, -13.7, 
-7.6, -6.8, -6.1, -3.9, 1.0, 2.5, 5.4, 7.0, 8.4,9.1,9.8, 10.2, 11.3, 11.4, 12.0, 22.6, 25.4, 30.9 
1 9 F NMR(CD3OD) -60.3 (6F, s), -61.1 (6F, s) IR(film) 3405 (br), 2926,1615, 1381,1280, 
1176,1131 MS(ES+) 1014,1015,1016.52 (M+Na), 1018,1019 (C 3 2 H 3 0 N 5 O 8 F 1 2 NaEu 
requires 1016.10) m.p. 210-215T (dec.) 
[La(18)]-
The ligand 18 (210mg, 0.256mmol) was dissolved in water (25ml). To this was added 
lanthanum oxide (41.6mg, 0.5equiv) and the mixture stirred for 8 hours at 80°C. The pH 
was modified to 6-7 (KOH), and the reaction left to continue for another 3 hours. The 
reaction mixture was allowed to cool. The complex was recrystallised from water, after 
filtration, to give colourless crystals which became opaque on losing water of crystallisation 
in vacuo. (201mg, 77%) 
lH NMR(D 20, pD ~6) 2.01 (4H, d (J=13Hz), CH 2), 2.18 (8H, d (J=13Hz), CH 2), 3.0-3.6 
(20H, br m, CH 2), 7.14(4H, br m, ArH), 7.22 (16H, br m, ArH) 1 3 C NMR (D 20) 41.4 (d 
(JCP=92Hz), ArCH2P), 54.5,54.7, 56.7, 58.5 (d (JCP=98Hz), NCH2P), 129.2,131.5(Ar), 
132.8 (d (3JC P=5Hz), AT), 136.7 (d (2JCP=8Hz), quaternary Ar) 3 1 P NMR (D 20) 37.6, 38.8 
ratio =8:1 IR (KBr disc) 1654, 1601, 1495, 1453, 1233, 1167, 1124, 1026 MS(ES-) 
979.24 (C4oH52N40gP4La) requires 979.18) An accurate analysis was not obtained for 
this complex mpt >250 (dec) The crystal structure analysis of this complex is nearing 
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completion. The preliminary data shows the complex has one water molecule in the inner 
co-ordination sphere. 
[Pr(18)]" 
The tetrabenzylphosphinic acid ligand 18 (134mg, 0.159mmol) and praesodymium nitrate 
hexahydrate (69mg, 0.159mmol) were stirred for 18 hours in water (10ml, pH=5) at 80°C. 
The complex was collected by filtration after concentration, as an off-white solid. (51mg, 
31%) 
lH NMR(D 2 0 , pD ~6) -37.1(4H), -3.8(4H), -1.1(4H), 7.8(4H), 8.9(4H), 9.1(8H), 
11.1(8H), 11.8(4H), 14.1(4H), 16.9(4H), 32.6(4H) 1 3 C NMR (D 2 0) 14.0 (d (JC P~100Hz)), 
36.0, 52.3, 53.2,76.7 (d ( J C P ~80Hz), 128.8,130.7,132.6,139.0 3 1 P NMR (D 2 0) 34.2 
IR(film) 1656, 1552,1500,1456,1158,1032 MS(ES-) 980.91 ( C ^ H ^ ^ O ^ P r 
requires 981.18) A satisfactory analysis was not obtained m.p. >250°C 
[Yb(18)]"4 
The ligand 18 (95mg, 0.113mmol) and ytterbium oxide (22.2mg, 0.056mmol) were stirred 
at 80°C for 18 hours. The pH was raised to 6, by addition of hydrochloric acid, and the 
reaction continued for a further 4 hours. The product, isolated by lyophilisation as a white 
solid (81mg, 69%), was found to be soluble in weakly basic solution. 
lH NMR(D 2 0 , pD -11) -68.2 , -35.4 , -28.4, -9.4, -2.8, 2.7(t), 7.4(2H, m), 14.9(2H, m), 
18.6(2H,m), 19.7, 33.0(2H) 104.0 3 1 P NMR (D 2 0) -40.7 MS(ES-) 1014.7 
(C4oH 5 2 N 4 0 8 P4Yb requires 1014.2) Crystals suitable for X-ray analysis were obtained of 
this complex. The preliminary data are consistent with the absence of an inner sphere water 
molecule. This is in accord with the analagous europium, gadolinium and yttrium 
complexes but not with the larger lanthanum complex. 
[La(36)]" 
The lanthanum complex was prepared in an analagous manner to the europium complex. 
The ester 42 (508mg, 0.472mmol) was subjected to base hydrolysis, followed by reaction 
with lanthanum acetate (166mg, 0.524mmol). Preparative HPLC afforded a white solid 
(130mg, 25%). 
HPLC R t=9.2 minutes *H NMR(D 2 0, pD ~6) 2.14 (4H, d (J=15Hz), CH 2 ) , 2.30 (8H, d 
(J=12Hz), CH 2 ) , 3.0-3.6 (20H, br m, CH 2 ) , 3.72(12H, s, OMe), 6.8(12H, br m, ArH), 7.21 
(4H, t, ArH) 3 1 P NMR (D 2 0) 37.5,38.8 ratio =8:1 (collapsed to a singlet on heating) 
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IR(KBrdisc) 3135, 3049,1762,1601,1405,1261, 1163 MS(ES-) 1099.34 
(C 4 4 H6QN 4 Oi 2 P 4 La requires 1099.22) A satisfactory analysis was not obtained m.p. 
>250°C (dec) 
[Tb(36)]" 
To the crude acid 36 (42.4mg, 43.9|imol) in water (0.5ml, pH=6) was added terbium 
triacetate (14.8mg, 43.9p.mol). Stirring at 80°C for 14 hours, followed by filtration and 
removal of the solvent under reduced pressure, afforded the complex. (42mg, 86%). A 
small sample was purified by preparative HPLC for the luminescence measurements. 
Synchropak AX100 (1.4ml min-1); elution A=MeCN; B=H 2 0 ; C=NH 4OAc pH=5.6 from 
20% A, 70% B, 10% C to 20% A, 0% B, 80% C in 20 minutes R t=9.7 minutes 
*H NMR(D 2 0 , pD ~6) -198 (v br), -126 (br), -117 (br), -93, -73 (br), -57, -42 (12H), 35 (v 
br), 51 (br), 140 (v br), 199 (v br), 290 (v br) 3 1 P NMR (D 2 0) 441 (br) IR (KBr disc) 3404, 
1600, 1487,1297,1268, 1231,1168,1119 uv (H 2 0) Amax=273, 278 e=3.6xl0 3 M " 1 cnr* 
x(H 2 0)= 4.08ms x(D20)=4.42ms <|> (H 2 0) = 0.40, (|> (D 2 0) = 0.46 q=0.08 MS(ES-) 
1119.3, 1120.3,1121.3 (C44H 6 0N 4O 1 2P4Tb requires 1119.24) m.p. >250°C (dec.) 
[Eu(36)]" 
The europium complex was prepared from the ester 42, without isolating the intermediate 
acid 36. The ester 42 (55mg, 51|i.mol) was taken up in ethanol (1ml) and water (10ml). A 
large excess of potassium hydroxide was added (0.5g) and the reaction stirred at 60°C for 3 
hours. Phosphorus NMR analysis verified the consumption of the ester 42 and the 
emergence of the potassium salt of the acid 36. The pH was modified to 6.5 (HC1) and 
europium acetate (16.8mg, 51|i.mol) was added, after filtration. The complexation was 
stirred for 12 hours at 60°C before concentrating. Preparative anion exchange HPLC gave 
the complex. (16mg, 28%). 
Synchropak AX 100 (5ml min' 1); elution A=MeCN; B = H 2 0 ; C=NH 4OAc pH=5.6 from 
20% A, 70% B, 10% C to 20% A, 0% B, 80% C in 20 minutes R t = l 1.9 minutes 
*H NMR(D 2 0) -18.0, -11.4, -7.4, -4.8, -1.6,0.4 (8H, d (collapses to a singlet on { 3 1 P } ) ) , 
5.3 (12H), 8.5 (d), 10.4,10.6,14.2, 34.3 3 1 P NMR ( D 2 0 ) 87.2 IR(KBr disc) 3428, 3148, 
3058,1610, 1488,1406, 1266,1229,1165,1117,1030 uv ( H 2 0 ) Xmax=273, 278 
£= 3.8xl0 3 M " 1 cm"1 Luminescence x(H 2 0)= 1.26ms t(D2O)=2.01ms q=0.31 MS(ES-) 
1111.3, 1113.2 (most abundant ion C44H 6 0N 4O 1 2P4Eu requires 1113.24), 1114.2 
m.p. >250°C (dec.) 
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[Gd(36)]" 
The gadolinium complex was prepared in an analagous manner to the europium complex, 
except that a 3 fold excess of gadolinium acetate was used. The ester 42 (370mg, 
343|imol) afforded the complex (34mg, 8.9%) after HPLC purification. 
HPLC Rt=13.3 minutes NMR spectra could not be obtained due to the paramagnetic line 
broadening induced by the gadolinium. IR(KBr disc) 3419, 1654,1601,1487, 1405,1266, 
1229,1167,1117,1027 uv (H 2 0) Xmax=273,278 MS(ES-) 1115.3,1116.3, 1117.3, 
1118.39 (most abundant ion C ^ H g o ^ O ^ G d requires 1118.24), 1119.6,1120.4, 1121.4 
A satisfactory analysis was not obtained m.p. >250°C 
[La(TRITA)]- complex [La(44)]" 
l,4,7,10-tetraazacyclotridecane-l,4,7,10-tetrayltetraacetic acid 44 (105mg, 0.33mmol) and 
lanthanum acetate (104mg, 0.33mmol) were stirred in water (15ml) at 80°C for 24 hours 
pH=4. Concentration afforded the complex as a white solid. (152mg, 83%) 
lH NMR(D 2 0 , pD ~4) 1.7(1H, br m, CH (methylene, axial)), 2.25-2.55(5H, m, CH 2N+CH 
equatorial), 2.7-3.4(20H, m (maxima at 2.78,2.88, 2.92,3.17, 3.26, 3.32), CH 2 N) 
1 3 C NMR (D 2 0) 24.9(CH2), 58.9, 59.0, 59.1, 61.3, 64.7, 66.7(CH2N), 183.3(CO) IR(film) 
3200-3500 (br), 1592 (br), 1452,1410,1342,1270,1202,1144,1084 MS(ES-) 553.11 
( [ C ^ H ^ N ^ g L a ] " requires 553.08) A satisfactory analysis was not obtained m.p. >250°C 
5.2.2. Chapter 3 
Diethylcyanobenzylmalonate 5 49 
EtO OEt EtO OEt 
NC 
CN 
To a stirred solution of sodium ethoxide (2.20g, 28.0mmol) in ethanol (100ml) was added 
diethylmalonate (8.9g, 55mmol) dissolved in ethanol (50ml), and the system left to 
equilibriate, stirring at room temperature. Bromobenzylnitrile (5.0g, 25.2mmol) dissolved 
in DMF (50ml) was then added slowly. Stirring continued at 60°C overnight. The reaction 
was. then quenched by the addition of water (150ml) and some dialkylated product (584mg, 
12%) was filtered off as a white solid. The remaining solution was extracted with ether 
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(400ml). The dried ether extract contained a little unreacted diethylmalonate, which was 
removed by heating in vacuo, to leave a pale yellow glassy oil. (6.2g, 89%) 
lU NMR(CDC13) 1.21(6H, t, CH 3 ) , 3.26(2H, d (J=8Hz), benzylic), 3.63(1H, t (J=8Hz), 
CH) 4.16(4H, qd, CH 2 0) 7.32 & 7.58(4H, dd, ArH) 
The isolated (584mg, 12%) dialkylated material was also characterised by NMR. 
! H NMR(CDC13) 1.12(6H, t, CH 3 ) , 3.24(4H, s, benzylic), 4.07(4H, q, C H 2 0 ) 7.27 & 
7.57(4H, dd, ArH) 
12-(4-cyanobenzyl)-l,4,7,10-tetraazacyclotridecane-ll,13-dione3 50 
The diester 49 (6.18g, 22.3mmol) and 1,4,7,10-tetraazadecane (3.26g, lequiv.) were boiled 
under reflux in dry ethanol (200ml) for 13 days. A white solid precipitated out during the 
reaction, which was filtered off after cooling. Recrystallisation from hot ethanol gave a 
white solid, (964mg, 13.1%). 
lH NMR (CD 3OD) 2.64(8H, m, CH 2N), 3.0(2H, m, CH 2 N), 3.22(2H, d, benzylic) 3.45(1H, 
t, CH), 3.6(2H, m, CH 2 N), 7.42(2H, d, ArH), 7.63(2H, d, ArH) m.p. 239-241°C (dec.) 
(lit.'3 245-247°C) 
12-(4-aminomethylbenzylamine)-l,4,7,10-tetraazacyclotridecane 3 48 
The diamide 50 (964mg, 2.93mmol) was dissolved in a solution of borane in THF (l.Omol 
dm" 3,70ml), and the mixture boiled under reflux for 2 days. An aliquot was taken and 
analysed by infra red spectroscopy, which revealed the absence of a carbonyl stretch. The 
C N 
H N 
c 
N H 
NH 
H H 
cN J A_r» H 
123 
reaction was then quenched by the slow addition of methanol (20ml), and concentrated 
under reduced pressure. Boiling in 6M HC1 (30ml) for 3 hours, followed by washing with 
ether (50ml), basifying to pH>13 with KOH pellets and extraction into chloroform 
(3x50ml), afforded a yellow oil (816mg, 92%) 
! H NMR (CDC13) 1.65-1.8 (6H, br m, NH+NH 2 ); 2.2-2.75(19H, m, CH 2 N + CH 
+benzylic), 3.60(2H, s, ArCH 2 NH 2 ) , 6.90 & 6.99(4H, dd, ArH) MS(ES+) 306.3 ( M + + l ) 
4-Nitrophenyl octadecanoate 51 
Stearic acid (542mg, 1.91mmol) and oxalyl chloride (1.2ml, large excess) were stirred 
in CH 2 C1 2 at room temperature. One drop of DMF was added, causing an initial 
effervescence, which ceased after a couple of minutes. Stirring was continued for a 
further two hours, followed by removal of CH 2 C1 2 and excess oxalyl chloride. DMF 
(20ml) was then added, and sodium 4-nitrophenoxide (307mg, 1.91mmol) dissolved in 
DMF (10ml) was added slowly to the stirrred solution. The reaction was terminated 
after 30 minutes. The solvent was removed, and the ester isolated (331mg, 43%) by 
column chromatography on silica, eluting with 20% ethyl acetate:hexane, as a white 
solid, which appeared iridescent under an optical microscope, melting to give a 
colourless oil. 
TLC (50% EtOAc:CH 2Cl 2) Rf=0.9 lH NMR (CDC13) 0.81(3H, t, CH 3 ) , 1.10(28H, m, 
C H ^ , 1.68(2H, p, CH 2CH 2CO), 2.52(2H, t, CH 2CO), 7.20(2H, d, ArH), 8.19(2H, d, ArH) 
1 3 C NMR (CDCI3) 14.6(CH3), 23.2, 25.2, 29.5, 29.7, 29.9, 29.9, 30.1, 30.2, 32.4, 
34.8(CH2), 122.9, 125.7(Ar), 145.7(CN02), 156.0(quaternary Ar, CO), 171.8(CO) 
IR (film) 2917, 2850,1752,1532,1346,1201,1144 MS (CI) 424 (M+NH 3 +1) + Found 
C=71.1, H=9.69, N=3.45 C 2 4 H 3 9 N 0 4 requires C=70.9, H=9.71, N=3.09 m.p. 54.5-56.0°C 
1 -(benzylcarbamoylmethyl)-l,4,7-triazacyclononane 55 
H H N N 
o 
1,4,7-Triazacyclononane 53 (375mg, 2.91mmol) in dry DMF (5ml) was stirred at 60°C, 
with potassium carbonate (fine mesh, 220mg, 1.6mmol). N-benzylchloroacetamide 54, 
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prepared by Gareth Williams, (267mg, 1.45mmol) in DMF (5ml) was added over a period 
of 3.5 hours, using a mechanical pump. Stirring continued at this temperature for 20 hours, 
before cooling to room temperature. The solid was then filtered off, and the DMF removed 
in vacuo, to afford 440mg of a crude yellow oil. A sample (80mg) was purified by HPLC, 
which was characterised as the trifluoroacetate salt. 
HPLC Dynamax 60A (10ml min"1); elution A=MeCN/TFA; B=H 2 0/TFA from 10% A, 
90% B to 90% A, 10% B over 20 minutes; observed A.=254nm; Rt=9.9 minutes; 
*H NMR(D 2 0 , pD ~4) 3.03 (4H, t (J=6Hz), CH 2NCH 2CO); 3.28 (4H, t (J=6Hz), CH 2 N); 
3.58 (2H, s, NCH 2CO); 3.64 (4H, s, CH 2 N (opp. alkylated N)); 4.39 (2H, s, benzylic); 7.3 
(5H, m, ArH). 1 3 C NMR (D 2 0) 45.7,46.1, 47.0, 51.8, 59.1(CH2N), 130.2, 130.5, 
131.7(Ar), 140.5(quaternary Ar), 176.5(CO). IR (film) 3277 (NH), 1676 (CO) MS(ES+) 
277.2,100% (M++1) 
7-(benzylcarbamoylmethyl)l,4-bis(ethoxycarbonylmethyl)-l,4,7-triazacyclononane 56 
N C O , E t EtO,C N 
t ;uO 
o 
To the crude amide 55 (356mg, ~1.3mmol), in dry ethanol (20ml), was added ethyl 
bromoacetate (431mg, 2.58mmol), and caesium carbonate (840mg, 2.58mmol). The 
temperature was raised to 60°C, and the reaction left to stir overnight. Purification by 
alumina chromatography (CH 2Cl 2:MeOH from 0-5% MeOH) afforded a yellow oil 
(196mg, 34%). 
TLC ( 1 % MeOH:CH 2Cl 2) Rf=0.4 *H NMR (CDC13) 1.24 (6H, t (J=7Hz), CH 3 ) ; 2.64 & 
2.79 (12H,m,CH 2 N ring); 3.08 (4H,s,NCH 2 C0 2 Et); 3.35 (2H, s, NCH 2CONH); 4.10 
(4H, q (J=7Hz), OCH 2 CH 3 ); 4.45 (2H, d, benzylic); 7.28 (5H, m, ArH); 9.30 (1H, br t, 
CONH) 1 3 C NMR (CDCI3) 14.1(CH3), 43.3(ArCH2N), 54.5, 55.6, 56.5, 57.6(CH2N), 
60.0(CH2O), 61.1(NCH2CO), 127.1,127.8,128.3,138.7,171.6, 172.5. IR(f i lm) 3194 
(NH), 2928,1738 (ester), 1666 (amide) MS (CI) 449 (100%, M++1) 
7-(benzylcarbamoylmethyl)-!,4-bis(caboxymethyl)-! ,4,7-triazacyclononane 57 
/—v N ^ C O , H H O , C N 
o 
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The ester 56, prepared above (170mg, 0.38mmol), was dissolved in aqueous potassium 
hydroxide (l.Omol dm"3, 20ml), and stirred overnight. The solvent was removed and the 
residues dissolved in ethanol. After filtration, a yellow oil was collected (135mg, 90%). A 
small amount was purified by HPLC. 
HPLC: Spherisorb 50DS2 (1.4ml min"1); elution A=MeCN/TFA; B=H 2 0/TFA from 5% 
A, 95% B to 95% A, 5% B over 20 minutes; observed X=254nm; R t=9.9 minutes; 
lH NMR(D 2 0) of TFA salt 2.85 (4H, t, C H 2 N ring), 3.0 (4H, t, C H 2 N ring), 3.10 (4H, s, 
C H 2 N ring), 3.52 (6H, s, NCH 2CO), 4.30 (2H, s, benzylic), 7.2 (5H, m, aromatic). [The 
presence of the amide was confirmed by acquiring a spectrum in trifluoroacetic acid. 
*H NMR (CF 3 C0 2 H + CH 2 C1 2 reference: 5.58ppm) 4.13 (10H, br s); 4.23 (4H, br s); 
4.66 (4H, br s), 4.87 (2H, br s, benzylic); 7.63 & 7.70 (5H, 2 x br s, ArH); -8.3 (1H, br s, 
CONH)] 1 3 C NMR (D 2 0 , pD ~3) 45.9(Ar£H 2N), 52.4, 52.5, 53.4, 59.0(CH 2N), 130.2, 
130.5, 131.8, 140.6(Ar), 174.1(1C, CONH), 174.8(2C, C 0 2 ) . IR (film) 3377 (OH), 1727 
(CO acid), 1672 (CO amide) MS(ES-) 391.4 (M), 505.4 (M+TFA) 
The ligand was also made using chloroacetic acid. To 55 (76mg, 0.275mmol), stirring in 
water (15ml), was added chloroacetic acid (65mg, 0.69mmol, 2.5 equiv.) The pH was then 
raised to 10 by the careful addition of LiOH, and the reaction temperature was then raised 
to 60°C. Stirring continued for 16 hours. Concentration followed by purification by 
preparative HPLC afforded the ligand (43mg, 40%). 
[Cu(57)] 
The ligand 57 (135mg, 0.344mmol) and copper perchlorate (128mg, 1 equiv.) were stirred 
together in water at pH=4.5 for 3 hours. The solution turned a darker blue. Hydrogen 
sulfide was bubbled through the solution, and the resulting suspension filtered. An attempt 
to crystallise the sample yielded a blue oil. The complex was then purified by HPLC to 
give the complex, as a blue solid (23mg, 15%). 
HPLC: Dynamax 60A (10ml min" 1); elution A=MeCN; B = H 2 0 from 10% A, 90% B to 
50% A, 50% B over 20 minutes; observed X=278nm; R t = l 1.3 minutes The presence of 
the paramagnetic Cu(II) ion broadens the NMR spectra *H NMR(D 2 0) 5.5(2H, v br, 
benzylic), 7.45(4H, br m, aromatic), 7.9(1H, br, aromatic) 1 3 C NMR ( D 2 0 , pD ~7) 
47.5(ArCH 2N), 128.0,128.4, 129.0,137.8(Ar) IR (film) 1682, 1633 W(H 20)= 705nm 
e= ~ 200 M " 1 cm"1 MS(ES+) 227.6 (14%), 228.7 (7%) ( M + l ) 2 + ; 454.1 (100%), 455.6 
(45%) ( M + l ) + Found C=46.25 H=5.89 N=l 1.08 C 1 9 H 2 6 N 4 0 3 C u . 2 H 2 0 requires C=46.63 
H=6.13 N = l 1.45 m.p. 117.5-118.5°C 
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N-Octadecanoylbutane-1,4-diamine 59 
NH 
N 
H 
To 1,4-diaminobutane (2g, large excess) in CH2CI2 (10ml) was added 51 (220mg, 
0.543mmol), dissolved in CH2CI2 (10ml). Analysis by TLC (SiC^) indicated an almost 
instantaneous reaction. The solvent was removed and the residue treated with dilute 
acid to produce a white solid, which was collected by filtration. The solid was then 
suspended in potassium hydroxide solution (l.Omol dm"3,10ml) and extracted into 
CHCI3 (4 x 20ml). Concentration afforded the amino amide, as a white solid (134mg, 
70%). 
*H NMR (CDCI3) 0.83(3H, t, CH 3 ) , 1.21(28H, br s, CH 2 ) , 1.46(6H, m, N C H 2 C H 2 + 
CH 2 CH 2 CO), 2.10(2H, t, CH 2CO), 2.67(2H, t, CH 2 NH 2 ) , 3.21(2H, q like m, 
CH 2NHCO), 6.10(1H, br s, NHCO) 1 3 C NMR (CDCI3) 13.9(CH3), 17.9, 25.6, 26.8, 
29.4, 30.7, 31.7, 36.5, 39.0, 41.5(CH2), 173.0(CONH) IR (film) 3309, 2919, 2848, 
1632,1548,1469 MS (ES+) 355.30 (C22H47N2O requires 355.37) An accurate 
analysis was not obtained for this product m.p. 98.0-98.5°C 
N'-(N"-Octadecanoylbutane-1,4-diamine ) chloroacetamide 60 
H 
N 
o 
N 
H 
The amine 59 (120mg, 0.339mmol) was dissolved in CH 2 C1 2 (10ml), and the 
temperature lowered to -10°C. NaOH (13.5mg, 0.339mmol) dissolved in water (1ml) 
was then added, followed by the slow addition of chloroacetylchloride (38mg, 21\ih, 
0.339mmol) in CH 2Cl2 (5ml). Concentration afforded an oil, which crystallised at 
-18°C. (103mg, 74%) The compound was deemed sufficiently pure for the next step, by 
inspection of *H and 1 3 C NMR spectra. 
lH NMR (CDCI3) 0.87(3H, t, CH 3 ) , 1.25(28H, br s, CH 2 ) , 1.56(6H, m, N C H 2 C H 2 + 
CH 2 CH 2 CO), 2.17(2H, t, CH 2CO), 3.3(4H, m, CH 2NHCO), 4.05(2H, s, ClCH 2CO), 
5.65 & 6.75(1H+1H, 2x br s, NHCO) 1 3 C NMR (CDC13) 14.1(CH3), 22.7, 25.8,26.7, 
26.9, 29.3,29.5, 29.7, 31.9, 36.8,38.9, 39.4,42.6(CH2), 166.1,173.3(CONH) IR (film) 
1643 MS (CI) 431,433 (3:1) (M+l) m.p. 93.0-94.0°C 
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l-(Octadecanylamido)butylcarbamoylmethyl)-1,4> 7-triazacyclononane 61 
IS* N C 1 7H3s 
The chlorodiamide 60 prepared above (90mg, 0.219mmol), dissolved in DMF (5ml), 
was slowly added to a stirred suspension of caesium carbonate (71mg, 0.219mmol) and 
1,4,7-triazacyclononane 53 (57mg, 0.438mmol) in DMF (20ml) at 80°C. After 18 
hours, the DMF was removed under reduced pressure, to leave a brown oil (140mg). 
*H NMR analysis of the oil revealed the absence of a resonance at 4.05ppm, due to the 
CH 2C1 group. The oil was used in the next step, without further purification. 
lH NMR (Crude, CDCI3) 0.84(3H, t, CH 3 ) , 1.22(28H, br s, CH 2 ) , 1.5(6H, m, 
N C H 2 C H 2 + CH 2CH 2CO), 2.1(2H, t, CH 2CO), 2.5-3.5(18H, m (maxima at 2J8&3.25), 
CH 2 N), 6.3 & 8.2(1H+1H, br s + br s, NHCO) MS(CI) 525 (M + +2) (no peak for 
dialkylated cycle was observed) 
7-(Octadecanylamido)butylcarbamoylmethyl)-l,4J-triazacyclononM 
C O , E t OS H A N 
N N ^ Y 
. . / O 
C„H N 17" '35 
H 
EtO,C 
The crude alkylated triamine 61 (140mg, assumed 0.263mmol) and caesium carbonate 
(255mg, 0.788mmol) were suspended in DMF(15ml) at 80°C. Ethyl bromoacetate (132mg, 
88|iL, 0.788mmol) was slowly added and the reaction was left to stir for 24 hours. The 
molecular ion was clearly seen in the CI mass spectrum of the crude reaction mixture. 
However, no product was isolable by column chromatography. 
1 -octadecanoyl-4,8,11 -tri(4-methylbenzenesulfonyl)-l,4,8,11-tetraazacyclotetradecane 63 
Me 
o'-s: 
Me Me 
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Stearoyl chloride was made by adding oxalyl chloride (1.2ml) to stearic acid (301mg, 
1.06mmol) in CH 2Cl2 (20ml), with one drop of DMF. The mixture was stirred for two 
hours. Excess oxalyl chloride was removed in vacuo after addition of CH2CI2 (2ml), 
repeated twice. The acid chloride was taken up in CH 2Cl2 (10ml) and added to the 
triprotected cyclam 62 (702mg, 1.06mmol, prepared by Dr. I . Helps), dissolved in CH 2Cl2 
(10ml). The mixture was left to stir at room temperature for two hours, followed by TLC. 
The reaction was stopped, and the mixture chromatographed on silica, with a gradient 
elution (0-0.5% MeOH:CH2Cl2). The title compound was isolated as a white foam. 
(431mg, 44%) 
TLC (10% MeOH:CH 2Cl 2) Rf=0.8 lE NMR (CDC13) 0.86(3H, t, CH 3 ) , 1.24(28H, m, 
CH 2 ) , 1.64(2H, br p, CH 2CH 2CO), 1.92(4H, m, NCH 2 CH 2 CH 2 N), 2.42(11H, ArCH 3 + 
CH 2CO), 2.9-3.7(16H, br m, CH2N), 7.33(6H, m, Ar), 7.65(6H, m, Ar) 1 3 C NMR (CDC13) 
16.2(CH3), 23.6, 24.7, 31.7, 33.9,35.0, 35.1(CH2), 44.9, 49.3,49.3,49.5, 51.7, 52.3, 
54.3(CH2N), 55.5(Ar£H 3), 129.1. 129.5, 129.7,130.0,131.9,134.7, 135.3, 137.5,146.0, 
146.1(Ar), 175.3(CO) IR(fi lm) 2920,2852, 1643,1597,1455,1338,1158,1091 MS(CI) 
The molecular ion was not detected under the probe conditions used. Found C=62.6 
H=8.05 N=5.81 C4 9H 7 6N4O 7S 3 .0.5(H 2O) requires C=62.7 H=8.27 N=5.97 
1 -octadecanyl-4,8,11 -tri(4-methylbenzenesulfonyl)-l,4,8,11-tetraazacyclotetradecane 64 
Me 
o'- s N N 
Me Me 
The amide 63 prepared above (412mg, 0.444mmol) was boiled under reflux with borane 
(l.Omol dm"3 solution in THF, 15ml) for 16 hours. Analysis of an aliquot by IR 
spectroscopy indicated the absence of the amide functionality. The reaction was worked up 
by cooling in ice, followed by the careful addition of MeOH. Evaporation under reduced 
pressure afforded a white solid, which was boiled under reflux with hydrochloric acid 
solution (6mol dm"3,10ml) for 6 hours. Neutralisation (KOH), followed by extraction into 
chloroform (3 x 20ml) and evaporation of solvent, afforded a yellow oil. (371mg, 92%) 
lH NMR (CDCI3) 0.83(3H, t, CH 3 ) , 1.22(28H, br s like m, CH 2 ) , 1.6(2H, br m, CH 2 CH 2 N 
(side chain)), 1.88(4H, m, NCH 2 CH 2 CH 2 N), 2.29(2H, br t, CH 2 N), 2.38(9H, m, ArCH 3), 
2.55(2H, br t, CH 2 N), 2.9-3.4(10H, m, CH 2N), 3.51(4H, m, CH 2 N), 7.30(6H, br s like m, 
Ar), 7.61(6H, m, Ar) 1 3 C NMR (CDC13) 14.1(CH3), 21.4, 22.6, 25.9, 27.0, 27.5, 27.6, 
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29.3,29.6, 31.8, (CH 2), 44.1,47.5,48.0,48.1,48.3,49.4, 50.4, 53.9, 55.1(CH 2N), 127.2, 
129.7, 135.1, 135.4, 143.6(Ar) IR (film) 2923, 2852,1598, 1454, 1337, 1156 MS(CI) 915 
( M + + l ) A satisfactory analysis was not obtained for this compound 
1 -octade cany I-1,4,8,11- tetraazacyclotetradecane 65 
H 
N N H H 
The unprotected amine 64 prepared above (344mg, 0.376mmol) was boiled under reflux 
with phenol (1.5g) in 45% HBr/glacial acetic acid solution (15ml) for 18 hours. More 
HBr/acetic acid was then added (15ml) and the reaction left for a further 24 hours. The 
mixture was cooled and added carefully to ether, giving a grey precipitate, which was 
separated by centrifugation. Basification (pH>13, KOH) was followed by extraction into 
chloroform to give, on concentration, a colourless oil. (150mg, 97%) 
lH NMR (CDC13) 0.86(3H, t, CH 3 ) , 1.23(32H, m, CH 2 ) , 1.69(4H, h like m, 
NCH 2 CH 2 CH 2 N), 2.3-2.8(18H, m, CH 2N) 1 3 C NMR (CDCI3) 14.1(CH3), 22.7, 25.5, 
26.4, 27.6,29.0, 29.3,29.7, 29.7, 31.9(CH2), 47.8,48.1,48.9,49.5,49.7, 51.2, 52.6,53.8, 
54.8(CH2N) IR (film) 3297, 2922, 2851, 2807,1466 MS(CI) 453 ( M + + l ) C 2 8 H 6 1 N 4 
requires 453.489 found 453.489 
linolenoyl chloride 
To linolenic acid (194mg, 1.40mmol) was added thionyl chloride (2ml). Immediately, a 
bright orange colour developed. The mixture was stirred at room temperature for a further 
hour. The excess thionyl chloride was removed in vacuo, followed by repeated cycles of 
adding dichloromefhane (2ml) and evaporating, to give the acid chloride as an orange oil. 
Analysis by infra red spectroscopy indicated quantitative conversion. No high frequency 
NMR signal was identifiable, indicating the absence of the carboxylic acid functional 
group, and the retention of unsaturation was noted. 
*H NMR (CDC13) 0.97(3H, t, CH 3 ) , 1.31(8H, br s, CH 2 ) , 1.7(2H, p, CH 2 CH 2 CO), 
2.05(4H, m, allylic C H 2 (to one double bond)), 2.88(6H, m, CH 2CO + allylic C H 2 (to two 
double bonds)), 5.36(6H, m, CH) IR (film) 1799 (A drop of methanol was added to the 
o 
ci 
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sample on the NaCl plate, and another spectrum obtained. The carbonyl peak moved to 
1739cm"1, consistent with the formation of an ester from the acid chloride) 
1 -linolenoyl-4,8,1 l-tri(4-methylbenzenesulfonyl)-l,4,8,11 -tetraazacyclotetradecane 66 
Me xxi 
o* C J ;N N; 
Me Me 
Linolenoyl chloride prepared above (1.40mmol) in CH2CI2 (10ml) was added to the 
triprotected amine 62 (938mg, 1.42mmol) in CH2CI2 (10ml). The mixture was left to stir 
for 18 hours, before removing the solvent under reduced pressure. The almost black glue 
was purified by flash chromatography on silica, using identical conditions to the saturated 
analogue, to give a yellow foam. (544mg, 41%) 
TLC (10% MeOH:CH 2Cl 2) Rf=0.8 lH NMR (CDCI3) 0.96(3H, t, CH 3 ) , 1.33(8H, br d like 
m, CH 2 ) , 1.6(2H, br m, CH 2CH 2CO), 2.03(8H, m, NCH2CH 2 CH 2 N + allylic C H 2 (to one 
double bond)), 2.33(2H, m, CH 2CO), 2.43(9H, m, ArCH 3 ), 2.79(4H, t, allylic C H 2 (to two 
double bonds)), 2.9-3.6(16H, m, CH 2N), 5.35(6H, m, CH), 7.33(6H, m, Ar), 7.66(6H, m, 
Ar) 1 3 C NMR (CDCI3) 14.2(CH3), 21.5, 24.7,25.1, 25.6,26.6, 27.2, 29.2,29.4, 32.7, 
33.1, 34.0(CH2), 42.8,46.6,47.2,48.4,48.8,49.6, 50.3,52.4(CH2N), 127.1,127.5, 127.7, 
127.9,129.2,129.8,130.0,130.1, 131.9,143.8,144.0(Ar + vinylic), 173.4(CO) IR (film) 
2929, 2857, 1726, 1622, 1598, 1792, 1453, 1339,1159, 1091 MS(CI) molecular ion not 
detected, 663 (macrocycle fragment following amide cleavage +1) 
l-(octadec-9,12,15-cis, cis, cis-trienoyl)-4,8,l 1 -tri(4-methylbenzenesulfonyl)-l,4,8,11-
tetraazacyclotetradecane 67 
Me 
N N 
HO 
Me Me 
To a solution of the acylated macrocyle 66 (128mg, 0.139mmol) in CH2Cl2(10ml) stirring 
at -78°C, was added lithium aluminium hydride(27mg, 0.694mmol) as a solid. The 
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temperature of the mixture was allowed to rise slowly to ambient temperature over 4 hours. 
The reaction was quenched by adding methanol (2 drops), followed by 15% sodium 
hydroxide solution (1ml). The suspension was extracted with chloroform, and the residue 
obtained on concentration was chomatographed on silica (elution: 0-0.5%MeOH:CH2Cl2), 
to give the title compound as a colourless glass. (23mg, 18%) 
TLC (10% MeOH:CH 2Cl 2) Rf=0.8 lH NMR (CDC13) 0.97(3H, t, CH 3 ) , 1.32(10H, br m, 
CH2), 1.6&1.9(2H+2H, br m, CH 2CH 2CO + homoallylic CH 2 ) , 2.03(4H, m, 
NCH 2 CH 2 CH 2 N), 2.3(4H, m, aUylic C H 2 (to one double bond)), 2.43(9H, m, ArCH 3 ) , 
2.79(4H, t, aUylic C H 2 (to two double bonds)), 2.9-3.6(18H, m, CH 2 N), 5.36(6H, m, CH), 
7.31(6H, m, Ar), 7.68(6H, m, Ar) 1 3 C NMR (CDC13) 14.0(CH3), 21.5, 25.6, 26.0,27.2, 
27.8, 29.2, 29.5(CH2), 47.6,48.0, 48.4, 49.4, 49.8, 50.5, 53.9, 55.2(CH2N), 127.3, 127.6, 
127.9,128.2,129.7,130.3, 135.2,143.4,143.8(Ar + alkene) IR(film) 2927, 2855, 1645, 
1597,1456,1343,1159,1091 MS(CI)909 (M++1) 
co-linolenol, formed by amide cleavage and reduction, was identified by *H NMR 
spectroscopy. 
R f=1.0 lU NMR (CDCI3) 0.97(3H, t, CH 3 ) , 1.34(8H, br s, CH 2 ) , 1.58(5H, br m, 
CH 2CH 2OH_+ homoallylic CH 2), 2.05(4H, q like m, C H 2 (allylic to one double bond)), 
2.81(4H, t like m, C H 2 (allylic to two double bonds)), 3.64(2H, t, CH 2 OH), 5.36(6H, m, 
CH) 
N-Biotinylethane-1,2-diamine 7 68 
To biotin-4-nitrophenyl ester (12mg, 0.033mmol) in chloroform (1ml) was added a 
solution of ethylenediamine (200mg, 0.30mmol) in chloroform (3ml) with rapid mixing 
(Fison's "Whirlimixer"). After 15 minutes, the mixture was concentrated, and the excess 
ethylenediamine removed via Kugelrohr distillation. The title compound crystallised from 
acidic solution (pH=4), to give the hydrochloride salt as a white solid (6mg, 56%), which 
gave data in accord with that synthesised via a different route.6 
! H NMR(D 2 0 , pD ~2) 1.4(2H, m, CH 2), 1.7(4H, m, CH 2 ) , 2.2(2H, t, CH 2CO), 2.6(2H, t, 
CH 2 N), 2.8(1H, d like m, CHS), 3.0(1H, dd like m, CHHS), 3.2(2H, t, CH 2 N), 3.3(1H, m, 
o 
NH HN • H 
H H 
N 
HoN 
O 
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CHHS), 4.1(1H, m, SCH2CHNH), 4.3(1H, m, SCHRCHNH) MS(ES+) 287.2 (100%, 
M++1) 
12-(4-(N-biotinylamidomethyl) benzylamine)-l,4,7,10-tetraazacyclotridecane 69 
The macrocycle 48 (24mg, 0.079mmol) was dissolved in PIPES buffer (0.5M, pH=6.8, 
0.7ml). The pH of the solution was restored to 6.5-7.0, by slowly adding lmol dm" 3 HC1 
dropwise. The biotin paranitrophenyl active ester (Aldrich, 25mg, 0.069mmol) was 
dissolved in 1,4-dioxane (0.7ml). The two solutions were mixed and the reaction held at 
40°C for 12 hours with periodic whirlimixing, with the course of the reaction being 
monitored by cation exchange HPLC. Concentrated HC1 was added to lower the pH to 1-2. 
Centrifugation then permitted removal of the precipitated PIPES buffer. The acidic 
supernatant was washed with ether to remove excess ester and paranitrophenol. The 
required conjugate was then isolated as a white solid, following purification by reverse 
phase HPLC (19mg, 55%). 
HPLC Synchropak CM300 (1.4ml min"1); elution A=MeCN; B=H20; C=NH40Ac pH=5.6 
from 20% A, 70% B, 10% C to 20% A, 0% B, 80% C in 20 minutes Rt(product)=7.3 
minutes *H NMR(D 2 0) 1.16(2H, m, CH 2 ) , 1.44(4H, m, CH 2 ) , 2.10(2H, t, CH 2CO), 
2.2(1H, m, CH), 2.52(3H, m, CHRS & CH 2S) 2.7-3.2(22H, m, CH 2 N), 4.09(1H, m, 
SCH 2CHNH), 4.15(2H, s, ArCH 2NHCO), 4.36(1H, m, CH ring fusion), 7.08(4H, q like 
2xd, ArH) 1 3 C NMR(D 2 0) 28.1, 30.6,30.7, 38.4, 38.8, 39.3,42.7,45.6,46.9,47.3,48.4, 
53.8, 58.3, 63.2,64.9(Aliphatic C), 130.6,132.4,139.9,139.9(Ar), 168.3(NCON), 
179.7(CON) IR(KBr disc) 3447, 1685, 1429,1203,1131 MS(ES+) 266.9 ( (M+2H) 2 + , 
100%)), 532.5 ((M+H) + , 65%) m.p. 91.0-92.0°C 
The copper complex [Cu(69)]2+was also characterised by electrospray mass spectoscopy, 
uv and IR. The complex was made by adding copper chloride (2mg, excess) to an aqueous 
solution of the KBr disc used to obtain the above infra red spectrum. Hydrogen sulfide was 
then bubbled through the solution, and the copper sulfide precipitate filtered off. 
IR(KBr disc) 3410(water), 3212, 2924,1648,1458,1204, 1152 uv ^ ^ ( ^ 0 ) 264, 558 
MS(ES+) 297.4(100%) 298.4(35%) ie M 2 + with statistical copper isotope pattern. 
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7.2.3. Chapter 4 
Diethylheptanenitrilemalonate 71 
EtO OEt 
C N 
Sodium (1.3g, 56.5mmol) was dissolved in dry ethanol (125ml). Diethyl malonate (17.6g, 
HOmmol) dissolved in dry ethanol (50ml), was then added dropwise, and the system left to 
equilibriate for 1 hour. Bromoheptanenitrile (lOg, 52.6mmol) was then added, dissolved in 
dry DMF (50ml). The reaction was left to boil under reflux for 26 hours. After cooling to 
room temperature, the solution was extracted into diethylether (400ml) and dried over 
MgS0 4 . Concentration afforded a pale yellow oil. (12.76g, 90%) 
lH NMR (CDC13) 1.1-1.5 (6H, br m, CH 2 ) , 1.27 (6H, t, CH 3 ) ; 1.63 (2H, p, 
CH 2 CH 2 CH 2 CN), 1.89 (2H, p, CH 2CH 2CN), 2.34 (2H, t, CH 2CN), 3.33 (1H, t, CH), 4.20 
(4H, q, OCH 2) 1 3 C NMR (CDCI3) 13.8(CH3), 16.7, 24.9, 26.7, 28.0, 28.1, 28.2, 
51.6(CH2+CH), 61.0(OCH2), 119.5(CN), 169.2(CO) IR(film) 2937, 2246, 1731 MS (CI) 
287 ( M + N H 4 ) + C 1 4 H 2 3 N 0 4 1 / 9 H 2 0 requires C=62.0; H=8.6; N=5.2; found C=61.8; H=8.7; 
N=5.4 
12-heptanenitrile-l,4,7,10-tetraazacyclotridecane-11,13-dione 72 
The diester 71 (12.76g, 47.4mmol) and 1,4,7,10-tetraazadecane (6.92g, lequiv.) were 
refluxed in dry ethanol for 16 days. Cooling afforded a white solid, which was 
recrystallised from hot ethanol, (2.05g, 13.4%). 
lH NMR (CDC13) 1.34 (6H, br m, CH 2 ) ; 1.65 (2H, p, CH 2 CH 2 CH 2 CN); 1.87 (2H, p, 
CH 2 CH 2 CN); 2.12 (2H, br s, NH); 2.32 (2H, t, CH 2CN); 2.67 (8H, br m, CH 2 N); 3.10 
(1H, t, CH); 3.39 (4H, br dm, CH 2NHCO); 7.08 (2H, br t, NHCO) 1 3 C NMR (CDCI3) 
17.1, 25.2, 27.4, 28.3, 28.5, 29.3, 39.3(CH2+CH), 46.8, 48.0, 55.9(CH2N), 119.8(CN), 
169.9(CONH). IR (KBr disc) 3342, 2938, 2245 (CN), 1663+1628 (sym + antisym CO) 
MS(EIZCI) 324 ( M + + l ) C 1 6 H 2 9 N 5 0 2 requires C=59.4, H=9.0, N=21.7 found C=59.4, 
H=9.3, N=21.4 Mpt. 181-184°C (dec) 
/ C N 
H H C 5 
H H 
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12-heptylamine-l,4,7,10-tetraazacyclotridecane 70 
NH 
H H 
,,N Nu H H 
The diamide 72 (1.3g, 4.02mmol) was reacted with a large excess of a solution of borane in 
THF (l.Omol dm"3, 20ml) under reflux overnight. An aliquot was analysed by infrared 
spectroscopy showing the absence of carbonyl functionality. The reaction was quenched by 
repeatedly adding methanol (20ml) and concentrating. The residue was stirred at 60°C 
overnight in HC1 (6mol dm"3,20ml). The mixture was then cooled, and washed with ether 
(2 x 10ml). The pH raised to 13, and extraction into dichloromethane (5 x 20ml), followed 
by concentration, afforded a yellow gum. (875mg, 73%). 
*H NMR (CDC13) 1.22 (13H, br m, alkyl side chain); 1.6 (2H, br m, CH 2 NH 2 ) ; 2.05 (6H, 
br s, NH); 2.62 (16H, br m, CH 2 N ring) 1 3 C NMR 27.8,29.8, 30.3, 32.9, 34.3, 
39.0(CH2+CH), 42.7,47.9,48.1,49.5,55.9(CH2N). IR (film) 3660 (primary NH), 3292 
(secondary NH), 3046, 2929, 2854,1464 MS(ES+) 150.6 ( M 2 + ) , 300.3 ( M + ) 
l,4,7-triazacyclononane-l,4,7-triyltriacetic acid1 23 
Chloroacetic acid (440mg, 4.65mmol) was added to a stirred solution of 1,4,7-
triazacyclononane 53 (200mg, 1.55mmol) in water (10ml). Lithium hydroxide was added 
periodically over 24 hours, to keep the pH at 10. The pH was then lowered to 1.5 (cone. 
HC1) and the solvent removed in vacuo. The solid remaining was taken up in water (1ml), 
and ethanol (10ml) was then added to give a white gluelike precipitate. The supernatant 
was then removed, and the tide compound was recrystallised from ethanol/water (5ml + 
5ml) to give a white solid (104mg, 22%), identical to an authentic sample. 
lH NMR(D 2 0) 3.40(12H, s, CH 2 N ring), 3.85(6H, s, NCH 2CO) m.p. 210-215°C (dec.) 
(l i t . 8 205°C) 
N \r HOoC 
C 0 2 H 
C 0 2 H 
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N-(paramethoxybenzenesulfonyl)-l,4-diaminobutane 8 73 
HoN N 
H 
OMe 
To a solution of 1,4-diaminobutane (22.05g, 0.25raol, ~7equivs.) in dichloromethane 
(200ml) was added paramethoxybenzenesulfonyl chloride (7.5g, 36.3mmol) in CH2CI2 
(100ml), over a period of 1 hour. The reaction was stirred for 16 hours at room temperature 
to give a turbid suspension. The solvent was removed, and then the product was extracted 
into chloroform, after washing with KOH solution. Removal of excess diamine afforded a 
white glue. (8.97g, 96%) 
lH NMR (CDCI3 ) 1.5(4H, m, CH 2); 2.68 (2H, t, CH 2NH 2) 2.92 (2H, t, CH2NHTs'); 3.88 
(3H, s, OMe); 6.98 (2H, d, S02CCH); 7.79 (2H, d, CHCOMe); 1 3 C NMR ((CD3)2SO) 
26.8, 30.7(CH2), 41.1, 42.8(CH2N), 55.8(OCH3), 114.5 (2C, Ar)), 128.9 (2C, Ar)), 
132.6(CS02), 162.2(£OCH3) 
The protected amine 73 (8.95g, 34.7mmol) was stirred below -10°C in CH 2C1 2 (100ml). 
To this solution was added sodium hydroxide (1 equiv.) in water (10ml), followed by 
chloroacetylchloride (3.92g, 2.77ml, 1 equiv.) in dichloromethane (100ml), over 30 
minutes. The temperature was kept at -10°C for the following two hours, before raising to 
room temperature overnight. Washing with NaOH (O.lmol dm"3, 50ml), HCl(0.1mol dm"3, 
50ml), and water (100ml), followed by drying (MgS04) and concentration, gave a yellow 
oil which crystallised to a white solid at -18°C. (9.64g, 83%). 
*H NMR (CDCI3) 1.54 (4H, m, CH 2); 2.95 (2H, t, CH2NHCO); 3.29 (2H, dt, CH2NHTs'); 
3.88 (3H, s, OMe); 4.04 (2H, s, ClCH2CO); 4.8 (1H, br s, NHTs'); 6.65 (1H, br s, 
CONH); 6.99 (2H, d, ArH); 7.80 (2H, d, ArH) 1 3 C NMR (CDC13) 26.4, 26.6(CH2), 
39.2(CH2C1), 42.5,42.6(CH2N), 55.6(OCH3), 114.2,129.1,131.3, 162.8(Ar), 166.1(CO). 
IR(film) 3281,2944,1662,1597. MS (DCI) 335:337 ratio 3:1 (M+ 3 5C1, 37C1); 352:354 
(plus NH 3) Found C=46.4, H=5.84, N=8.63; C 1 3 H 1 9 N 2 0 4 SC1 requires C=46.6, H=5.68, 
N=8.37 m.p. 84.0-85.0°C 
N'-(2-chloroethanoyl)-N' '-4-methoxybenzenesulfonyl-1,4-diaminobutane 74 
H 
N 
o 
N 
H 
OMe 
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[l-(4-methoxybenzenesulfonamido)butylcarbamoylmethyl]-lAJ-triamcyclononane 75 
H H N N 
H 
O 
N 
"0 N H OMe 
1,4,7-Triazacyclononane 53 (460mg, 3.48mmol) was stirred at 60°C in DMF (10ml), with 
caesium carbonate (240mg). The chloroamide 74 (582mg, 1.75mmol) in DMF (5ml) was 
added over 6 hours, using a mechanical pump. Stirring continued for a further 18 hours, 
before cooling. The solid was filtered off, and the DMF / excess triazacyclononane 
removed under reduced pressure. Some dialkylated material was produced, in addition to 
the required monoalkylated product. Conversion was estimated to be 65-80%. A portion 
of the product was purified by HPLC, for characterisation purposes. 
HPLC: Dynamax 60A (10ml min"1); elution A=MeCN/TFA; B=H20/TFA from 0% A, 
100% B to 60% A, 40% B over 30 minutes; observed X=275nm; Rt=17.5 minutes. 
*H NMR (D 2 0, pD ~4) 1.36 (4H, m, CH2); 2.78 (2H, t, CONHCH2); 2.95 (4H, t, CH 2N, 
ring a to alkylated N); 3.06 (2H, t, CH2NHS02); 3.22 (4H, t, CH 2N, (3 to alkylated N); 3.41 
(2H, s, NCH2CO); 3.59 (4H, s, NCH 2, ring 8 to alkylated N); 3.80 (3H, s, OMe); 7.05 & 
7.70 (2 x 2H, 2 x d, ArH) 1 3 C NMR (D 20) 28.1, 28.9(CH2), 41.8, 45.1, 45.7, 47.0, 
51.8(CH2N), 58.6, 59.1(N£H2CO+OCH3), 117.6, 131.9, 132.7(Ar), 165.8(COMe), 
176.3(CO). IR (film) 1677 (amide) MS(DCI) 428 (M + +l) Found M + + l 428.2348 
C 1 9H3 5N 504S requires 428.2332 
7-[(4-methoxybenzenesulfonamido)butylcarbamoylmethylJ-l,4,7-triazacy 
diyldiacetate 78 
N N co2Et N NC C 0 2 E t EtOoC E t O , C 
Q .P H H 
O 
T 
o 
N N XX N' N H J OMe EtO,C OMe 
The crude amide 75 (1.49g, ~3.5mmol), caesium carbonate (2 equiv.), and ethyl 
bromoacetate (2 equiv.) were stirred in ethanol (30ml) at room temperature, raising to 60°C 
overnight. The ethanol was removed by concentrating repeatedly after addition of 
CH2C12, decanting the liquid from the residual solid. Repeated attempts at 
chromatographic purification, gradient elution EtOH:CH2Cl2 (0-5% EtOH) afforded a 
yellow oil 92mg, 4.4%. 
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TLC (2% EtOH:CH2Cl2) Rf=0.7 *H NMR (CDC13) 1.23 (6H, t, CH 3); 1.47 (4H, br m, 
CH 2); 2.61 (2H, br m, CH2NHS02); 2.80 (8H, m, CH2); 3.20 (6H, m, CH 2); 3.35 (2H, s, 
NCH2CONH); 3.83 (3H, s, OMe); 4.12 (4H, q, OCH2); 5.45 (1H, t, NHS02); 6.93 & 7.76 
(2 x 2H, 2 x d, ArH); 8.9 (1H, t, NHCO) 1 3 C NMR (CDCI3) 14.2(CH3), 26.6, 
27.0(CH2), 38.3,42.6, 55.0, 55.5, 56.0,56.3, 58.2, 60.3, 61.3(CH2N+OCH3+OCH2), 114.1, 
129.0, 131.7(Ar),162.6(COMe), 171.8, 172.8(CO). IR (film) 3188, 2931, 1738 (ester), 
1652 (amide) MS (DCI) 600 (M + +l) C 2 7 H4 5 N 5 0 8 S requires 599.2989 found 599.2985 
The alkylated sulfonamide product 79 was characterised by *H NMR and MS. 
lH NMR (CDCI3) 1.20 (3H, t, Ts'NCH2C02CH2CH3), 1.27 (6H, t, CH 3), 1.5(4H,brm, 
CH 2 , side chain), 2.6-3.4(22H, br m, CH2N), 3.8 (3H, s, OMe), 4.08 (2H, q, 
Ts'NCH 2C0 2CH 2CH 3), 4.16 (4H, q, OCH2CH3), 6.9 & 7.8(4H, 2 x d, ArH) MS (DCI) 
686 (M + +l ) 
7-[ (4-methoxybenzenesulfonamido)carbamoylmethyl]-l,4,7-triazacyclononane-l,4-
diyldiacetic acid 76 
C O , H N N H 0 2 C H O , C 
H H 
O o 
N N 
NT N 
H 
OMe OMe H O , C 
To a stirred solution of the previously prepared crude amine 75 (1.93g, ~3.6mmol) and 
chloroacetic acid (1.70g, 18mmol) at 60°C, was slowly added lithium hydroxide (432mg, 
18mmol), to keep the pH in the range 9.5-10.5. The reaction was monitored by anion 
exchange HPLC. The reaction was stopped after 3 days, as the NHS0 2 alkylated material 
77 was observed on the HPLC trace. The pH was lowered to 3 and repeated washes with 
diethylether removed much of the unreacted chloroacetic acid. The pH was then raised to 
neutral and the volume reduced to make the sample amenable to preparative HPLC. Two 
columns were required to give a yellow oil (675mg, 34%). 
HPLC: Dynamax 60A (10ml min"1); elution A=MeCN/TFA; B=H20/TFA from 10% A, 
90% B to 25% A, 75% B over 20 minutes; observed A,=278nm; R t=l 1-14 minutes. 
Synchropak AX100 (5ml min"1); elution A=MeCN; B=H 20; C=NH4OAc pH=5.6 from 
20% A, 70% B, 10% C to 20% A, 0% B, 80% C in 20 minutes Rt(product)=8.0 minutes 
lH NMR(D 20, pD ~4) 1.24(4H,br, CH^; 2.61(4H, br m, CH2N); 2.77(2H, m, 
CH 2NHS0 2); 2.91(6H, m, CH2N); 3.03(4H, m, CH2N); 3.23(2H, s, NCH2CONH); 
3.45(4H, s, NCH 2C0 2H); 3.73(3H, s, OMe); 6.97 & 7.64(2 x 2H, 2 x d (J=8.8Hz), ArH) 
1 3 C NMR(D 20) 24.6,29.0,41.7,45.3,51.4, 52.0,53.7, 58.6, 58.6, 60.1, 62.9 
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(CH2N+OCH3), 117.5, 131.9, 133.1(Ar), 165.6, 176.3(CO) IR(film) 3376, 3272, 3098, 
2948, 1725, 1672, 1597, 1498, 1321, 1261, 1199, 1153 MS(DCI) 259(100%, fragment in 
which the NCH2--CONH bond has been cleaved) 544(M++1) 
The side product, Rt(NHS02 alkylated side product 77)= 15.2 minutes, was characterised by 
proton NMR 
lH NMR(D 20) 1.3(4H, br m, CH2), 2.6(4H, br m, CH2N), 2.96(6H, m, CH2N), 3.08(6H, 
m, CH2N), 3.28(2H, s, NCH2CONH), 3.50(4H, s, NCH 2C0 2H exo to ring), 3.68(2H, s, 
NCH 2C0 2H diagnostic peak), 3.76(3H, s, OMe), 7.0 & 7.7(2 x 2H, 2 x d (J=8.9Hz), ArH) 
7-[(4-aminobutyl)carbarmylmethyl]-lA,7-triamcyclononane-l,4-diyldiacetic acid 58 
The diester 78 (74mg, 0.124mmol) and phenol (150mg, large excess) were stirred at 110°C 
for 24 hours in HBr solution (45% w/v in acetic acid, 8ml). Additional HBr solution (4ml) 
was then added, and the reaction continued for a further 24 hours. Cooling to room 
temperature gave a brown solid. (58mg), mixed counter ions (AcO~, Br) 
! H NMR (D 20) 1.4(4H, m, alkyl CH2); 2.76(2H, t, CH2N), 3.02(2H, t, CH2N), 3.33(8H, br 
m, CH 2N (ring)), 3.4(4H, s, CH 2N (ring)), 3.76(2H, s, NCH2CONH), 3.93(4H, s, 
NCH 2C0 2H) 1 3 C NMR 24.0,25.1(CH2), 38.9,42.8, 50.1,51.2, 56.8, 58.0(CH2N), 168.0, 
170.4(CO) IR (film) 1737 (acid), 1673 (amide) MS(ES+) 374.1 (M++1), 187.7 ( M + l ) 2 + 
Detpsylation of 76 
The above compound was also prepared by deprotection of 76. The sulfonamide 
(319mg, 0.588 mmol, TFA salt) and phenol (600mg, a large excess) were dissolved in 
45%HBr/AcOH (10ml) and stirred at 110°C for 2 days. The cooled solution was then 
added dropwise to a flask containing ether (200ml), whereupon the product precipitated 
as a beige solid (257mg, 96%). 
H 0 2 C ^ N N ^ C 0 2 H 
s N COoN 
H 
N 
N H , + B r 
O 
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4-[(4-methoxybenzenesulfonamido) carbamoylmethylj-1,4,7-triazacyclononane-1-
ylacetic acid 80 
H N N C 0 2 H 
H 
N 
N 
H 
O 
OMe 
The crude diamine 75 (1.46g, 2.73mmol, assumed from previous step) was dissolved in 
water (25ml) with chloroacetic acid (645mg, 6.83mmol). Solid lithium hydroxide was 
added carefully over a period of two days, to maintain the pH=10. When the reaction 
was complete, the volume was reduced to 1ml. The title compound was isolated by 
preparative HPLC as the trifluoroacetate salt (482mg, 29%). 
HPLC: Dynamax 60A (10ml min"1); elution A=MeCN/TFA; B=H20/TFA from 10% 
A, 90% B to 25% A, 75% B over 20 minutes; observed A=278nm; Rt=10-11 minutes. 
lH NMR(D 20, pD ~4) 1.08(4H,br, CH2); 2.47(2H, br m, CH 2NHS0 2); 2.80(2H, m, 
CH2NHCO); 3.02(4H, s, CH2N); 3.21(8H, m, CH2N); 3.49(3H, s, OMe), 3.58 & 
3.74(2H+2H, 2x s, NCH2CONH + NCH 2C0 2H); 6.70 & 7.39(2 x 2H, 2 x d (J=8.8Hz), 
ArH) 1 3 C NMR(CDC13) 28.1,28.8(CH2), 41.8,45.0,45.4,45.7,52.7, 53.6, 53.8, 
54.1(CH2N), 58.3(CH3), 58.6, 60.4(NCH2CO), 117.3,131.7,132.8(Ar), 165.5(COMe), 
171.2,174.9(CO) IR(film) 2500, 3500 (v br), 1680,1596,1496,1446, 1318, 1266, 
1202,1148 MS(ES+) 486.46 
2-[4-[(4-methoxybenzenesulfonamido) carbamoylmethyl]-!,4,7-triazacyclononane-7-
ylacetic acid]-N-benzoyl-5-aminopentyl ethanoate 82 
To the TFA salt of 80 (347mg, 0.579mmol) and caesium carbonate (480mg, 
1.529mmol) in DMF (15ml) was added 2-bromo-N-benzoyl-5-aminopentyl ethanoate 
81, prepared by Fiona Smith (190mg, 0.579mmol), dissolved in DMF (5ml) over a 
period of 3 hours at 60°C. The mixture was allowed to stir for a further 18 hours. The 
DMF was then removed. Preparative HPLC afforded the N,N'-diprotected cycle (71mg, 
14%). 
a. H N 
E t D 2 C ^ h T " C 0 2 H lOoC N 
H 
O XL N N H 
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HPLC: Dynamax 60A (10ml min'1); elution A=MeCN/TFA; B=H20/TFA from 10% 
A, 90% B to 90% A, 10% B over 20 minutes; observed k=254nm; Rt=16.2 minutes. 
lH NMR(CDC13) 1.17(3H, t, CH3), 1.42(4H, br, CH2); 1.57(2H, br, CH 2); 1.88(2H, 
br, CH 2); 2.5-3.7(23H, br m (maxima at 2.75, 3.10, 3.38, 3.56), CH2N), 3.76(3H, s, 
OMe), 4.10(2H, q, OCH2CH3), 5.01(1H, br t, NHS02), 6.85(2H, d , ArH), 7.02(1H, br 
t, CONH), 7.34(4H, m, ArH + CONH), 7.69(4H, t like m, ArH) 1 3 C NMR(CDC13) 
14.0(CH3), 25.2, 26.3 (m), 28.3(CH2), 39.2 (m), 42.6, 43.8(CH2N), 55.5(OCH3), 
61.8(OCH2), 72.7(CHN), 114.2,127.0,128.5,129.0,131.3, 131.5, 134.2,162.7(Ar), 
168.0,169.7,169.7,171.4(CO) IR(film) 3400 (br), 1744,1688,1660,1552, 1496, 
1456,1314, 1262, 1194,1150 MS(CI) 733 An accurate mass could not be obtained at 
the Swansea Centre due to the low intensity of the molecular ion under the probe 
conditions. 
N-(6-carboxyhexyl)maleamic acid9 88 
H 
N CO,H 
\ o HOoC 
Maleic anhydride (1.13g, 11.5mmol) and 6-aminocaproic acid (1.51g, 11.5mmol) were 
suspended in diethyl ether (~30ml), then brought to reflux overnight. Cooling afforded a 
white solid, a mixture of the starting materials, and the desired product (-25:75% estimated 
from NMR intensities.) The product was used in the next step, without further purification. 
*H NMR (CD3OD) 1.4 (2H, m, CH2), 1.6 (4H, m, CH 2), 2.31 (2H, t, CH 2C0 2H), 6.25 
(1H, d (J=13Hz), CH vinylic, cis), 6.46 (1H, d (J=13Hz), CH vinylic, cis) 
N-(6-carboxyhexyl)maleimide9 89 
o 
CO,H 
The crude maleimic acid 88 prepared above was stirred in acetic anhydride (30ml). To this 
was added sodium acetate (1.06g), and the reaction left to stir at 50°C overnight. Water 
(100ml) was then added and the mixture stirred at 60°C for 3 hours. Extraction into ethyl 
acetate (3 x 100ml), and concentration, afforded a brown oil. Addition of CHC13 gave a 
beige precipitate of trans maleimic acid. This was filtered off and the remainder 
recrystallised (EtOAc/ hexane) to give the product as a white solid. (712mg, 29%). 
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lH NMR (CDCI3) 1.31 (2H, m, CH2), 1.59 (4H, m, CH 2), 2.32 (2H, t, CH 2C0 2H), 3.50 
(2H, t, CH 2N), 6.69 (2H, s, CH),-11.5 (1H, br s, C0 2H) 1 3 C NMR (CDCI3) 24.5, 26.6, 
34.3, 38.0, 134.5,171.4,180.0 m.p. 81.0-82.0'C (lit . 1 0 89-90°C) 
N-succinimidyl-6-maleimidohexanoate9 85 
o o 
The acid 89 prepared above (130mg, 0.62mmol) and N-hydroxysuccinimide (71mg, 
lequiv.) were dissolved at 0°C in DMF (10ml). To this was added 
dicyclohexylcarbodiimide, DCC, (155mg, 1.2equiv.) in DMF (20ml). The reaction was 
kept at 0°C for 2 hours, and then left to raise to room temperature overnight. The DMF was 
removed, and CH2C12 added. The DCU was filtered off. Column chromatography on flash 
silica (100% EtOAc) gave a white solid after concentration (80mg, 42%). 
TLC (50%EtOAc:Hexane) R f = 0.3 *H NMR (CDC13) 1.38 (2H, m, CH 2), 1.60 (2H, p, 
CH2), 1.73 (2H, p, CH 2), 2.56 (2H, t, CH 2C0 2N), 2.80 (4H, s, CH2CO), 3.49 (2H, t, 
CH2N), 6.66 (2H, s, CH) m.p. 60-65°C (lit. 9 62-65°C) 
4-nitrophenyl-6-maleimidohexanoate 86 
(712mg, 3.37mmol) at 0°C in DMF (20ml), was added dicyclohexylcarbodiimide (DCC, 
834mg, 4.05mmol) in DMF (20ml) over a period of 10 minutes. Stirring continued, and the 
reaction raised to room temperature over 16 hours. The DMF was then removed under 
reduced pressure, and the residue taken up in dichloromethane. The precipitated 
dicyclohexyl urea was filtered off, and silica chromatography (flash, 20-100% 
EtOAcrhexane) afforded a lilac solid. (275mg, 25%) 
TLC (50%EtOAc:Hexane) R f = 0.3 *H NMR(CDC13) 1.4(2H, m, CH 2), 1.65(2H, m, 
CH^, 1.8(2H, m, CH 2), 2.60(2H, t, CH2CO), 3.55(2H, t, CH2N), 6.70(2H, s, CH vinylic), 
7.27(2H, d, ArH), 8.27(2H, d, ArH) 1 3 C NMR (CDC13) 23.9, 24.6, 25.8, 27.9, 33.7(CH2), 
37.2(CH2N), 122.2,124.9,133.9(Ar+maleimide), 144.9,155.2(Ar), 170.6, 170.7(CO) 
IR(film) 2933,1765 (ester), 1705 (amide), 1615,1592,1523 MS(DCI) 211 (acid), 350 
NO 
O 
To a mixture of paranitrophenol (468mg, 3.37mmol) and N-(6-carboxyhexyl)maleimide 89 
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(M+NH4)+ Found C=57.6 H=4.97 N=8.34 C 1 6 H 1 6 N 2 0 6 requires C=57.8 H=4.82 
N=8.43 m.p. 63.0-64.0°C 
Bis-4-nitrophenyl-l ,4-butanoate 1 187 
Paranitrophenol (4.72g, 33.9mmol) and succinic acid (2.0g, 16.9mmol) were stirred in THF 
(100ml) at 0°C. DCC (7.33g, 35.6mmol) dissolved in THF was then added slowly. 
Dicyclohexyl urea was precipitated during the course of the reaction, as the temperature 
was allowed to increase to room temperature over 24 hours. The precipitate was filtered 
off, and the crude ester columned on silica, using 100% CH2CI2 as an eluent. The crude 
material was loaded on silica, due to poor solubility in dichloromethane. A white solid was 
collected (2.0g, 33%). Unreacted bis active ester was reclaimed from future reactions, 
purified by recrystallisation from 1,4-dioxane. 
TLC (100% CH2C12) Rf=0.8 lH NMR(CDC13, poorly soluble) 3.06(4H, s, CH2CO), 
7.31(4H, d (J=9.2Hz), ArH), 8.28(4H, d (J=9.2Hz), ArH) m.p. 178-180°C (dec.) 
12-(4-(N-(3-maleimidopropyl)amidomethyl) benzylamine)-l,4,7,10-tetraazacyclotridecane 
The reaction was performed similarly to the above preparation of the biotin conjugate 69. 
Following with cation exchange HPLC, the macrocycle 48 (32mg, 0.106mmol) and the 
hydroxysuccinimidyl active ester 90 (22mg, 0.083mmol) were reacted in the equivolume 
PIPES/dioxane solvent. The reaction went to completion in under 30 minutes. Acidifying 
precipitated the PIPES, which was filtered off. Washing with ether was followed by 
reverse phase HPLC purification. An off white glass was obtained (20mg, 53%) 
NO 
0 ,N 
91 
o 
N N 
H 
H H 
C 1 
„N Nu H H V-/ 
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HPLC Synchropak CM300 (1.4ml min"1); elution A=MeCN; B=H20; C=NH40Ac pH=5.6 
from 20% A, 70% B, 10% C to 20% A, 0% B, 80% C in 20 minutes Rt(product)=6.0 
minutes ! H NMR(D 20, pD ~4) 2.13(1H, m, CH), 2.5(2H, t, COCH2CH2N), 2.65(2H, d, 
ArCH2CH), 2.8-3.2(16H, m, CH 2N ring), 3.75(2H, t, CH2N(mal)), 4.23(2H, s, ArCH2N), 
6.73(2H, s, vinylic), 7.18(4H, s, ArH) 1 3 C NMR(D20) 34.3, 34.4, 35.9, 36.5,42.5,43.9, 
45.6, 51.9(CH+£H2CO+CH2Ar+CH2N), 127.6,129.2,134.1,138(Ar+Maleimide), 173, 
174(CO) IR(KBr disc) 3446, 1711, 1681, 1203, 1132 MS(ES+) 229.3 ((M+2H) 2 +, 85%)), 
457.6 ((M+H)+, 100%) 
The copper complex [Cu(91)]2+ was made as for the biotin complex [Cu(69)]2+ above. 
IR(KBr disc) 3413(water), 1694,1631,1405, 1196 MS(ES+) 516.3:518.3 (3:1) ieM +-3 
with expected copper isotope pattern. Also 599.7(+Br"), 633.9(+Br"+2H20), peaks every 
120 mass units, corresponding to a clustering of KBr, 8 & 11 KBr units more intense than 
neighbouring multiples 
7-[4-((4-amidobutyl)-4-maleimidobutyl)carboxyethyl) carbamoyl-1,4,7-
triazacyclononane-l,4-diyldiactic acid 92 
C O , H N N H O , C 
1} H 
O 
N 
N 
H 
To the HBr salt of 58 (lOOmg, 0.22mmol) in PIPES buffer (0.75ml) was added N-
succinimidyl-4-maleimidobutyric acid (250mg, O.88mmol) in 1,4-dioxane (0.75ml). A 
suspension formed, but the majority of material remained in solution. After 4 hours, 
with periodic vortex mixing, the supernatant was subjected to preparative HPLC. The 
ligand was collected as an offwhite solid (9.8mg, 8.3%) 
HPLC: Dynamax 60A (10ml muT1); elution A=MeCN/TFA; B=H20/TFA from 10% 
A, 90% B to 25% A, 75% B over 20 minutes; observed A,=302nm; Rt=11.6 minutes. 
*H NMR (D 2 0) 1.29(4H, m, CH2), 1.69(2H, p, CH2), 2.04(2H, t, CH2CO), 2.8-
3.1(12H, m (maxima at 2.86, 3.02, 3.05), CH 2N (sidechain), CH 2N (ring y, 8 to amide 
carbonyl)), 3.13(4H, s, CH 2N (ring, opposite unique nitogen)), 3.27(2H, t, CH 2N 
(maleimide)), 3.46(2H, s, NCH2CO), 3.69(4H, s, NCH2CO), 6.64(2H, s, CH) 
1 3 C NMR(D 20) 26.6, 28.8, 28.9, 35.9(CH2), 40.0,42.1, 52.3, 52.5, 52.6, 53.5, 59.4, 
61.7(CH2N), 137.3(CH, maleimide), 174.5(CO), 175.3 (2C, CO, maleimide), 176.1, 
178.3(CO) IR(film) 3200-3600, 2942, 2872, 1705 (with shoulder to low frequency), 
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1553, 1411,1200,1135 MS(ES+) 539.41 (100%, M + 1) 561.35 (93%, M + Na) 
C24H3gN60gNa requires 561.35 
7-( 1-carboxylic acid-4-amidobutyl)-4-nitrophenyl)carboxyethyl) -1,4,7-
triazacyclononane-l,4-diyldiactic acid12 29 
HO. ) 2 C ^ N N ^ C 0 2 H N 
O 
To crude 52 (42mg, 0.106mmol) in DMSO (1ml) was added solid bisnitropheny 1-1,4-
butanoate 87 (115mg, 0.318mmol) and triethylamine (75mg, 103|il, 0.742mmol) with 
vigorous mixing. The reaction was followed by HPLC, and terminated by cooling the 
solution to -78°C after 40 minutes at room temperature. The title compound was 
isolated by preparative HPLC, to give a lemon solid. (15mg, 23%) 
HPLC: Dynamax 60A (10ml min"1); elution A=MeCN/TFA; B=H20/TFA from 10% 
A, 90% B to 25% A, 75% B over 20 minutes; observed X=278nm; Rt=15.5 minutes. 
*H NMR (D 20) 1.5-1.9(4H, br m, CH2), 2.53(2H, t, CH 2C0 2Ar), 2.79(2H, t, 
CH2CONH), 2.8-3.2(10H, m (maxima at 2.84, 2.91, 3.02), CH2N), 3.42(2H, m, CH2N), 
3.53(2H, m, CH2N), 3.65(4H, s, NCH2C02H), 3.83(1H, s, NCHC02H), 7.22 & 
8.19(2H, 2x d, Ar) 
7-[4-((4-amidobutyl)-4-nitrophenyl)carboxyethyl) carbamoyl-l,4,7-triazacyclononane-
1,4-diyldiactic acid 93 
To 58 (40mg, 0.088mmol) in PIPES buffer (1ml) was added bis-4-nkrophenyl-l,4-
butanoate 87 (95mg, 0.264mmol) in 1,4-dioxane (1ml). The reaction was heated to 
60°C with periodic vortex mixing. The reaction was stopped after 4 hours. Preparative 
HPLC afforded a minute sample of a pale yellow solid (<lmg), which slowly 
decomposed in deuterium oxide, liberating 4-nitrophenol. 
CO,H N N HOoC 
| H 0 
NO 
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HPLC: Dynamax 60A (10ml min' 1); elution A=MeCN/TFA; B=H20/TFA from 10% 
A, 90% B to 25% A, 75% B over 20 minutes; observed X=278nm; Rt=14.2 minutes. 
lH NMR (D 20) 1.35(4H, m, CH2), 2.5(2H, t, CH2CO), 2.6-3.8(24H, m (maxima at 
2.9(t like), 3.0(t like), 3.1, 3.6)), 7.15(2H, d, ArH), 8.1(2H, d, ArH) MS(ES-) 593.40 
(M+-1) 
9-Acridine carbamoylethyl-2-(2-aminoethyl)-2-methyl amine 94 
The amino amide was prepared by a similar method to Fiona Smith,13 but, in the 
absence of DMAP. To an ice cold stirred solution of N-methyldiethylenetriamine 96 
(590mg, 5mmol) in CH2C12 (1ml) was added 9-acridine carboxylic acid chloride 
(prepared by dissolving the carboxylic acid (200mg, 0.9mmol) in thioyl chloride 
(1.5ml), and removing the excess in vacuo, followed by reconstituting the acid chloride 
in CH2C12 (5ml)). A white precipitate formed immediately. The reaction was allowed 
to rise to room temperature, whilst stirring continued for a further 15 hours. Aqueous 
potassium hydroxide (l.Omol dm"3, 10ml) was then added, followed by extraction with 
CHCI3. The compound was purified by HPLC to give the required amine, a viscous 
yellow glass, as the trifluoroacetate salt (391mg, 80%) 
HPLC: Dynamax 60A (10ml min"1); elution A=MeCN/TFA; B=H20/TFA from 10% A, 
90% B to 90% A, 10% B over 20 minutes; observed X=320nm; Rt=10.4 minutes. 
*H NMR(D 20, pD ~3) 2.90(3H, s, NCH3), 3.36(2H, m, CH 2NH 2), 3.49(4H, m, CH2N), 
3.91(2H, t, CONHCH2), 7.66(2H, m, ArH), 7.97(6H, m, ArH) MS(ES+) 323.11 (M++1) 
( C 1 9 H 2 2 N 4 0 requires 323.18) 
9-Acridine carbamoylethyl-2-(2-(4-nitrophenyl carboxyethyl) amidoethyl-N-
methylamine 95 
Following a procedure adapted from Fiona Smith,12 to a vortex mixed solution of the 
previously prepared acridine amine 94 (60mg, 0.1 lmmol) in DMSO (0.5ml) was added 
H 
N NH 
N 
Me 
N 
NO 
O 
H H 
N N 
N 
Me 
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the bis ester (120mg, 0.33mmol), which was only partially soluble. Triethylamine 
(22.4mg, 31p,L, 0.22mmol) was added with violent mixing. After 5 minutes mixing, 
the reaction was quenched by the addition of TFA (1 drop). Purification by HPLC 
afforded the acridine active ester (14mg, 20%) as a TFA salt. 
HPLC: Dynamax 60A (10ml min"1); elution A=MeCN/TFA; B=H20/TFA from 10% 
A, 90% B to 75% A, 25% B over 20 minutes then 100% A; observed X=353nm; 
Rt=14.6 minutes. X H NMR(D20) 2.25(4H, m, CH2CO), 2.94(3H, s, NCH3), 3.35(2H, 
m, CH2NHCO), 3.54(4H, m, CH2N), 3.88(2H, t, CONHCH2), 6.82(2H, d, ArH), 
7.8(2H, m, ArH (acridine)), 7.77(2H, m, ArH), 7.97(6H, m, ArH (Acridine) MS(ES+) 
544.29 (M + +l) (C 29H3 0N 5O 6 requires 544.22) A sharp decomposition point was not 
observed for this compound. 
9-Acridine carbamoylethyl-2-(bis(2-aminoethyl)) amine 97 
Acridine-9-carboxylic acid (250mg, 1.12mmol) was refluxed for 3 hours in thionyl 
chloride (5ml). The excess thionyl chloride was removed in vacuo, followed by the 
four times repeated cycle of addition of CH2C12 and evaporation to dryness. The acid 
chloride was taken up in CH2C12 (5ml), and slowly added to a stirred ice cold solution 
of tris(aminoethyl) amine (1.2g, 8.22mmol) in CH2C12 (5ml), immediately forming a 
precipitate of the hydrochloride salt The temperature of the reaction was then allowed 
to rise to room temperature over 30 minutes, when KOH solution was added to attain a 
pH = 13. Extraction into CHCI3 (3 x 20ml) gave a sample which, on concentration, was 
amenable to HPLC purification, to give a yellow oil, the TFA salt. (415mg, 54% yield) 
HPLC: Dynamax 60A (10ml min"1); elution A=MeCN/TFA; B=H20/TFA from 10% 
A, 90% B to 75% A, 25% B over 20 minutes then 100% A; observed X=302nm; Rp8.0 
minutes. *H NMR(D 20) 3.04(10H, symmetric m, CH2N), 3.72(2H, t, CONHCH2), 
7.75(2H, m, ArH (acridine)), 8.05(6H, m, ArH (Acridine) MS(ES+) 176.8 ( M + l ) 2 + 
NH 
N 
H-.N 
NH 
N 
147 
Acridine maleimide amines 98 and 99 
o 
H,N 
o 
H H 
N N 
N N 
O NH NH 
To the triamine 97 prepared above (54mg, 0.155mmol), dissolved in PIPES buffer 
(0.5ml), was added a solution of N-hydroxysuccinimide-4-maleimidobutanoate 
(43.4mg, 0.155mmol) in 1,4-dioxane (0.5ml). The reaction went turbid on addition, as 
the buffer came out of solution. The pH remained at 6.8. The reaction at room 
temperature was followed by reverse phase HPLC, and was terminated by the addition 
of acid after 4 hours. The PIPES was filtered off, and the filtrate purified by HPLC, to 
give 98 as the TFA salt, a bright yellow solid (14mg, 13% ) 
HPLC: Dynamax 60A (10ml min"1); elution A=MeCN/TFA; B=H20/TFA from 10% 
A, 90% B to 75% A, 25% B over 40 minutes; observed X=302nm; Rt=14.4 minutes. 
lU NMR(D 20, pD ~4) 1.50(2H, p, CH2), 2.03(2H, t, CH2CO), 3.16(2H, t, 
CH2N(maleimide)), 3.2-3.5(10H, m, CH2N+CONHCH2), 3.94(2H, br t, 
ArCONHCH2), 6.57(2H, s, CH), 7.87(2H, m, ArH), 8.22(8H, m, ArH) 1 3 C NMR(D 20) 
23.2(CH2), 32.0, 34.3, 35.3, 35.8, 36.5,49.8, 51.8, 52.7, 54.0(CH2N), 120.1, 122.2, 
125. 9,129.3, 134.1,137.7,141.1,149.5,166.8(Ar+maleimide), 172.7,176.6(CO) 
IR(film) 3400 (br), 1676,1551,1432,1202,1133 MS(ES+) 517.42 (M + +l ) 
The acridine bismaleimide compound 99 was identified as well, also a yellow solid 
(20mg, 33%). 
HPLC: Rt=17.9 minutes *H NMR(D 20, pD ~4) 1.41(4H, p, CH^, 2.03(4H, t, 
CH2CO), 3.12(4H, t, CH2N(maleimide)), 3.51(8H, m, CH2N+CONHCH2), 3.68(2H, br 
t, CH2N), 3.98(2H, br t, ArCONHCH2), 6.59(4H, s, CH), 7.87(2H, m, ArH), 8.21(8H, 
m, ArH) 1 3 C NMR(D20) 23.1(CH2), 32.1, 34.6, 35.6, 36.4, 38.4, 53.2, 54.6(CH2N), 
120.2,122.1, 126.0, 129.2, 134.0,137.6,140.1,153.8,166.8(Ar+maleimide), 172.6, 
176.6(CO) IR (film) 3423(br), 1704, 1553, 1414,1203,1138 MS(ES+) 683.10 
(M++2) 
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Appendix 
Research Colloquia, Seminars and Lectures 
The author attended the following lecture courses: 
NMR Spectroscopy, by Dr. A.M. Kenwright, Dr. P.G. Steel and Prof. D. Parker 
Organometallic Chemistry, by Prof. V.C. Gibson and Prof. D. Parker 
Diffraction Techniques, by Prof. J.A.K. Howard 
Amino Acids, Peptides and Proteins by Dr. M. Richardson 
The author attended the following colloquia between October 1993 and September 1996: 
1993 
October 14 Dr. P. Hubberstey, University of Nottingham 
Alkali Metals: Alchemist's Nightmare, Biochemist's Puzzle and 
Technologist's Dream 
October 20 Dr. P. Quay let, University of Manchester 
Aspects of Aqueous ROMP Chemistry 
October 27 Dr. R.A.L. Jonest, Cavendish Laboratory, Cambridge 
Perambulating Polymers 
November 25 Dr. R.P. Wayne, University of Oxford 
The Origin and Evolution of the Atmosphere 
December 1 Prof. M.A. McKerveyt, Queen's University, Belfast 
Synthesis and Applications of Chemically Modified Calixarenes 
December 8 Prof. O. Meth-Cohnt, University of Sunderland 
Friedel's Folly Revisited - A Super Way to Fused Pyridines 
1994 
February 9 Prof. D. Youngt, University of Sussex 
Chemical and Biological Studies on the Coenzyme Tetrahydrofolic Acid 
March 2 Dr. C. Huntert, University of Sheffield 
Noncovalent Interactions between Aromatic Molecules 
151 
March 10 
March 25 
April 28 
November 16 
November 23 
1995 
January 11 
January 18 
January 25 
February 8 
March 1 
April 26 
Prof. S.V. Ley, University of Cambridge 
New Methods for Organic Synthesis 
Dr. J. Dilworth, University of Essex 
Technetium and Rhenium Compounds with Applications as Imaging 
Agents 
Prof. R. J. Gillespie, McMaster University, Canada 
The Molecular Structure of some Metal Fluorides and Oxofluorides: 
Apparent Exceptions to the VSEPR Model. 
Prof. M. Page, University of Huddersfield 
Four-membered Rings and ^-Lactamase 
Dr J. M. J. Williams, University of Loughborough 
New Approaches to Asymmetric Catalysis 
Prof. P. Parsons, University of Reading 
Applications of Tandem Reactions in Organic Synthesis 
Dr G. Rumbles, Imperial College, London 
Real or Imaginary Third Order Non-linear Optical Materials 
Dr D. A. Roberts, Zeneca Pharmaceuticals 
The Design and Synthesis of Inhibitors of the Renin-angiotensin System 
Dr D. O'Hare, Oxford University 
Synthesis and Solid-state Properties of Poly-, Oligo- and Multidecker 
Metallocenes 
Dr M . Rosseinsky, Oxford University 
Fullerene Intercalation Chemistry 
Dr M . Schroder, University of Edinburgh 
Redox-active Macrocyclic Complexes : Rings, Stacks and Liquid 
Crystals 
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May 4 
October 13 
October 18 
November 1 
November 8 
December 8 
1996 
January 10 
January 17 
January 24 
February 12 
February 28 
March 6 
Prof. A. J. Kresge, University of Toronto 
The Ingold Lecture Reactive Intermediates : Carboxylic-acid Enols and 
Other Unstable Species 
Prof. R. Schmultzer, Univ Braunschwieg, FRG. 
Calixarene-Phosphorus Chemistry: A New Dimension in Phosphorus 
Chemistry 
Prof. A. Alexakis, Univ. Pierre et Marie Curie, Paris, 
Synthetic and Analytical Uses of Chiral Diamines 
Prof. W. Motherwell, UCL London 
New Reactions for Organic Synthesis 
Dr. D. Craig, Imperial College, London 
New Stategies for the Assembly of Heterocyclic Systems 
Professor M.T. Reetz, Max Planck Institut, Mulheim 
Perkin Regional Meeting 
Dr Bil l Henderson, Waikato University, NZ 
Electrospray Mass Spectrometry - a new sporting technique 
Prof. J. W. Emsley, Southampton University 
Liquid Crystals: More than Meets the Eye 
Dr Alan Armstrong, Nottingham Univesity 
Alkene Oxidation and Natural Product Synthesis 
Dr Paul Pringle, University of Bristol 
Catalytic Self-Replication of Phosphines on Platinum(O) 
Prof. E. W. Randall, Queen Mary & Westfield College 
New Perspectives in NMR Imaging 
Dr Richard Whitby, Univ of Southampton 
New approaches to chiral catalysts: Induction of planar and metal centred 
asymmetry 
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March 7 Dr D.S. Wright, University of Cambridge 
Synthetic Applications of Me2N-p-Block Metal Reagents 
March 12 RSC Endowed Lecture - Prof. V. Balzani, Univ of Bologna 
Supramolecular Photochemistry 
t Invited specially for the graduate training programme. 
Conferences 
The author attended the following meetings: 
1. North of England Cancer Research Campaign Meeting,* University of 
Newcastle, 26th July 1994 
2. Stereochemistry at Sheffield, University of Sheffield, 14th December 1994 
3. RSC UK Macrocycles Group, University of Newcastle, 4-5th January 1995 
4. International Isotope Society, UK Group Meeting, Fison's Pharmaceuticals, 
Loughborough, 22nd May 1995 
5. International Symposium on Radiopharmaceutical Chemistry,* Vancouver, 
Canada, 13-17th August 1995 
6. Workshop on Targetry and Target Chemistry, Vancouver, Canada, 17-19th 
August 1995 
7. Stereochemistry at Sheffield, University of Sheffield, 19th December 1995 
8. Easter School in Radiopharmaceutics,* King's College, London, 24-29th March 
1996 
Indicates a poster presentation by the author. 
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